Document:

exv10w36

Exhibit 10.36

     EXECUTION COPY

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

LICENSE AGREEMENT

     This License Agreement (the “Agreement“) is entered into on November 6, 2009 (the
“Effective Date“) between Nippon Kayaku Co., Ltd., a Japanese corporation with its
principal place of business at 11-2, Fujimi 1-chome, Chiyoda-ku,
Tokyo 102-8172, Japan (“NK”), and Spectrum Pharmaceuticals, Inc., a
Delaware corporation with its principal place of business at 157 Technology Drive, Irvine, CA 92618
(“Spectrum“). Spectrum and NK are sometimes referred to herein individually as a “Party” and
collectively as the “Parties.”

RECITALS

     Whereas, Spectrum has developed certain intellectual property relating to the use of
Apaziquone for treatment of bladder cancer;

     Whereas, Spectrum has granted the right to develop and commercialize certain products
containing Apaziquone outside of Asia to Allergan, Inc. and its affiliates, under a License,
Development, Supply and Distribution Agreement by and among Allergan Sales, LLC, Allergan USA,
Inc., Allergan, Inc. and Spectrum, effective October 28, 2008 (the Allergan entities collectively,
together with any successors or assigns of Allergan with respect to such agreement with Spectrum,
“Allergan”, such agreement, the “Allergan Agreement” and such date, the “Allergan Agreement
Effective Date”);

     Whereas, NK has substantial expertise in the research, development, manufacture,
distribution, sales and marketing of pharmaceutical products in Japan and in the distribution,
sales and marketing of pharmaceutical products through distributors in Asia; and

     Whereas, Spectrum desires to grant to NK, and NK desires to obtain, the right to
develop, manufacture and commercialize product(s) containing Apaziquone for certain indications in
all countries and territories of Asia except for Korea, all on the terms and conditions set forth
herein.

     Now Therefore, in consideration of the foregoing premises and the mutual promises,
covenants and conditions contained in this Agreement, the Parties agree as follows:

 

 

ARTICLE 1

DEFINITIONS

     As used in this Agreement, the following initially capitalized terms, whether used in the
singular or plural form, shall have the meanings set forth in this Article 1.

     1.1 “Affiliate” means, with respect to a particular Party, a person, corporation, partnership,
or other entity that controls, is controlled by or is under common control with such Party. For
the purposes of this definition, the word “control” (including, with correlative meaning, the terms
“controlled by” or “under the common control with”) means the actual power, either directly or
indirectly through one or more intermediaries, to direct or cause the direction of the management
and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting
stock of such entity, or by contract or otherwise.

     1.2 “Apaziquone” means the compound having the structure set forth on Exhibit A attached
hereto.

     1.3 “Asia” means Bangladesh, Bhutan, Brunei, Burma (Myanmar), Cambodia, China, Hong Kong,
India, Indonesia, Japan, Laos, Macao, Malaysia, Maldives, Mongolia, Nepal, North Korea, Pakistan,
Philippines, Qatar, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, and Vietnam, as their
boundaries are defined as of the Allergan Agreement Effective Date, and including any successors of
the foregoing countries to the extent within the boundaries of the countries set forth above as of
the Allergan Agreement Effective Date.

     1.4 “Closed-System Packaging” means a packaging system that allows reconstitution of drug
product with diluent in a closed system in a manner that does not expose the individual performing
the reconstitution to any direct contact with either lyophilized or reconstituted Apaziquone.

     1.5 “Commercialization” with a correlative meaning for “Commercialize” and “Commercializing”,
means all activities undertaken before and after obtaining Regulatory Approvals relating
specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison
activities, marketing, pricing, reimbursement, sale, and distribution of the Product, including:
(a) strategic marketing, sales force detailing, advertising, medical education and liaison, and
market and Product support; (b) any postmarketing clinical studies for use in generating data to
be submitted to Regulatory Authorities (and all associated reporting requirements); and (c) all
customer support, Product distribution, invoicing and sales activities.

     1.6 “Commercially Reasonable Efforts” means those efforts consistent with the exercise of
prudent scientific and business judgment in an active and ongoing program as applied by a Party to
the development and commercialization of its own pharmaceutical products at a similar stage of
development and with similar market potential. Commercially Reasonable Efforts requires that a
Party, at a minimum, assigns responsibility for such obligations to qualified employees, sets
annual goals and objectives for carrying out such obligations, and allocates resources designed to
meet such goals and objectives.

2.

 

     1.7 “Confidential Information” means, with respect to a Party, all reports and other
Information of such Party that is disclosed to the other Party under this Agreement, whether in
oral, written, graphic, or electronic form. All Information disclosed by either Party pursuant to
the Mutual Confidentiality Agreement between the Parties dated April 16, 2009, shall be deemed to
be such Party’s Confidential Information disclosed hereunder.

     1.8 “Control” means, with respect to any material, Information, or intellectual property
right, that a Party owns or has a license to such material, Information, or intellectual property
right and, in each case, has the ability to grant to the other Party access, a license, or a
sublicense (as applicable) to the foregoing on the terms and conditions set forth in this Agreement
without violating the terms of any then-existing agreement or other arrangement with any Third
Party.

     1.9 “Cost of Goods Sold” means the cost incurred by Spectrum in manufacturing the Product
(including the production of the active ingredient and the fill and finish of the Product) supplied
to NK under this Agreement and transporting such Product to the airport(s) where such Product will
be exported to NK, including material costs, labor costs and overhead costs (including allocated
facility costs, testing costs and delivery costs). In the event Spectrum engages any Third Party
contract manufacturer for the manufacture and supply of the Products, Cost of Goods Sold shall mean
Spectrum’s costs actually incurred in such engagement, the procurement of such Products from such
Third Party and transporting such Product to such airport(s).

     1.10 “Develop” or “Development” means all activities relating to preparing and conducting
preclinical testing, toxicology testing, human clinical studies, and regulatory activities (e.g.,
regulatory applications) with respect to the Product, together with the manufacturing of the
Product for the purpose of conducting the foregoing activities.

     1.11 “Development Costs” means the internal costs and out-of-pocket costs incurred as an
expense in accordance with generally accepted accounting principles by or on behalf of a Party or
its Affiliates in carrying out the Development of the Product in accordance with the approved
Development Plan, including, without limitation, (i) the costs of clinical trials (including costs
of procuring the Product(s), placebos and comparator drugs used in such clinical trials), (ii)
filing fees and other costs associated with any Regulatory Filings; (iii) costs related to
manufacturing development; and (iv) all other costs that are directly attributable and reasonably
allocable to the Development activities for the Products. For purposes of this definition: (a)
out-of-pocket costs mean the actual expense incurred with respect to a Third Party for specific
Development activities relating to the Products; and (b) internal costs means the applicable FTE
Rate multiplied by the number of FTE hours expended in carrying out the Development activities in
accordance with the Development Plan. For clarity, the costs associated with attending or
participating in meetings of the JPT are expressly excluded from this definition.

     1.12 “Development Plan” has the meaning set forth in Section 4.2(a).

     1.13 “Dollar” means a U.S. dollar, and “$” shall be interpreted accordingly.

3.

 

     1.14 “FDA” means the United States Food and Drug Administration and any successors thereof.

     1.15 “Field” means the intravesical treatment of non-muscle invasive bladder cancer in humans.

     1.16 “First Commercial Sale” means the first sale to a Third Party of a Product in a given
regulatory jurisdiction after Regulatory Approval has been obtained in such jurisdiction.

     1.17 “Generic Product” means, with respect to a Product in the Field in a particular country
in the NK Territory, another pharmaceutical product that is: (a) a Product; (b) approved for use in
such country by the Regulatory Authority; and (c) commercialized by a Third Party who has not
obtained the right or access to such product (through sublicense, subcontract or chain of
distribution) from NK or its Affiliates or sublicensees.

     1.18 “Governmental Authority” means any multi-national, federal, state, local, municipal,
provincial or other government authority of any nature (including any governmental division,
prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or
other tribunal).

     1.19 “Immediate Instillation Indication” means the intravesical instillation of a Product into
the bladder for the treatment of non-muscle invasive bladder cancer, administered immediately after
transurethral resection of bladder tumor (TUR-BT).

     1.20 “Information” means any data, results, technology, business information and information
of any type whatsoever, in any tangible or intangible form, including, without limitation,
know-how, trade secrets, practices, techniques, methods, processes, inventions, developments,
specifications, formulations, formulae, materials or compositions of matter of any type or kind
(patentable or otherwise), software, algorithms, marketing reports, expertise, technology, test
data (including pharmacological, biological, chemical, biochemical, toxicological, preclinical and
clinical test data), analytical and quality control data, stability data, other study data and
procedures.

     1.21 “Joint Inventions” has the meaning set forth in Section 9.1.

     1.22 “Joint Patent” has the meaning set forth in Section 9.1.

     1.23 “Joint Product Team” or “JPT” means the Product team formed by the Parties as described
in Section 3.2.

     1.24 “Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements
having the effect of law of any federal, national, multinational, state, provincial, county, city
or other political subdivision, domestic or foreign.

     1.25 “Major Markets” means each of the following countries: (a) Japan; (b) mainland China; (c)
Taiwan; (d) Hong Kong; (e) Singapore; and (f) India.

4.

 

     1.26 “Multiple Instillation Indication” means the intravesical instillation of a Product into
the bladder for the treatment of non-muscle invasive bladder cancer, administered as multiple
instillations. For clarity, multiple instillations shall mean a repeat and/or sequential dosing
regimen which may include an immediate instillation dose as part of such regimen.

     1.27 “Net Sales” means, with respect to a particular time period, the total amounts invoiced
by NK, its Affiliates and their respective sublicensees for sales of Products made during such time
period to unrelated Third Parties, less the following deductions to the extent actually allowed or
incurred with respect to such sales:

          (a) reasonable and customary discounts, including cash and quantity discounts, charge-back
payments, administrative fees incurred directly in such discounting, and rebates actually granted
to trade customers and distributors (including wholesalers);

          (b) reasonable and customary credits or allowances actually granted for damaged, outdated,
spoiled, returned or rejected Products, including, without limitation, in connection with recalls;
and

          (c) Taxes, tariffs, duties or other governmental charges (other than income taxes) levied on,
absorbed or otherwise imposed on sales of the Product in the NK Territory, as adjusted by any
refunds, provided that such Taxes, tariffs, duties or other government charges are included in the
applicable invoiced amount and identified in the applicable invoice.

Notwithstanding the foregoing, amounts billed by NK, its Affiliates, or their respective
sublicensees for the sale of Products among NK, its Affiliates or their respective sublicensees for
resale, or for use in clinical development (at or below cost incurred for procuring and shipping
the Product), shall not be included in the computation of Net Sales hereunder. A sale of Products
by NK, its Affiliates or their respective sublicensees to a wholesaler shall be regarded as the
sale of Product to unrelated Third Parties for the purpose of calculating Net Sales. For purposes
of determining Net Sales, the Products shall be deemed to be sold when shipped and a “sale” shall
not include reasonable transfers or dispositions, at no cost, as samples or for charitable
purposes, or transfers or dispositions at no cost for preclinical, clinical or regulatory purposes.

Each of the deductions set forth above shall be reasonable and customary, and in accordance with
accounting principles generally accepted in Japan. NK, its Affiliates, and their respective
sublicensees will sell Products as stand-alone products and will not sell such Products as part of
a bundle with other products or offer packaged arrangements to customers that include Products,
except with the prior written consent of Spectrum.

     1.28 “NK Know-How” means all Information that is Controlled by NK or its Affiliates as of the
Effective Date or during the Term and is necessary or reasonably useful for the Development,
manufacture and/or Commercialization of the Product in the Field in accordance with the terms of
this Agreement. For clarity, NK Know-How excludes rights granted under the NK Patents. For further
clarity, NK Know-How includes (i) all data, results and other Information generated from or
obtained by the Development conducted by or for NK in the NK Territory under this Agreement, (ii)
all data, results and other Information generated from or obtained by the clinical Development
conducted by or for NK in South Korea pursuant

5.

 

to Section 2.1(a)(ii), and (iii) NK’s interest in the data, results and other Information
generated from or obtained by the clinical Development conducted by NK and Korean Partner pursuant
to Section 2.1(a)(ii).

     1.29 “NK Patent” means any Patent that (a) is Controlled by NK or its Affiliates as of the
Effective Date or at any time during the Term (excluding NK’s interest in any Joint Patents), and
(b) claims the Products or their use, composition, formulation, preparation, method of
administration or manufacture.

     1.30 “NK Technology” means the NK Patents and NK Know-How.

     1.31 “NK Territory” means all countries and territories in Asia, excluding North Korea and
South Korea.

     1.32 “Patents” means (a) pending patent applications, issued patents, utility models and
designs; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations,
additions, continuations, continued prosecution applications, continuations-in-part, or divisions
of or to any patents, patent applications, utility models or designs; and (c) the equivalent or
counterpart of the foregoing.

     1.33 “Product” means any formulation that includes Apaziquone that is suitable for use in
treating non-muscle invasive bladder cancer via intravesical instillation.

     1.34 “Regulatory Approval” means, with respect to a Product in any country or jurisdiction,
all approvals (including, where required, pricing and reimbursement approvals), registrations,
licenses or authorizations from the relevant Regulatory Authority in a country or jurisdiction that
is specific to Product and necessary to market and sell such Product in such country or
jurisdiction.

     1.35 “Regulatory Authority” means, in a particular country or regulatory jurisdiction, any
applicable Governmental Authority involved in granting Regulatory Approval and/or, to the extent
required in such country or regulatory jurisdiction, pricing or reimbursement approval of a Product
in such country or regulatory jurisdiction.

     1.36 “Regulatory Exclusivity” means market exclusivity granted by a Governmental Authority
designed to prevent the entry of Generic Product(s) onto the market in the Field, including new
chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan
drug exclusivity, pediatric exclusivity and 180-day generic product exclusivity, or any equivalent
of the foregoing in the NK Territory.

     1.37 “Regulatory Filings” means, with respect to the Products, any submission to a Regulatory
Authority of any appropriate regulatory application specific to Products, and shall include,
without limitation, any submission to a regulatory advisory board and any supplement or amendment
thereto.

     1.38 “Retained Territory” means all countries and territories in the world outside the NK
Territory.

6.

 

     1.39 “Sole Inventions” has the meaning set forth in Section 9.1.

     1.40 “Spectrum Know-How” means all Information that is Controlled by Spectrum or its
Affiliates as of the Effective Date or during the Term and is necessary or reasonably useful for
the Development, manufacture and/or Commercialization of the Product in the Field in accordance
with the terms of this Agreement. For clarity, Spectrum Know-How includes all data, results and
other Information generated from or obtained by clinical studies and other tests conducted under
the Allergan Agreement and any Information described in Regulatory Filings filed with any
Regulatory Authority in the Retained Territory with respect to the Product, in each case to the
extent Controlled by Spectrum or its Affiliates. For further clarity, Spectrum Know-How excludes
rights granted under the Spectrum Patents. Notwithstanding the foregoing, Spectrum Know-How shall
not include Information controlled by an acquiror or merger partner of Spectrum that: (a) existed
as of the date of closing of such acquisition or merger; or (b) was developed after the date of
closing of such acquisition or merger without using Spectrum Know-How or inventions claimed in
Spectrum Patents.

     1.41 “Spectrum Patents” means all Patents in the NK Territory that (a) are Controlled by
Spectrum or its Affiliates as of the Effective Date or at any time during the Term (excluding
Spectrum’s interest in any Joint Patents), and (b) but for the licenses granted herein, would be
infringed by the developing, making, using and/or selling of the Products by NK, its Affiliates or
sublicensees in the Field in the NK Territory. Notwithstanding the foregoing, Spectrum Patents
shall not include Patents controlled by an acquiror or merger partner of Spectrum that: (a) existed
as of the date of closing of such acquisition or merger; or (b) were developed after the date of
closing of such acquisition or merger without using Spectrum Know-How or inventions claimed in
Spectrum Patents. The Spectrum Patents existing as of the Effective Date in the NK Territory are
set forth on Exhibit B attached hereto.

     1.42 “Spectrum Technology” means the Spectrum Patents and Spectrum Know-How.

     1.43 “Taxes” means taxes (other than income taxes), duties, tariffs or other governmental
charges levied on the sale of Products, including, without limitation, consumption taxes.

     1.44 “Term” means the term of this Agreement, as determined in accordance with Article 13.

     1.45 “Third Party” means any person or entity other than Spectrum or NK or an Affiliate of
either of them.

     1.46 “TPP” means the target product profile of the Product existing as of the Effective Date
and attached to this Agreement as Exhibit C.

     1.47 “Valid Claim” means, with respect to any country: (a) a claim of an issued and unexpired
patent (as may be extended through supplementary protection certificate or patent term extension or
the like) included within the Spectrum Patents to the extent such claim has not been revoked, held
invalid or unenforceable by a patent office, court or other governmental agency of competent
jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken
within the allowable time period) and which claim has not been

7.

 

disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination
or disclaimer or otherwise; and (b) a claim of a pending patent application included within the
Spectrum Patents.

ARTICLE 2

LICENSES AND EXCLUSIVITY

     2.1 License to NK under Spectrum Technology.

          (a) License.

               (i) Subject to the terms of this Agreement, Spectrum hereby grants NK: (A) an exclusive,
royalty-bearing license, with the right to grant sublicenses at one or more tier(s) subject to
Section 2.1(c) below, under the Spectrum Technology, to research, Develop, use, sell, offer for
sale, have sold, import and otherwise Commercialize the Products in the Field in the NK Territory;
and (B) a non-exclusive license under the Spectrum Technology to make and have made the Products in
the NK Territory and have made the Products in the Retained Territory, solely for use or sale of
such Products pursuant to Section 2.1(a)(i)(A).

               (ii) The Parties acknowledge that Spectrum is actively seeking a licensee for the Product in
South Korea (such licensee, the “Korean Partner”). Spectrum hereby grants to NK a co-exclusive
license (with such Korean Partner) under the Spectrum Technology to conduct clinical Development
activities (but not seek Regulatory Approval) in South Korea with respect to the Products solely to
support NK’s or its sublicensees’ Regulatory Filings in the NK Territory. Promptly after the
Effective Date or the execution of a license agreement between Spectrum and such Korean Partner
granting such Korean Partner the right to develop and commercialize the Products in Korea,
whichever is later, NK shall discuss in good faith with such Korean Partner to coordinate the
Development activities for the Products in South Korea. Further, the Parties acknowledge that in
order to facilitate the Regulatory Filings in the NK Territory, it is essential for NK to conduct
clinical Development in South Korea and, therefore, the Parties agree that, in the event such
license agreement between Spectrum and such Korean Partner is not executed by the expiration of a
period of [***] after the Effective Date: (A) North Korea and South Korea shall be included in the
NK Territory hereunder; (B) South Korea shall be included as an additional Major Market hereunder;
and (C) NK shall deliver to Spectrum a payment in the amount of $[***] as a consideration for such
inclusion.

          (b) Spectrum Retained Rights.

               (i) Notwithstanding the licenses granted to NK under Section 2.1, Spectrum retains the right
to practice the Spectrum Technology in the NK Territory to fulfill its obligations under this
Agreement.

               (ii) Subject to Section 2.5 below, Spectrum retains the right to practice and license the
Spectrum Technology outside the scope of the license granted to NK in Section 2.1(a)(i) above,
including to develop and commercialize in the NK Territory any formulation

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

8.

 

including Apaziquone that is not a Product.

          (c) Sublicenses.

               (i) NK shall have the right to grant sublicenses under the license in Section 2.1(a) to its
Affiliates or other Third Parties only with the prior written consent from Spectrum, such consent
not to be unreasonably withheld or delayed for the grant of sublicenses in countries and
territories in the NK Territory outside Japan. NK shall remain primarily responsible for the
performance of its Affiliates’ and sublicensees’ obligations set forth herein by each of its
Affiliates and sublicensees.

               (ii) NK shall, within thirty (30) days after granting any sublicense under Section 2.1(a)
above, notify Spectrum of the grant of such sublicense and provide Spectrum with a true and
complete copy of such sublicense agreement. Each sublicense agreement shall not conflict with the
terms and conditions under this Agreement. For clarity, NK may determine the terms and conditions
of such sublicense agreement at its sole discretion so long as they do not conflict with the terms
and conditions of this Agreement. NK shall, in each agreement under which it grants a sublicense
under the license set forth in Section 2.1(a) (each, a “Sublicense Agreement“), include the
following terms and conditions: (i) the sublicensee is required to carry out such tasks to ensure
that NK will comply with its obligations to Spectrum hereunder, to, among other things, allow
Spectrum to comply with its obligations to Allergan under the Allergan Agreement, including by
providing all Product-related Information to NK so that NK may comply with its obligations under
Section 5.5; (ii) the sublicensee is required to provide the following to NK if such Sublicense
Agreement terminates during the term of this Agreement: (A) the assignment and transfer of
ownership and possession of all Regulatory Filings and Regulatory Approvals held or possessed by
such sublicensee, and (B) the assignment of, or a freely sublicenseable exclusive license to, all
intellectual property Controlled by such sublicensee that covers or embodies a Product or its
respective use, manufacture, sale, or importation and was created by or on behalf of such
sublicensee during the exercise of its rights or fulfillment of its obligations pursuant to such
Sublicense Agreement; and (iii) if this Agreement terminates pursuant to Section 13.2 prior to the
expiration of the Term, then Spectrum may, at its sole discretion: (C) assume NK’s rights and
obligations under such Sublicense Agreement; or (D) terminate such Sublicense Agreement. Each
Sublicense Agreement shall include the sublicensees’ obligations set forth herein.

               (iii) NK shall pay to Spectrum [***] percent ([***]%) of all Sublicense Revenues within [***]
after the receipt of each payment of the Sublicense Revenue from each sublicensee. “Sublicense
Revenue” means all upfront payments and milestone payments made by any sublicensee to NK under any
Sublicense Agreement. For the avoidance of doubt, Sublicense Revenue shall not include: (A) any
sales-based royalty payment; (B) any payment in exchange for the fair market value for actual
services performed by or on behalf of NK to such sublicensee or the fair market value for the
supply of Products by NK to such sublicensee; and (C) any payment in exchange for the fair market
value of NK’s equity.

     2.2 License to Spectrum. NK hereby grants Spectrum: (a) a non-exclusive, fully-

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

9.

 

paid, royalty free license, with the right to grant sublicenses, under the NK Technology to
perform Spectrum’s obligations under this Agreement; (b) an exclusive license, with the right to
grant sublicenses, under the NK Technology to research, Develop, make, have made, use, sell, offer
for sale and import products containing Apaziquone (including Products) for all fields of use in
the Retained Territory and outside the Field in the NK Territory; provided, however, that NK may
use or have used the NK Technology when NK has made the Product in the Retained Territory pursuant
to Section 2.1(a)(i)(B) and NK conducts the clinical Development in South Korea pursuant to Section
2.1(a)(ii); further provided that such license shall be royalty-free with respect to NK Know-How
and shall be royalty-bearing with respect to NK Patents (with reasonable royalty rates to be agreed
upon by the Parties through good faith negotiations upon Spectrum’s request prior to Spectrum’s
utilization of such NK Patents); and (c) an exclusive option to obtain an exclusive,
royalty-bearing license, (with reasonable royalty rates to be agreed upon by the Parties through
good faith negotiations upon Spectrum’s request prior to Spectrum’s utilization of the Joint
Patents), with the right to grant sublicenses, under NK’s interest in the Joint Patents to
research, Develop, make, have made, use, sell, offer for sale and import products containing
Apaziquone (including Products) for all fields of use in the Retained Territory and outside the
Field in the NK Territory; provided, however, that NK may use or have used such Joint Patents when
NK has made the Product in the Retained Territory pursuant to Section 2.1(a)(i)(B) and NK conducts
the clinical Development in South Korea pursuant to Section 2.1(a)(ii).

     2.3 Negative Covenant; No Implied License. NK covenants that it will not, and it will not
permit any of its Affiliates to, use or practice any Spectrum Technology outside the scope of the
license granted to it under Section 2.1 above. Spectrum covenants that it will not, and it will
not permit any of its Affiliates to, use or practice any NK Technology outside the scope of the
license granted to it under Section 2.2. Except as set forth herein, neither Party shall acquire
any license or other intellectual property interest, by implication or otherwise, under any
trademarks, patents or patent applications owned or Controlled by the other Party.

     2.4 Diversion.

          (a) NK hereby covenants and agrees that it will not, and will ensure that its Affiliates,
sublicensees and subcontractors will not, either directly or indirectly, promote, market,
distribute, import, sell or have sold Products, including via the Internet or mail order, to any
Third Party, address or Internet Protocol (“IP”) address in the Retained Territory. As to such
countries in the Retained Territory: (i) NK shall refrain from establishing or maintaining any
branch, warehouse or distribution facility for the Product in such countries; (ii) NK shall not
engage in any advertising or promotional activities relating to the Product directed primarily to
customers or other buyers or users of the Product located in such countries; and (iii) NK shall not
solicit orders from any prospective purchaser located in such countries. If NK receives any order
from a prospective purchaser located in a country in the Retained Territory, NK shall immediately
refer that order to Spectrum. NK shall not accept any such orders. NK may not deliver or tender
(or cause to be delivered or tendered) any Product outside of the NK Territory.

          (b) If any of NK’s Product is diverted for use in the Retained Territory, the following shall
apply: (i) if such Product were diverted by an identifiable customer, distributor, employee,
consultant or agent of NK then, upon the request of Spectrum, NK shall not sell such

10.

 

category of Product to, or allow the sale of such category of Product by, any such customer,
distributor, employee, consultant or agent for the remaining Term and shall use commercially
reasonable efforts to buy back all such Product from such customer, distributor, employee,
consultant or agent within seven (7) business days of receiving such request from Spectrum; or (ii)
NK shall use commercially reasonable efforts to investigate the location of such diverted Product
and buy it back; but, if and to the extent that, NK elects not to, or is unable to, buy back the
applicable diverted Product, then Spectrum may, in its sole discretion, buy back the applicable
diverted Product and NK shall reimburse Spectrum for all reasonable costs incurred by Spectrum in
connection with the buy-back of any such diverted Product.

          (c) If any formulation containing Apaziquone sold by NK, its Affiliates or sublicensees (the
“NK Product”) is used in the Retained Territory, NK shall pay to Spectrum an amount equal to the
amount Spectrum is obligated to pay to Allergan as a result of such sales.

     2.5 Exclusivity. For the period commencing on the Effective Date and ending ten (10) years
after the First Commercial Sale of a Product in the Field in the NK Territory: (a) neither Party or
its Affiliates will, either by itself or through the grant of licenses or sublicenses, without the
other Party’s written consent, commercialize any formulation that includes Apaziquone in the Field
in the NK Territory except under this Agreement; and (b) NK will not, and will ensure that its
Affiliates will not, either by itself or through the grant of licenses or sublicenses: (i)
commercialize any formulation that includes Apaziquone outside the Field in the NK Territory; (ii)
develop or commercialize any formulation that includes Apaziquone for any field of use in the
Retained Territory (except having made the Product in the Retained Territory pursuant to Section
2.1(a)(i)(B)), to the extent such obligation is not in conflict with applicable antitrust Laws in
Japan; or (iii) commercialize another low-molecular intravesical therapeutic agent for the
treatment of non-muscle invasive bladder cancer in the NK Territory, except: (A) those which have
already been commercialized by NK before the Effective Date; and (B) doxorubicin. This Section 2.5
shall not be construed as expanding the scope of license granted to either Party under this Article
2 in any manner.

     2.6 Registration of License. NK shall have the right to record or register the licenses
granted hereunder, and allow its sublicensees to record or register the sublicenses granted under
the Sublicense Agreement, at any patent office or other relevant authority in the NK Territory.
Spectrum shall execute all documents and give all declarations regarding the licenses or
sublicenses and reasonably cooperate with NK or its sublicensees at the costs of NK or its
sublicensees to the extent such documents, declarations and/or cooperation are required for such
record or registration of the licenses or sublicenses for the benefit of NK or its sublicensees.

     2.7 Disclosure of Spectrum Know-How. Spectrum shall, as soon as practicable after the
Effective Date but in no event later than six (6) months after the Effective Date, and from time to
time thereafter during the Term, disclose to NK all Spectrum Know-How material or necessary for the
Development and Commercialization of the Product that are set forth on Exhibit D attached hereto.

11.

 

ARTICLE 3

OVERVIEW; MANAGEMENT

     3.1 Alliance Managers. Within thirty (30) days following the Effective Date, each Party will
appoint (and notify the other Party of the identity of) a representative having the appropriate
qualifications including a general understanding of pharmaceutical Development and
Commercialization issues to act as its alliance manager under this Agreement (“Alliance Manager”).
The Alliance Managers will serve as the primary contact points between the Parties for the purpose
of providing each Party with information on the progress of the other Party’s Development and
Commercialization of the Product(s). The Alliance Managers will also be primarily responsible for
facilitating the flow of information and otherwise promoting communication, coordination and
collaboration between the Parties, providing single point communication for seeking consensus both
internally within each Party’s respective organization, including facilitating review of external
corporate communications, and raising cross-Party and/or cross-functional disputes in a timely
manner. Each Party may replace its Alliance Manager on written notice to the other Party.

     3.2 Joint Product Team.

          (a) Formation. Within thirty (30) days after the Effective Date, the Parties will establish a
joint product team (the “Joint Product Team” or “JPT”) to plan, administer, evaluate and carry out
all aspects of the Development, manufacture, regulatory and Commercialization activities by NK or
its Affiliates hereunder with respect to the Products.

          (b) Members. The JPT will primarily consist of the internal product team of NK for the
Products, include members from various NK functional groups (e.g., research, preclinical, safety,
clinical, regulatory, marketing, manufacturing, as appropriate) which are or which will be expected
to be involved in Developing, manufacturing and/or Commercialization of the Product and obtaining
Regulatory Approval for the Product. Spectrum shall have the right (but not the obligation) to
have its representatives on the JPT who will from time to time represent some or all of the
following functional groups of Spectrum: clinical development, regulatory, medical affairs,
pharmacovigilance, commercial and manufacturing. NK will appoint a chair of the JPT.

          (c) Meetings. NK shall schedule the half-yearly JPT meetings and shall inform Spectrum of
such schedule at least quarterly in advance. Spectrum shall inform NK as to whether it will
participate in each of such JPT meetings reasonably in advance. Either Party may call additional
ad hoc meetings of the JPT as the needs arise with reasonable advance notice to the other Party,
and such ad hoc meetings shall be conducted at times that are mutually agreed upon by the Parties,
if Spectrum chooses to participate in such meeting. No later than five (5) business days prior to
any regularly scheduled meeting of the JPT, the chairperson of the JPT shall prepare and circulate
an agenda for such meeting and, as soon as practicable, all materials, documents and information
for the meeting for distribution to both Parties (in the case of Spectrum, even in the event
Spectrum chooses not to participate in such meeting); provided, however, that either Party may
propose additional topics to be included on such agenda, either prior to or in the course of such
meeting. The JPT may meet in person, by videoconference or by

12.

 

teleconference. The chairperson of the JPT will be responsible for preparing reasonably
detailed written minutes of all JPT meetings that reflect, without limitation, material decisions
made at such meetings. The JPT chairperson shall send draft meeting minutes to the NK members and
the Spectrum members of the JPT (regardless of whether Spectrum chooses to participate in such
meeting) for review and approval within ten (10) business days after each JPT meeting. Such
minutes will be deemed approved unless one or more members of the JPT objects to the accuracy of
such minutes within ten (10) business days of receipt. Further, upon NK’s request, Spectrum will
use commercially reasonable efforts to coordinate any meeting among Spectrum, Allergan and NK for
the exchange of information helpful for the Development of the Product. In addition to the
regularly scheduled meetings, NK shall call additional ad hoc meetings of the JPT prior to making
any major decisions in the Development of the Product in the NK Territory, including without
limitation the decisions set forth in Sections 3.2(d)(A) through (F) below. The Parties shall also
maintain regular, frequent and informal communications for Spectrum to obtain updates from NK and
for the Parties to discuss the progress of the Development of the Product in the NK Territory.

          (d) JPT Actions. The JPT shall strive to seek consensus in its actions and decision making
process. In the event of a disagreement between the Spectrum members and NK members of the JPT,
either Party may refer the matter to one senior executive of each Party (i.e., the Chief Executive
Officer or Managing Director of such Party or an executive of such Party who reports directly to
the Chief Executive Officer or Managing Director) for resolution. If such senior executives cannot
resolve the matter within ten (10) business days, then such senior executive of NK shall have the
final decision making authority on such matter, provided that any final determination made by such
senior executive of NK shall be consistent with the terms of this Agreement, further provided that
NK shall not make any decision with respect to the following critical issues without the consent of
Spectrum, such consent not to be unreasonably withheld or delayed: (A) discontinue the Development
of any Product; (B) initiate or discontinue any clinical trial; (C) modify the TPP of the Product
under Development; (D) unreasonably delay the process of or cease to seek Regulatory
Approval for any Product; (E) unreasonably delay or cancel the commercial launch of any Product;
and (F) remove any Product from the market, other than for safety reasons.

     3.3 Costs of Governance. The Parties agree that the costs incurred by each Party in
connection with its participation at any meetings under this Article 3 shall be borne solely by
such Party.

     3.4 Discontinuation of Participation in the JPT. Spectrum shall have the right, at any time
during the Term and in its sole discretion, to provide NK with written notice of its intention to
no longer participate in the JPT. Once Spectrum has provided such written notice to NK, NK shall
continue with the JPT structure with NK members only, and all decisions formerly made within or by
the JPT shall be determined by NK, consistent with the principles set forth in Sections 3.2(d). NK
will continue to provide Spectrum with Information provided to its members at such JPT meetings.

13.

 

ARTICLE 4

PRODUCT DEVELOPMENT

     4.1 Overview of Product Development. The Parties desire and intend to collaborate with
respect to the clinical development of the Product by or for NK or its Affiliates or sublicensees
in the NK Territory in the Field (including the clinical Development pursuant to Section
2.1(a)(ii)), with the oversight by the JPT, as and to the extent set forth in this Agreement. As
described in more detail in this Article 4, NK shall be solely responsible for the conduct of NK
Development Plan of the Product by or for NK or its Affiliates and for the overseeing of the
conduct of the Sublicensee Development Plan by its sublicensees, in order to obtain Regulatory
Approval for the Product in the NK Territory (including the clinical Development pursuant to
Section 2.1(a)(ii)). Spectrum will provide assistance to NK in an advisory role through the JPT.
The Parties agree that NK will seek the approval from the Regulatory Authority in Japan for the
final form of a Product to be used in clinical trials to be conducted to support Regulatory Filings
in Japan, and NK agrees to use the Product in such final form in connection with NK’s Development
activities in clinical trials conducted by or on behalf of NK to support Regulatory Filing
throughout the NK Territory. The Parties anticipate that NK will initially seek Regulatory
Approval for the Product in Closed-System Packaging.

     4.2 Development Plan.

          (a) General. As of the Effective Date, the Parties have agreed upon a development plan for
the Development of the Product in Japan, and such development plan is attached to this Agreement as
Exhibit E (the “NK Development Plan”). The NK Development Plan includes all clinical studies to be
performed for the Immediate Instillation Indication(s) and Multiple Instillation Indication(s),
including those that are required for Regulatory Approval for such indications for the Product(s)
in Japan. The development plan for the Development of the Product in the NK Territory other than
Japan will be, in accordance with Section 4.2(b): (i) prepared by NK to the extent such Development
activities are to be conducted by NK or its Affiliates, and such development plan shall be
incorporated into the NK Development Plan; and (ii) prepared with the input of sublicensees of NK
or its Affiliates to the extent such Development activities are to be conducted by such
sublicensees, and such development plan shall be deemed the “Sublicensee Development Plan”. The NK
Development Plan and the Sublicensee Development Plan are referred to collectively as the
“Development Plan” hereunder. The NK Development Plan and the Sublicensee Development Plan will
also set forth timelines regarding the activities set forth thereunder, respectively. The NK
Development Plan and Sublicensee Development Plan shall also each specify the plans and timeline
for preparing the necessary Regulatory Filings and for obtaining Regulatory Approval for such
Immediate Instillation Indication and such Multiple Instillation Indication in the respective
territories. NK shall conduct the Development activities in accordance with the then-current NK
Development Plan (including the timelines set forth therein) and under the direction of the JPT,
and NK shall oversee the Development activities in accordance with the then-current Sublicensee
Development Plan (including the timelines set forth therein) and under the oversight of the JPT.

          (b) Updates to Development Plan. From time to time during the Term, the JPT shall update and
amend (with input from the applicable sublicensees with respect to any

14.

 

Sublicensee Development Plan), as appropriate, the then-current Development Plan and submit
such updated or amended Development Plan for the Parties’ approval, such approval not to be
unreasonably withheld or delayed. Once approved by the Parties, each updated or amended
Development Plan shall become effective and supersede the previous Development Plan as of the date
of such approval.

4.3 NK Development Activities

          (a) NK shall Develop the Product and seek Regulatory Approval in each of the Immediate
Instillation Indication and the Multiple Instillation Indication in Japan, by timely and diligently
conducting all Development activities under the NK Development Plan (the “NK Development
Activities”). With respect to each of the Major Markets other than Japan, NK shall (i) Develop the
Product and seek Regulatory Approval in each of the Immediate Instillation Indication and the
Multiple Instillation Indication, or (ii) grant sublicenses to do so under Section 2.1(c), in
accordance with Section 4.3(c).

          (b) The status, progress and results of the Development activities in the NK Territory shall
be discussed at meetings of the JPT, and NK shall provide the JPT with a written report on the
status and progress of such Development activities on a half-yearly basis at least five (5)
business days prior to each scheduled JPT meeting. In addition, NK shall make available to
Spectrum such information about such Development activities as may be reasonably requested by
Spectrum from time to time.

          (c) NK shall: (i) in Japan, carry out the NK Development Activities in accordance with the NK
Development Plan; (ii) in mainland China, (A) grant a sublicense in accordance with Section 2.1(c)
to a sublicensee who will undertake to initiate activities under the applicable Sublicensee
Development Plan within [***] after the Effective Date or (B) initiate activities under the NK
Development Plan within [***] after the Effective Date; and (iii) in every country that is a Major
Market other than Japan and mainland China, initiate activities under the applicable Development
Plan within [***] after the first Regulatory Approval for the Product in the U.S., provided that,
NK may fulfill such obligation under this subsection (iii) within such timeframe in each such
country through a sublicensee pursuant to Section 2.1(c) if such sublicensee agrees to carry out
development activities pursuant to the applicable Sublicensee Development Plan. In the event NK
does not fulfill the foregoing obligation as set forth above within a particular country in the NK
Territory other than Japan, Spectrum may remove such country from the NK Territory by giving NK a
written notice to that effect. Notwithstanding anything to the contrary in this Agreement, in all
countries in the NK Territory other than Japan, Spectrum shall have no other remedy in respect of
the NK’s failure to fulfill the foregoing obligation, and for such NK’s failure NK’s sole liability
and the sole remedy of Spectrum shall be such removal of such country from the NK Territory.

     4.4 Compliance.

          (a) NK agrees that in performing its obligations under this Agreement: (i) it shall comply
with all applicable Laws; and (ii) it will not employ or engage any person who has

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

15.

 

been debarred by any Regulatory Authority, or, to such Party’s knowledge, is the subject of
debarment proceedings by a Regulatory Authority. NK shall have the right to engage subcontractors
for the performance of its obligations under the Development Plan. NK remains responsible for the
performance of such subcontractor(s) and the engagement of such subcontractors shall not relieve NK
from its obligations to comply with the terms and conditions of this Agreement.

          (b) NK shall maintain complete, current and accurate records of all work conducted by it under
the NK Development Plan, and all data and other Information resulting from such work. NK shall
cause the sublicensees to maintain complete, current and accurate records of all work conducted by
such sublicensees under the applicable Sublicensee Development Plan, and all data and other
Information resulting from such work. Such records shall fully and properly reflect all work done
and results achieved in the performance of the Development activities in good scientific manner
appropriate for regulatory purposes. Spectrum shall have the right to review all records
maintained by NK or such sublicensees at reasonable times, upon Spectrum’s written request.

          (c) NK shall document all preclinical studies and clinical trials conducted by or for it in
written study reports and shall provide Spectrum with a summary of each such report in English
promptly after its completion.

     4.5 Development Costs. As between the Parties, NK shall bear all Development Costs for the
Development: (a) conducted by or for NK and incurred by NK; or (b) conducted by Spectrum for NK at
the written request of or with the written consent of NK and incurred by Spectrum, in each case
after the Effective Date in connection with the research, manufacture and Development (including
development of manufacturing processes for the Products and other matters relating to the
chemistry, manufacture and controls of the Products) of the Products in accordance with the
Development Plan or the other provisions of this Agreement, as well as any other research,
manufacture and development of the Products by NK.

ARTICLE 5

REGULATORY MATTERS

     5.1 NK Regulatory Responsibilities.

          (a) NK shall own all Regulatory Filings and Regulatory Approvals for the Products in Japan,
and shall be solely responsible for preparing any and all Regulatory Filings for the Product in
Japan at its sole expense in accordance with the NK Development Plan, with the direction of the JPT
and subject to the terms of this Article 5. With respect to the countries in the NK Territory other
than Japan, the relevant Regulatory Filings and Regulatory Approvals for the Products shall be
owned by NK or NK’s sublicensees, and NK may delegate to its sublicensees the responsibility for
preparing any and all Regulatory Filings for the Product subject to the terms of this Article 5,
subject to Section 2.1(c), at the expense of NK or such sublicensees in accordance with the
Sublicensee Development Plan. Spectrum shall assist NK or

16.

 

its sublicensees as they may reasonably request in connection with the preparation and filing
of such Regulatory Filings, at NK’s or its sublicensees’ reasonable request and expense;

          (b) NK shall keep Spectrum informed of regulatory developments specific to Products throughout
the NK Territory, and Spectrum shall have the right to contribute to the regulatory plans and
strategies for the Products in the NK Territory;

          (c) NK shall, and shall ensure that its sublicensees will, lead discussions with any
Regulatory Authority related to any Development of any Products. NK will, and will cause its
sublicensees to, inform Spectrum of any such discussions in advance to the extent practicable, and
NK will, and will ensure that its sublicensees will, reasonably consider any input from Spectrum in
preparation for such discussions;

          (d) NK shall, and shall ensure that its sublicensees will, be responsible to ensure, at its
sole expense, that the Development, manufacture and Commercialization of the Products in the NK
Territory are in compliance with all applicable Laws, including without limitation all rules and
regulations promulgated by any of the Regulatory Authorities in the NK Territory. Specifically and
without limiting the foregoing, NK shall, and shall ensure that its sublicensees will, file all
compliance filings, certificates and safety reporting (subject to Section 5.2(a)) in the NK
Territory at its sole expense;

          (e) to the extent permitted by the applicable Regulatory Authority and as requested by
Spectrum, NK shall, and shall ensure that its sublicensees will, allow representatives of Spectrum
to participate in any scheduled conference calls and meetings between NK or its sublicensees and
the Regulatory Authority in the Major Markets at Spectrum’s expense. If Spectrum elects not to
participate in such calls or meetings, NK shall, and shall ensure that its sublicensees will,
provide Spectrum with written summaries of such calls and meetings in English as soon as
practicable after the conclusion thereof; and

          (f) with respect to all Regulatory Filings, NK shall, and shall ensure that its Affiliates and
sublicensees will: (i) submit only data and information that are free from fraud or material
falsity; (ii) not use bribery or the payment of illegal gratuities in connection with its
Regulatory Filings for the Product; and (iii) submit only data and information that are accurate
and reliable in all material respects for purposes of supporting Regulatory Approval.

     5.2 Adverse Events.

          (a) Within one (1) year prior to the planned first Regulatory Approval of the Product in the
NK Territory, the Parties shall discuss in good faith and enter into a pharmacovigilance and
adverse event reporting agreement setting forth the worldwide pharmacovigilance procedures for the
Parties with respect to the Product, such as safety data sharing, adverse events reporting and
prescription events monitoring (the “Pharmacovigilance Agreement”). Such Pharmacovigilance
Agreement shall govern the global pharmacovigilance procedures to be agreed upon by NK, Spectrum
and the commercial partners of each Party (including without limitation Allergan and the Korean
Partner).

          (b) Prior to the execution of such Pharmacovigilance Agreement, the Parties agree to
coordinate the pharmacovigilance procedures in connection with the Development of the

17.

 

Products, and NK shall submit to Spectrum all safety information and reporting in a manner
that meets the reporting requirements in the Retained Territory, as outlined in Exhibit F attached.
Each Party shall notify the other Party within twenty-four (24) hours of such Party’s learning of
any Serious Adverse Events (as defined below) that is attributed to or potentially attributable to
the use of the Products. Each Party shall also provide the other Party, on an annual basis and
more frequently as reasonably requested by the other Party, a summary report of Adverse Events (as
defined below), as well as those Serious Adverse Events that are not attributable to the use of the
Products. As used herein, unless defined differently by the FDA, “Adverse Events” means any side
effect, injury, toxicity or sensitivity reaction, or any unexpected incident, and the severity
thereof, whether or not determined to be attributable to any Product, and “Serious Adverse Events”
means an Adverse Event which results in death, is immediately life-threatening, results in
persistent and significant disability/incapacity or requires in-patient hospitalization or
prolongation of existing hospitalization.

          (c) After the execution of the Pharmacovigilance Agreement, the Parties shall comply with the
such Pharmacovigilance Agreement with respect to all aspects of pharmacovigilance activities with
respect to the Products, and Section 5.2(b) above shall be of no further effect.

     5.3 No Harmful Actions. If either Party believes that the other Party, as the case may be, is
taking or intends to take any action with respect to the Product that could reasonably be expected
to have a material adverse impact upon the regulatory status of the Product in the Retained
Territory or the NK Territory, such Party shall have the right to bring the matter to the attention
of the JPT. Without limiting the foregoing, unless the Parties otherwise agree: (a) except as
necessary for the clinical Development in South Korea pursuant to Section 2.1(a)(ii), NK shall not
communicate with any Regulatory Authority having jurisdiction in the Retained Territory, unless so
ordered by such Regulatory Authority, in which case NK shall provide immediately to Spectrum notice
of such order; and (b) NK shall not submit any Regulatory Filings (except as necessary for the
clinical Development in South Korea pursuant to Section 2.1(a)(ii)) or seek Regulatory Approvals
for the Product in the Retained Territory.

     5.4 Notification of Threatened Action. Each Party shall immediately notify the other Party of
any information it receives regarding any threatened or pending action, inspection or communication
by or from any party, including, without limitation, a Regulatory Authority, which may affect the
safety or efficacy claims of the Product or the continued marketing of the Product. Upon receipt
of such information, the Parties shall consult with each other in an effort to arrive at a mutually
acceptable procedure for taking appropriate action.

     5.5 Data Exchange and Use. This Section 5.5 shall not apply to any pharmacovigilance data
(which is addressed in Section 5.2). NK shall, and shall ensure that its sublicensees will,
provide Spectrum with copies of all final submissions and correspondence to and from all Regulatory
Authorities relating to the Product in the Field within seven (7) days of submission or receipt, as
applicable, and shall, and shall ensure that its sublicensees will, provide Spectrum a summary of
each significant submission (such as application for approval for clinical trials, Regulatory
Approval and fast track or orphan drug designation, the protocol for clinical trials and any
modifications thereof) in English as soon as practicable but in any event within ten (10) business
days after such submission. Each Party shall permit the other Party to access, and

18.

 

shall provide the other Party with rights to reference and use in association with the Product
in the Field, all of its, its Affiliates’, and its or their licensees’ and sublicensees’
regulatory, preclinical and clinical data documentation, Regulatory Filings, and Regulatory
Approvals with respect to the Product in the Field.

     5.6 Remedial Actions. Each Party will, and will ensure that its Affiliates and sublicensees
will, notify the other Party immediately, and promptly confirm such notice in writing, if it
obtains information indicating that the Product may be subject to any recall, corrective action or
other regulatory action with respect to a Product taken by virtue of applicable Law in the NK
Territory (a “Remedial Action”). The Parties (or NK’s sublicensees and Spectrum), as the case may
be, will assist each other in gathering and evaluating such information as is necessary to
determine the necessity of conducting a Remedial Action. NK shall, and shall ensure that its
Affiliates and sublicensees will, maintain or have maintained adequate records to permit the
Parties to trace the manufacture of the Product and the distribution and, to the extent feasible,
the use of the Product. In the event NK or its any sublicensee determines that any Remedial Action
with respect to the Product in the Field in the NK Territory should be commenced or Remedial Action
is required by any Regulatory Authority having jurisdiction over the matter, NK will, and will
ensure that its sublicensees will, as the case may be, control and coordinate all efforts necessary
to conduct such Remedial Action. In the event Spectrum determines that any Remedial Action with
respect to the Product outside the Field in the NK Territory should be commenced or Remedial Action
is required by any Regulatory Authority having jurisdiction over the matter, Spectrum will control
and coordinate all efforts necessary to conduct such Remedial Action. For clarity, as between the
Parties, Spectrum shall have sole discretion with respect to any matters relating to any Remedial
Action in the Retained Territory, except the Remedial Action relating to the manufacture of the
Product for NK in the Retained Territory pursuant to Section 2.1(a)(i)(B) or the clinical
Development by NK in South Korea pursuant to Section 2.1(a)(ii). The cost and expense of a
Remedial Action arising from the development, manufacture or commercialization of the Product in
the Field in the NK Territory shall be borne solely by NK or its sublicensees, unless, to the
extent the Product subject to such Remedial Action is supplied by Spectrum to NK, such Remedial
Action is caused by (i) such Product’s non-conformity to specifications at the time such Product is
delivered by Spectrum to NK or any of its Affiliates or sublicensees or (ii) such Product’s
manufacture not in compliance with applicable Laws including applicable Good Manufacturing
Practice.

ARTICLE 6

COMMERCIALIZATION

     6.1 Overview of Commercialization in the NK Territory. NK or its sublicensees will be solely
responsible for all aspects of the Commercialization of the Product in the Field in the NK
Territory, in compliance with all applicable Laws and, in case of Commercialization of the Product
in Japan, in accordance with a commercialization plan to be prepared by NK and approved by both
Parties (such approval not to be unreasonably withheld or delayed) prior to the First Commercial
Sale of the Product in Japan (the “Japan Commercialization Plan”), and in the case of each country
in the NK Territory outside of Japan where NK or any of its Affiliates or sublicensees has received
Regulatory Approval for the Product, in accordance with a commercialization plan to be prepared by
NK and/or such Affiliate or sublicensee, as applicable,

19.

 

and approved by the Parties and any applicable sublicensee (such approval not to be
unreasonably withheld or delayed) prior to the First Commercial Sale of the Product in such country
(such commercialization plans collectively, the “Outside Japan Commercialization Plan”, and
together with the Japan Commercialization Plan, the “Commercialization Plan”). Such
Commercialization Plan shall include the activities and timelines in preparation for the launch of
the Product and after such Product launch in the respective countries, and shall be updated on an
annual basis by NK or its sublicensees subject to the approval of the Parties, such approval not to
be unreasonably withheld or delayed. NK or its sublicensees shall book sales for the Products in
the NK Territory.

     6.2 NK Performance.

          (a) Commercial Diligence. NK shall Commercialize the Product in Japan in accordance with the
Japan Commercialization Plan. NK shall, by itself or through an Affiliate or sublicensee,
Commercialize the Product in other countries and territories in the NK Territory, in accordance
with the applicable Outside Japan Commercialization Plan. Without limiting the foregoing, NK shall
launch the first Product in at least one of the Major Markets (including Japan) within [***] after
obtaining relevant Regulatory Approval to do so, and, with respect to Commercialization in Japan,
after such launch, shall commit at least the same number of sales representatives, the same level
of resources and infrastructure in connection with the Commercialization of such Product as that
are expended by NK and comparable pharmaceutical companies having operations in Japan in connection
with the commercialization of products with similar market potential.

          (b) Reports. NK shall update Spectrum periodically regarding NK’s Commercialization
activities with respect to the Product in the NK Territory. In addition, NK shall present a
written report to Spectrum summarizing NK’s Commercialization activities with respect to the
Product in the NK Territory pursuant to this Agreement to the extent practicable, covering subject
matter at a level of detail reasonably requested by Spectrum and sufficient to enable Spectrum to
determine NK’s compliance with its diligence obligations pursuant to this Section 6.2. NK shall
provide such written reports on a quarterly basis for the Commercialization activities in Japan and
on an annual basis for the Commercialization activities in the other countries and territories in
the NK Territory.

     6.3 Trademark. NK shall have the right to brand the Products using NK related trademarks and
any other trademarks and trade names it determines appropriate for the Products in consultation
with Spectrum, which may vary by country or within a country (“Product Marks”). NK shall own all
rights in the Product Marks and register and maintain the Product Marks in the countries and
regions it determines reasonably necessary. NK shall not, and shall ensure that its Affiliates and
sublicensees will not, make any use of the trademarks assigned by Spectrum to Allergan under the
Allergan Agreement, or any trademark that includes any such trademark or is confusingly similar
thereto, on or in connection with the Commercialization of the Product in the NK Territory.

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

20.

 

ARTICLE 7

MANUFACTURING

     7.1 Overview. The Parties recognize that Spectrum manufactures the Products for the Retained
Territory through certain Third Party contract manufacturer(s) as of the Effective Date and may
engage other Third Party contract manufacturers after the Effective Date (collectively, the
“Manufacturers”). The Parties agree that Spectrum assists NK with the manufacture and supply of the
Product for use or sale by NK or its sublicensees in the NK Territory as follows:

          (a) Spectrum shall: (i) procure from Manufacturers and supply to NK all requirements (in
accordance with standard forecast terms) of the Product, in the form used by Spectrum and its
licensees in the Retained Territory at the time of such supply, for use by NK or its sublicensees
in conducting its or their Development activities under the Development Plan in the NK Territory
(including South Korea in case NK needs the Product for clinical Development pursuant to Section
2.1(a)(ii)); and (ii) procure from Manufacturers and supply to NK all requirements (in accordance
with standard forecast terms) of either the Brite Stock or Kitted Product (each as defined below),
pursuant to the Parties’ agreement as set forth below, for commercial sale by NK and its
sublicensees for a period of [***] after the First Commercial Sale (the “Initial Supply Period”) in
the NK Territory, and, subject to Section 7.1(c), for an additional [***] period after the Initial
Supply Period. “Brite Stock” means all components of the Kitted Product, including the drug vials
containing Apaziquone and the diluent vials, for incorporation into the final Kitted Product.
“Kitted Product” means the Brite Stock that has been labeled and packaged in final form ready for
sale. As soon as practicable after the Effective Date but in any event prior to the third
(3rd) anniversary of the Effective Date, the Parties shall discuss in good faith and
agree as to whether Spectrum will supply the Brite Stock or Kitted Product to NK under Section
7.1(a)(ii). If the Parties agree that Spectrum will supply NK with the Brite Stock, then NK or its
sublicensees will be responsible for the labeling and packaging of the Brite Stock into Kitted
Product for Development and commercial sale in the NK Territory, using such Brite Stock supplied by
Spectrum. Spectrum shall supply Brite Stock or Kitted Product to NK under Section 7.1(a) above at
[***] percent ([***]%) of Spectrum’s Cost of Goods Sold for such Products (i.e., if the Cost of
Goods Sold is $100, NK shall pay Spectrum $[***]).

          (b) Notwithstanding Section 7.1(a) above, in the event the form or packaging of the Product
used in the Development of the Product in the NK Territory or commercialized in the NK Territory is
different from the form or packaging of the product used by Spectrum or its commercial partners in
the Retained Territory, then Spectrum’s obligation to supply as set forth above shall apply only
with respect to Apaziquone and the Parties shall discuss in good faith to allocate the
responsibilities for the fill and finish of the Product in such alternative form or packaging.
Spectrum will consult with NK as to the selection of packaging materials for the Product or
materials used in the components of the Product and will take into consideration NK’s comments in
such consultation. For clarity, for the purpose of this Section 7.1(b), so long as the

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

21.

 

components of the Product are same, Brite Stock shall not be deemed to be different from
Kitted Product and vice versa.

          (c) Notwithstanding the provisions of 7.1(a)(ii), in the event, at Spectrum’s reasonable
determination, it is no longer practicable for Spectrum to continue to supply NK with commercial
supply under Section 7.1(a)(ii) after the Initial Supply Period, (for reasons including, but not
limited to, the termination of Spectrum’s agreement with a Manufacturer or Allergan’s assumption of
manufacturing obligations outside of Asia), Spectrum shall inform NK in writing of its desire to
cease such supply at the end of the Initial Supply Period (or anytime thereafter) at least eighteen
(18) months prior to the end of the Initial Supply Period (or at least eighteen (18) months prior
to such later time) and may cease the supply of the Product (Brite Stock or Kitted Product) at the
end of the Initial Supply Period (or such later time). In such event, (1) Spectrum shall ensure
that NK enters into direct supply agreement(s) with Spectrum’s then-current Manufacturer(s) for the
supply of the same Brite Stock or Kitted Product for at least an additional [***] period after the
Initial Supply Period on the terms and conditions similar to those which Spectrum used to be
provided with during the Initial Supply Period, (2) Spectrum shall arrange the supply of such
Product (Brite Stock or Kitted Product) from the then-current Manufacturer(s) to NK until such time
NK has entered into such direct supply agreement(s) with such Manufacturers, so that NK and its
sublicensees are able to continue to sell such Product in the NK Territory without interruption and
(3) NK shall cooperate with Spectrum in such arrangements.

     7.2 Manufacturing Technology Disclosure. As soon as practicable after the Effective Date but
no later than sixty (60) days after the Effective Date in any event, Spectrum shall make available
and transfer copies to NK of the Spectrum Technology that are necessary or reasonably useful in the
manufacture of Product and as of the Effective Date are being used by Spectrum or its Manufacturers
to manufacture Product, as set forth in Exhibit G, including without limitation Drug Master File of
the Product if applicable (the “Spectrum Manufacturing Know-How”). During the Term, Spectrum shall
continue to provide information relating to the chemistry, manufacture and control of the Product,
and NK shall promptly provide Spectrum with its feedback and/or comments to such information
relating to the supply of Product for the NK Territory. During the Initial Supply Period, if NK
desires to assume the responsibility to procure the Product for the NK Territory by itself, NK
shall notify Spectrum in writing, and, upon Spectrum’s agreement, the Parties shall discuss in good
faith with respect to an orderly transfer of such responsibility from Spectrum to NK.

     7.3 Manufacture of Product by Spectrum or its Manufacturer. Spectrum shall manufacture or
procure the manufacture of the Product to be supplied to NK hereunder in accordance with applicable
Good Manufacturing Practice, other applicable Laws and specifications of the Product agreed by the
Parties. If Spectrum or its Manufacturers intend to make a change to (a) manufacturing site of the
Product, (b) manufacturing process of the Product or (c) such specification, Spectrum shall
promptly notify NK of such change and shall provide NK with all information and data obtained by
any tests conducted by or on behalf of Spectrum in respect of any such proposed change for the
purpose of NK or its sublicensees applying for an amendment to any Regulatory Approval of the
Product in the NK Territory which is required

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

22.

 

with respect to such change. Further, Spectrum shall provide NK with test samples manufactured
at the proposed manufacturing site or in accordance with such proposed new process or proposed new
specification for the purpose of NK or its sublicensees applying for such amendment. NK shall use
commercially reasonable best efforts to complete the amendment process with the relevant Regulatory
Authority as quickly as possible, and shall notify Spectrum immediately on receipt by NK of
notification from the relevant Regulatory Authority that such amendment has been completed.
Spectrum shall not supply any Product manufactured with such change until such time as NK or its
sublicensees are notified by the Regulatory Authority that such amendment has been completed. Until
such time as NK or its sublicensees are notified by the Regulatory Authority that such amendment
has been completed, Spectrum shall use commercially reasonable best efforts to continue to supply
NK with the Product manufactured at the current manufacturing site in accordance with the current
process and specifications. Spectrum shall be responsible for and shall bear the costs for (as
part of the Costs of Goods Sold) the delivery of the Product to airport(s) from where such Product
will be exported to NK, where the title to such Product and the risk of loss and damage shall
transfer to NK and NK shall bear the costs of the shipment of such Product thereafter (including
the cost for air transportation).

     7.4 Regulatory Inspections. Each Party shall use good faith efforts to obtain and reveal to
the other Party, all inspection reports for itself, its Affiliates, or for any of its vendors,
suppliers or other Third Parties by any Regulatory Authority arising from an inspection of the
facilities where a Product is manufactured, packaged or stored (a “Facility Inspection”), and the
progress and outcome of any Facility Inspection as it may relate to the Product. Upon receipt of
notice of any Facility Inspection, the receiving Party will promptly notify the other Party thereof
and the receiving Party will provide the other Party with the inspection report and any other
relevant information available about the progress and outcome of such inspection available to the
receiving Party.

     7.5 Audits. Each Party and its duly authorized representatives shall have the right to
inspect all facilities utilized by the other Party or any of its subcontractors (either directly or
with the contracting Party, as permitted in the agreement governing the engagement of such
subcontractor) in connection with the development, manufacture, sale, storage or distribution of
the Product in the NK Territory, upon reasonable prior written notice during normal business hours
to ensure compliance with the terms and conditions of this Agreement, and compliance with industry
standard and applicable Law. For clarity, NK shall have the right to inspect facilities of
Spectrum or its subcontractors where the Product is manufactured or stored for supply to NK and
facilities of the manufacture and storage of Apaziquone which is used for the manufacture of the
Product for NK Territory. All audits shall be without any undue disruption to the business and
operations of the audited Party, and in the case of an inspection involving facilities of a
subcontractor of Spectrum, consistent with the terms under the applicable agreement between
Spectrum and such subcontractor, and the Allergan Agreement to the extent applicable. Any Third
Parties conducting such audits shall enter into confidentiality agreements with the audited Party
in a form suitable to the audited Party, and all information or reports gained by the auditing
Party as a result of such audit shall be deemed Confidential Information of the audited Party. In
the event of a disagreement between the Parties as to the outcome of a particular audit, an
independent, mutually agreed upon arbiter shall be selected by the Parties to resolve the dispute.
The cost of such arbiter shall be borne by the Party whose position is overruled by such arbiter.
Spectrum shall have the right to appoint Allergan as its authorized

23.

 

representative for the purpose of this Section 7.5.

ARTICLE 8

FINANCIAL PROVISIONS

     8.1 Upfront Fee. After the sixtieth (60th) day after the Effective Date and before
the seventy-fifth (75th) day after the Effective Date, NK shall pay to Spectrum a
one-time, non-refundable and non-creditable upfront fee of fifteen million Dollars ($15,000,000).

     8.2 Milestone Payments. NK shall make the following non-refundable and non-creditable
milestone payments to Spectrum within [***] after the first achievement of each milestone event for
a Product as set forth in this Section 8.2 by NK, its Affiliates or sublicensees. Each milestone
payment by NK to Spectrum hereunder shall be payable only once, regardless of the number of times
achieved by the Products, provided that, if more than one sales milestones that are triggered by
annual aggregate Net Sales that have not been previously paid are triggered at the end of any
particular calendar year, then each and every of such sales milestones shall be deemed to have been
achieved upon the end of such calendar year and the corresponding milestone payments triggered by
each and every of such sales milestones shall become due at the end of such calendar year.

	 	 	 
	Milestone Event	 	Milestone Payment
	Regulatory Milestones

	Regulatory Approval of a Product in the United States
for the Immediate Instillation Indication

	 	$[***]
	Regulatory Approval of a Product in the United States
for a Multiple Instillation Indication

	 	$[***]
	First NDA Filing for a Product in Japan

	 	$[***]
	First Regulatory Approval for a Product in Japan

	 	$[***]
	First Regulatory Approval for a Product in the NK 

Territory excluding Japan

	 	$[***]
	Sales Milestones

	The aggregate Net Sales of all Products in Japan during
the Term equal or exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in Japan during
the Term equal or exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in Japan during
any calendar year equal or exceed $[***]

	 	$[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

24.

 

	 	 	 
	Milestone Event	 	Milestone Payment
	The aggregate Net Sales of all Products in Japan during
any calendar year equal or exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in Japan during
any calendar year equal or exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in the NK
Territory (excluding Japan) during the Term equal or
exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in the NK
Territory (excluding Japan) during the Term equal or
exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in the NK
Territory (excluding Japan) during any calendar year
equal or exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in the NK
Territory (excluding Japan) during any calendar year
equal or exceed $[***]

	 	$[***]
	The aggregate Net Sales of all Products in the NK
Territory (excluding Japan) during any calendar year
equal or exceed $[***]

	 	$[***]

     8.3 Royalties.

          (a) Royalty Rates. NK shall pay to Spectrum a running royalty at the following royalty rates,
on Net Sales of the Products in all countries of the NK Territory during the Royalty Term.

	 	 	 
	Aggregate Annual Net Sales of all Products in the	 	Royalty Rate Applicable to All
	NK Territory for a Particular Calendar Year	 	Net Sales in such Calendar Year
	For a calendar year in which the
aggregate annual Net Sales
throughout the NK Territory are less
than $[***]

	 	[***]%
	For a calendar year in which the
aggregate annual Net Sales
throughout the NK Territory equal to
or greater than $[***]

	 	[***]%

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

25.

 

     For clarity, for each calendar year, NK shall initially calculate its royalty payments to
Spectrum and submit such royalty payments at the royalty rate of [***]% until the aggregate annual
Net Sales for all Products throughout the NK Territory reaches $[***]. Thereafter, NK shall
calculate royalty payments to Spectrum and submit such royalty payments at the royalty rate of
[***]%. In addition, NK shall submit to Spectrum a true-up payment at the end of the calendar
quarter during which such aggregate annual Net Sales reaches $[***], in the amount of $[***].

          (b) Royalty Term. The royalty payment obligation under Section 8.3 shall be due, on a
country-by-country basis, during the period of time beginning upon the First Commercial Sale of the
Product in such country, and ending upon the later of (i) the expiration of the last-to-expire
Valid Claim covering the Product sold in such country; (ii) the expiration of Regulatory
Exclusivity covering the Product sold in such country; and (iii) the tenth (10th)
anniversary after the First Commercial Sale of the Product in such country (the “Royalty Term”).

          (c) Royalty Payments and Reports. NK shall deliver to Spectrum a report containing the
following information for the prior calendar quarter: (i) the gross sales associated with each
Product sold by NK, its Affiliates and sublicensees; (ii) a calculation of Net Sales of each
Products that are sold by NK, its Affiliates and (if applicable) sublicensees; and (iii) a
calculation of payments due to Spectrum with respect to the foregoing. NK shall use commercially
reasonable efforts to deliver the foregoing report to Spectrum within thirty-five (35) days after
the end of such calendar quarter, but in any event NK shall provide to Spectrum such report within
forty-five (45) days after the end of such calendar quarter. If, despite commercially reasonable
efforts, NK is unable to provide Spectrum with such report within the foregoing thirty-five (35)
day period, NK shall provide Spectrum with a report containing reasonable estimates of the amounts
described in subsections (i) through (iii) above by the end of such thirty-five (35) day period for
Spectrum to comply with its quarterly reporting obligations. Within sixty (60) days after the end
of each calendar quarter, NK shall remit to Spectrum any payment due for the applicable calendar
quarter. If no royalties are due to Spectrum for such reporting period, the report shall so state.
The method of payment shall be wire transfer to an account specified in writing by Spectrum.

     8.4 Foreign Exchange. The rate of exchange to be used in computing the amount of currency
equivalent in Dollars of Net Sales invoiced in other currencies shall be made at the average of the
closing exchange rates reported in The Wall Street Journal (U.S., Western Edition) over the
applicable reporting period for the payment due.

     8.5 Payment Method; Late Payments. All payments due to Spectrum hereunder shall be made by
wire transfer of immediately available funds into an account designated by Spectrum. If Spectrum
does not receive payment of any sum due to it on or before the due date, simple interest shall
thereafter accrue on the sum due to Spectrum until the date of payment at the per annum rate of
[***] percent ([***]%) over the then-current prime rate reported in The

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

26.

 

Wall Street Journal (U.S., Western Edition) or the maximum rate allowable by applicable Law,
whichever is lower.

     8.6 Records; Audits. NK will, and will assure that its sublicensees will, maintain complete
and accurate records in sufficient detail to permit Spectrum to confirm the accuracy of the
calculation of royalty payments under this Agreement. Upon reasonable prior notice, such records
shall be available during regular business hours for a period of three (3) years from the end of
the calendar year to which they pertain for examination at the expense of Spectrum, and not more
often than once each calendar year, by an independent certified public accountant selected by
Spectrum and reasonably acceptable to NK or its sublicensees, for the sole purpose of verifying the
accuracy of the financial reports furnished by NK pursuant to this Agreement. Any such auditor
shall not disclose to Spectrum NK’s Confidential Information or sublicensees’ confidential
information, except to the extent such disclosure is necessary to verify the accuracy of the
financial reports furnished by NK or the amount of payments due by NK under this Agreement. Any
amounts shown to be owed but unpaid shall be paid within [***] from the receipt by NK of the
accountant’s report, plus interest (as set forth in Section 8.5) from the original due date. If
such audit discloses an underpayment by NK of more than [***] percent ([***]%), then NK shall also
pay to Spectrum a premium equal to [***] percent ([***]%) of such underpayment. Spectrum shall
bear the full cost of such audit unless such audit discloses an underpayment by NK of more than
[***] percent ([***]%) of the amount due, in which case NK shall bear the full cost of such audit.

     8.7 Taxes.

          (a) Taxes on Income. Each Party shall be solely responsible for the payment of all taxes
imposed on its share of income arising under this Agreement or directly or indirectly from the
efforts of the Parties under this Agreement.

          (b) Tax Responsibility. The Parties understand that, in accordance with the applicable Laws
existing as of the Effective Date, none of the payments to be submitted by NK to Spectrum under
Sections 8.1, 8.2 and/or 8.3 shall be subject to any deduction of tax or withholding tax.
Consequently, NK shall submit to Spectrum the upfront fee under Section 8.1 above without any
deduction or withholding. If, after the Effective Date, as a result of any modification to the
applicable Laws, any payment required to be made by NK to Spectrum (other than the upfront fee
under Section 8.1) is subject to a deduction of tax or withholding tax, NK may deduct such tax or
withholding tax.

          (c) Tax Cooperation. The Parties agree to cooperate with one another and use reasonable
efforts to reduce or eliminate tax withholding or similar obligations in respect of royalties,
milestone payments, and other payments made by NK to Spectrum under this Agreement. To the extent
NK is required to deduct and withhold taxes on any payment to Spectrum, NK shall pay the amounts of
such taxes to the proper Governmental Authority in a timely manner and promptly transmit to
Spectrum an official tax certificate or other evidence of such withholding sufficient to enable
Spectrum to claim such payment of taxes. Spectrum shall provide NK any tax forms that may be
reasonably necessary in order for NK to not withhold tax

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

27.

 

or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.
Spectrum shall use reasonable efforts to provide any such tax forms to NK at least thirty (30) days
prior to the due date for any payment for which Spectrum desires that NK applies a reduced
withholding rate. Each Party shall provide the other with reasonable assistance to enable the
recovery, as permitted by applicable law, of withholding taxes, value added taxes, or similar
obligations resulting from payments made under this Agreement, such recovery to be for the benefit
of the Party bearing such withholding tax or value added tax. NK shall require its sublicensees in
the NK Territory to cooperate with Spectrum in a manner consistent with this Section 8.7(c).

ARTICLE 9

INTELLECTUAL PROPERTY

     9.1 Ownership of Inventions. Each Party shall own any inventions made solely by its own
employees, agents, or independent contractors in the course of conducting its activities under this
Agreement, together with all intellectual property rights therein (“Sole Inventions”). The Parties
shall jointly own any inventions that are made jointly by employees, agents, or independent
contractors of each Party in the course of performing activities under this Agreement, together
with all intellectual property rights therein (“Joint Inventions”). Inventorship shall be
determined in accordance with U.S. patent laws. All Patents claiming patentable, jointly owned
Joint Inventions shall be referred to herein as “Joint Patents.” Except to the extent otherwise
set forth in this Agreement, each Party shall be entitled to practice and exploit (including
through the grant of licenses) the Joint Inventions without the duty of accounting or seeking
consent from the other Party.

     9.2 Disclosure of Inventions. Each Party shall promptly disclose to the other Party any
invention disclosures, or other similar documents, submitted to it by its employees, agents or
independent contractors describing inventions that are either Sole Inventions or Joint Inventions.
Further, each Party shall promptly disclose to the other Party all Information relating to Joint
Inventions to the extent necessary for the preparation, filing and maintenance of any Joint Patent
with respect to such Joint Invention.

     9.3 Prosecution of Patents.

          (a) Spectrum Patents.

               (i) Subject to Sections 9.3(a)(ii). 9.3(a)(iii) and 9.3(a)(iv) below, Spectrum shall have the
sole right to prepare, file, prosecute and maintain Spectrum Patents and Joint Patents
(collectively, the “Spectrum Prosecuted Patents”). Spectrum shall provide NK reasonable
opportunity to review and comment on such prosecution efforts regarding such Spectrum Prosecuted
Patents in the NK Territory. Spectrum shall provide NK with a copy of material communications from
any patent authority in the NK Territory regarding such Spectrum Prosecuted Patents, and shall
provide drafts of any material filings or responses to be made to such patent authorities a
reasonable amount of time in advance of submitting such filings or responses for NK’s review and
comment. Spectrum shall reasonably consider such comments by

28.

 

NK in connection with the prosecution of Spectrum Prosecuted Patents.

               (ii) The costs and expenses incurred after the Effective Date by Spectrum in connection with
the preparation, filing, prosecution and maintenance of Spectrum Patents and Joint Patents under
Section 9.3(a)(i) above shall be allocated between the Parties as follows: (A) NK shall reimburse
Spectrum for all out-of-pocket costs incurred by Spectrum in connection with the preparation,
filing, prosecution and maintenance of: (1) the [***] in the [***]; (2) the [***] in [***]; and (3)
the [***], and Spectrum shall bear its internal costs incurred in connection with the activities
set forth in [***]; (B) Spectrum shall bear its own internal and out-of-pocket costs incurred: (1)
in connection with the preparation, filing, prosecution and maintenance of [***] in [***]; and (2)
in connection with the preparation, filing, prosecution and maintenance of [***] in the [***]; and
(C) [***], NK may request that Spectrum prepare, file, prosecute and maintain [***] in such country
provided that NK reimburses Spectrum for all out-of-pocket costs incurred by Spectrum in connection
with such activities. Notwithstanding the foregoing, NK shall have the right to opt out of its
payment obligations for the [***] under [***] by providing Spectrum with written notification
thereof, and NK hereby assigns to Spectrum all of its rights and interests in such [***], effective
upon Spectrum’s receipt of such notification.

               (iii) If Spectrum wishes to cease the prosecution or maintenance of any Spectrum Prosecuted
Patents in the NK Territory, it shall notify NK to that effect in writing, and NK may, at its
discretion, assume the rights to the prosecution or maintenance of such Spectrum Prosecuted
Patents, at NK’s sole expense, by informing Spectrum in writing within sixty (60) days after
receiving such notification from Spectrum. If NK notifies Spectrum of its intention to assume such
rights, Spectrum shall assign to NK all rights and interests in and to such Spectrum Prosecuted
Patents, and NK hereby grants to Spectrum a royalty-free, fully-paid, worldwide, perpetual,
irrevocable, non-exclusive license, with the right to grant sublicenses, under such Spectrum
Prosecuted Patents so assigned to NK for all purposes other than to develop, make, have made, use,
sell, offer for sale or import the Product in the Field in the NK Territory.

               (iv) Spectrum shall not assign or transfer Spectrum’s rights and interests in and to the
Spectrum Technology to any Third Party in conflict with the terms of this Agreement; provided,
however, that Spectrum shall assign and transfer Spectrum’s all rights and interests in and to the
Spectrum Technology to the Third Party when Spectrum assigns or transfers this Agreement to such
Third Party pursuant to Section 15.5.

          (b) NK Patents.

               (i) NK shall have the sole right to prepare, file, prosecute and maintain NK Patents at NK’s
costs and expense.

               (ii) If NK decides to cease the prosecution or maintenance of any NK Patents, it shall notify
Spectrum in writing sufficiently in advance. Spectrum may, at its discretion, assume the rights to
the prosecution or maintenance of such NK Patents, at Spectrum’s sole expense by informing NK in
writing within sixty (60) days after receiving such

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

29.

 

notification from NK, in which event NK shall assign to Spectrum all rights and interests in
and to such NK Patents.

          (c) Cooperation in Prosecution. Each Party shall provide the other Party all reasonable
assistance and cooperation with respect to the assignment of Spectrum Prosecuted Patents by
Spectrum to NK or the assignment of NK Patents by NK to Spectrum pursuant to Sections 9.3(a) or
9.3(b), as the case may be, including providing any documents necessary to complete such
assignments.

     9.4 Infringement of Patents by Third Parties.

          (a) Notification. Each Party shall promptly notify the other Party in writing of any existing
or threatened infringement of the Spectrum Patents through the Development or Commercialization of
a Product in the Field in the NK Territory by a Third Party, of which such Party becomes aware,
including any certification or the like in the NK Territory similar to “patent certification” of 21
U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) and of any declaratory judgment, opposition, or similar
action alleging the invalidity, unenforceability or non-infringement of any of the Spectrum Patents
(collectively “Product Infringement”).

          (b) Product Infringement.

               (i) For any Product Infringement in the Field in the NK Territory, each Party shall share with
the other Party all Information available to it regarding such existing or threatened infringement.
NK shall have the first right, but not the obligation, to bring an appropriate suit or other action
against any person or entity engaged in such Product Infringement, subject to Section 9.4(b)(ii)
through 9.4(b)(iv), below. If NK fails to institute and prosecute an action or proceeding to abate
such Product Infringement within a period of ninety (90) days after the first notice under Section
9.4(a) to elect to enforce such Spectrum Patent or otherwise having knowledge of such Product
Infringement, then Spectrum shall have the right, but not the obligation to, commence a suit or
take action to enforce the applicable Spectrum Patent against such Third Party perpetrating such
Product Infringement in the NK Territory at its own cost and expense. In this case, NK shall take
appropriate actions, if any, in order to enable Spectrum to commence a suit or take the actions set
forth in the preceding sentence.

               (ii) Each Party shall provide to the Party enforcing the Spectrum Patent under this Section
9.4(b) reasonable assistance in such enforcement, at such enforcing Party’s request and expense,
including joining such action as a party plaintiff if required by applicable Law to pursue such
action. The enforcing Party shall keep the other Party regularly informed of the status and
progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any
such efforts, and shall seek consent of the other Party in any important aspects of such
enforcement including, without limitation, determination of litigation strategy, filing of
important papers to the competent court, which shall not be unreasonably withheld or delayed.

               (iii) Each Party shall bear all of its own internal costs incurred in connection with its
activities under this Section 9.4(b). In the event NK commences a Product Infringement action, it
shall bear all external costs and expenses for such action. In the event

30.

 

that Spectrum commences a Product Infringement action, it shall bear all external costs and
expenses for such action.

               (iv) The Party not bringing an action with respect to Product Infringement under this Section
9.4(b) shall be entitled to separate representation in such matter by counsel of its own choice and
at its own expense, but such Party shall at all times cooperate fully with the Party bringing such
action.

          (c) Infringement Other Than a Product Infringement. For any and all infringement of any
Spectrum Patent other than a Product Infringement in the Field in the NK Territory, as between the
Parties, Spectrum shall have the sole and exclusive right to bring an appropriate suit or other
action against any person or entity engaged in such other infringement, in its sole discretion, and
as between the Parties shall bear all related expenses and retain all related recoveries.

          (d) Settlement. NK shall not settle any claim, suit or action that it brought under this
Section 9.4 involving Spectrum Patents in any manner that would negatively impact such Spectrum
Patents or that would limit or restrict the ability of Spectrum to Develop, make, import, use,
offer for sale, sell or otherwise Commercialize Products anywhere in the Retained Territory or to
make or have made Product anywhere in the world for such Development, use, sale or import anywhere
in the Retained Territory, without the prior written consent of Spectrum, which consent shall not
be unreasonably withheld or delayed. Nothing in this Article 9 shall require Spectrum to consent
to any settlement that is reasonably anticipated by Spectrum to have a substantially adverse impact
upon any Spectrum Patent in the Retained Territory, or to the commercialization, manufacture, use,
importation, offer for sale or sale of the Product in the Retained Territory.

          (e) Allocation of Recoveries. [***].

     9.5 Infringement of Third Party Rights in the NK Territory. If any Product used or sold by
NK, its Affiliates or sublicensees becomes the subject of a Third Party’s claim or assertion of
infringement of a Patent granted by a jurisdiction within the NK Territory, NK shall promptly
notify Spectrum thereof and [***].

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

31.

 

ARTICLE 10

REPRESENTATIONS AND WARRANTIES

     10.1 Mutual Representations and Warranties. Each Party hereby represents, warrants, and
covenants (as applicable) to the other Party as follows:

          (a) Corporate Existence and Power. It is a company or corporation duly organized, validly
existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and
has full corporate power and authority and the legal right to own and operate its property and
assets and to carry on its business as it is now being conducted and as contemplated in this
Agreement, including, without limitation, the right to grant the licenses granted by it hereunder.

          (b) Authority and Binding Agreement. As of the Effective Date, (i) it has the corporate power
and authority and the legal right to enter into this Agreement and perform its obligations
hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the
execution and delivery of this Agreement and the performance of its obligations hereunder; and
(iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes
a legal, valid, and binding obligation of such Party that is enforceable against it in accordance
with its terms.

          (c) No Conflict; Covenant. It is not a party to any agreement that would materially prevent
it from granting the rights granted to the other Party under this Agreement or performing its
obligations under this Agreement.

          (d) No Debarment. In the course of the development of Products, each Party shall not use,
during the Term, any employee or consultant who has been debarred by any Regulatory Authority, or,
to the best of such Party’s knowledge, is the subject of debarment proceedings by a Regulatory
Authority.

     10.2 Additional Representations and Warranties of Spectrum. Spectrum represents and warrants
to NK that, as of the Effective Date:

          (a) it has the right under the Spectrum Technology to grant the licenses to NK as purported to
be granted pursuant to this Agreement;

          (b) as of the Effective Date, Spectrum or its licensee has not received any written notice
from any Third Party asserting or alleging that any research or development of any Product by
Spectrum or its licensee prior to the Effective Date infringed or misappropriated the intellectual
property rights of such Third Party; and

          (c) there are no actual, pending, alleged or threatened adverse actions, suits, claims,
interferences or formal governmental investigations involving the Product and/or the Spectrum
Technology relating to the Product by or against Spectrum or any of its Affiliates or licensees in
or before any court, governmental or regulatory authority.

32.

 

     10.3 Disclaimer. NK understands that the Products are the subject of ongoing clinical
research and development and that Spectrum cannot assure the safety or efficacy of the Products.
In addition, Spectrum makes no warranties except as set forth in this Article 10 concerning the
Spectrum Technology.

     10.4 No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS
AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING,
WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, IS MADE OR
GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES OTHER THAN THOSE EXPRESSLY
STATED IN THIS AGREEMENT, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY
EXCLUDED.

ARTICLE 11

INDEMNIFICATION

     11.1 Indemnification by Spectrum. Spectrum hereby agrees to defend, hold harmless and
indemnify (collectively “Indemnify”) NK and its Affiliates, sublicensees, agents, directors,
officers and employees (the “NK Indemnitees”) from and against any and all liabilities, expenses
and/or losses, including without limitation reasonable legal expenses and attorneys’ fees
(collectively “Losses”) in each case resulting from Third Party suits, claims, actions and demands
(each, a “Third Party Claim”) arising directly or indirectly out of (a) a breach of any of
Spectrum’s obligations under this Agreement, including without limitation Spectrum’s
representations and warranties or covenants set forth in Article 10, or (b) the negligence or
willful misconduct of any Spectrum Indemnitee. Spectrum’s obligation to Indemnify the NK
Indemnitees pursuant to this Section 11.1 shall not apply to the extent that any such Losses arise
from: (A) the negligence or willful misconduct of any NK Indemnitees; (B) the research, Development
or Commercialization of Products by NK or its Affiliates, or sublicensees in the NK Territory
without negligence or willful misconduct of any Spectrum Indemnitee and Spectrum’s breach of this
Agreement; or (C) NK’s breach of this Agreement.

     11.2 Indemnification by NK. NK hereby agrees to Indemnify Spectrum and its Affiliates,
licensees, agents, directors, officers and employees (the “Spectrum Indemnitees”) from and against
any and all Losses resulting from Third Party Claims arising directly or indirectly out of (a) a
breach of any obligations of NK under this Agreement, including without limitation NK’s
representations and warranties or covenants set forth in Article 10; (b) the research, Development,
manufacture or Commercialization of Products by NK or its Affiliates or sublicensees in the NK
Territory (including any activities undertaken by Spectrum under this Agreement at the direction of
or on behalf of NK); or (c) the negligence or willful misconduct of NK Indemnitees. NK’s
obligation to Indemnify the Spectrum Indemnitees pursuant to the foregoing sentence shall not apply
to the extent that any such Losses arise from: (A) the negligence or willful misconduct of any
Spectrum Indemnitees; or (B) Spectrum’s breach of this Agreement.

33.

 

     11.3 Procedure. The indemnified Party shall provide the indemnifying Party with prompt
notice of the claim giving rise to the indemnification obligation pursuant to this Article 11 and
the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or
settle any such claim; provided, however, that the indemnifying Party shall not enter into any
settlement for damages other than monetary damages without the indemnified Party’s written consent,
such consent not to be unreasonably withheld. The indemnified Party shall have the right to
participate, at its own expense and with counsel of its choice, in the defense of any claim or suit
that has been assumed by the indemnifying Party. If the Parties cannot agree as to the application
of Sections 11.1 and 11.2 to any particular Third Party Claim, the Parties may conduct separate
defenses of such Third Party Claim. Each Party reserves the right to claim indemnity from the
other in accordance with Sections 11.1 and 11.2 above upon resolution of the underlying claim,
notwithstanding the provisions of this Section 11.3 requiring the indemnified Party to tender to
the indemnifying Party the exclusive ability to defend such claim or suit.

     11.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL,
INCIDENTAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES OR LOSS OF PROFITS ARISING FROM OR
RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH
DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT
OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 OR 11.2, OR
DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 12, PROVIDED THAT
A PARTY’S LIABILITY TO THE OTHER PARTY UNDER THIS SENTENCE SHALL NOT EXCEED $10,000,000, EXCEPT
WHEN SUCH LIABILITY ARISES FROM SUCH PARTY’S INTENTIONAL BREACH OF, OR WILLFUL MISCONDUCT
REGARDING, ITS OBLIGATIONS UNDER ARTICLE 12, IN WHICH CASE THERE SHALL BE NO LIMIT TO SUCH
LIABILITY.

     11.5 Insurance. Each Party shall procure and maintain insurance, including product liability
insurance, adequate to cover its obligations hereunder and which are consistent with normal
business practices of prudent companies similarly situated at all times during which any Product is
being clinically tested in human subjects or commercially distributed or sold by such Party. It is
understood that such insurance shall not be construed to create a limit of either Party’s liability
with respect to its indemnification obligations under this Article 11. Each Party shall provide
the other Party with written evidence of such insurance upon request, if insurance company so
agrees. Each Party shall provide the other Party with written notice at least thirty (30) days
prior to the cancellation, non-renewal or material change in such insurance or self-insurance which
materially adversely affects the rights of the other Party hereunder.

ARTICLE 12

CONFIDENTIALITY

     12.1 Confidentiality. Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and
shall not publish or otherwise disclose and shall not use for any purpose other than as provided

34.

 

for in this Agreement (which includes the exercise of any rights or the performance of any
obligations hereunder) any Confidential Information of the other Party pursuant to this Agreement.
The foregoing confidentiality and non-use obligations shall not apply to any portion of the
Confidential Information that the receiving Party can demonstrate by competent written proof:

          (a) was already known to the receiving Party or its Affiliate, other than under an obligation
of confidentiality, at the time of disclosure by the other Party;

          (b) was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the receiving Party;

          (c) became generally available to the public or otherwise part of the public domain after its
disclosure and other than through any act or omission of the receiving Party in breach of this
Agreement;

          (d) is subsequently disclosed to the receiving Party or its Affiliate by a Third Party who has
a legal right to make such disclosure; or

          (e) is subsequently independently discovered or developed by the receiving Party or its
Affiliate without the aid, application, or use of the disclosing Party’s Confidential Information,
as evidenced by a contemporaneous writing.

     12.2 Authorized Disclosure. Notwithstanding the obligations set forth in Section 12.1, a
Party may disclose the other Party’s Confidential Information and the terms of this Agreement to
the extent:

          (a) such disclosure: (i) is reasonably necessary for the filing or prosecuting patent rights
as contemplated by this Agreement; or (ii) is reasonably necessary for the prosecuting or defending
litigation as contemplated by this Agreement; or

          (b) such disclosure is reasonably necessary: (i) to such Party’s directors, attorneys,
independent accountants or financial advisors for the sole purpose of enabling such directors,
attorneys, independent accountants or financial advisors to provide advice to the receiving Party,
provided that in each such case on the condition that such directors, attorneys, independent
accountants and financial advisors are bound by confidentiality and non-use obligations consistent
with those contained in this Agreement; or (ii) to actual or potential investors and/or acquirors
solely for the purpose of evaluating an actual or potential investment or acquisition; provided
that in each such case on the condition that such actual or potential investors and/or acquirers
are bound by confidentiality and non-use obligations consistent with those contained in this
Agreement;

          (c) such disclosure is required by judicial or administrative process, provided that in such
event such Party shall promptly inform the other Party such required disclosure and provide the
other Party an opportunity to challenge or limit the disclosure obligations.
Confidential Information that is disclosed by judicial or administrative process shall remain
otherwise subject to the confidentiality and non-use provisions of this Article 12, and the Party
disclosing Confidential Information pursuant to law or court order shall take all steps reasonably

35.

 

necessary, including seeking of confidential treatment or a protective order to ensure the
continued confidential treatment of such Confidential Information; and

          (d) such disclosure is reasonably necessary to its collaborators in its respective territory
(including CROs, hospitals, doctors, consultants, subcontractors and Affiliates) for the purpose of
the development, manufacture and/or commercialization of the Products, solely for the purpose of
carrying out such collaboration, on the condition that such collaborators are bound by
confidentiality and non-use obligations consistent with those contained in this Agreement. For
clarity, Spectrum shall have the right to disclose to its commercial partners in the Retained
Territory (including without limitation Allergan and the Korean Partner), and such commercial
partners shall have the right to use, the Confidential Information of NK, in each case in
connection with the research, development, manufacture and commercialization of products in the
Retained Territory on condition that such partners are bound by confidentiality and non-use
obligations consistent with those contained in this Agreement. For further clarity, NK shall have
the right to disclose to its sublicensees in the NK Territory, and such sublicensees shall have the
right to use, the Confidential Information of Spectrum in accordance with the right granted under
the sublicense under Section 2.1(a) on condition that such sublicensees are bound by
confidentiality and non-use obligations consistent with those contained in this Agreement.

          (e) such disclosure is reasonably necessary to its potential sublicensees to have such
potential sublicensees to evaluate the possibility of sublicenses under Section 2.1(a) on condition
that such potential sublicensees are bound by confidentiality and non-use obligations consistent
with those contained in this Agreement.

     12.3 Publication. NK shall deliver to Spectrum a copy of any proposed publication or
presentation for Spectrum’s review and approval. Spectrum shall have the right to require
modifications of the proposed publication or presentation for reasons such as: (a) to protect
Spectrum’s Confidential Information; (b) for trade secret reasons or business reasons; and/or (c)
to delay such submission for an additional ninety (90) days as may be reasonably necessary to seek
patent protection for the Sole Inventions owned by Spectrum or the Joint Invention disclosed in
such proposed submission.

     12.4 Publicity; Use of Names. Subject to Section 12.2 and the rest of this Section 12.4, no
disclosure of the terms of this Agreement may be made by either Party or its Affiliates, and no
Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their
respective employee(s) in any publicity, promotion, news release or other public disclosure
relating to this Agreement or its subject matter, without the prior express written permission of
the other Party, except as may be required by law.

          (a) A Party may disclose this Agreement and its terms in securities filings with the
Securities Exchange Commission or other regulatory agency (“SEC”) (or equivalent foreign agency) to
the extent required by law after complying with the procedure set forth in this Section 12.4. In
such event, the Party seeking such disclosure will prepare a draft confidential treatment request
and a proposed redacted version of this Agreement to request confidential
treatment for this Agreement, and the other Party agrees to promptly (and in any event, no
less than seven (7) days after receipt of such confidential treatment request and proposed
redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to
file its

36.

 

request within the time lines proscribed by applicable SEC regulations or equivalent
foreign agency regulations. The Party seeking such disclosure shall exercise Commercially
Reasonable Efforts to obtain confidential treatment of this Agreement from the SEC or equivalent
foreign agency as represented by the redacted version reviewed by the other Party.

          (b) Further, each Party acknowledges that the other Party may be legally required to make
public disclosures (including in filings with the SEC or other agency) of certain material
developments or material information generated under this Agreement and agrees that each Party may
make such disclosures as required by law, provided that the Party seeking such disclosure first
provides the other Party a copy of the proposed disclosure, and provided further that (except to
the extent that the Party seeking disclosure is required to disclose such information to comply
with applicable laws or regulations) if the other Party demonstrates to the reasonable satisfaction
of the Party seeking disclosure, within three (3) business days of such Party’s providing the copy,
that the public disclosure of previously undisclosed information will materially adversely affect
the development and/or commercialization of a Product being developed and/or commercialized, the
Party seeking disclosure will remove from the disclosure such specific previously undisclosed
information as the other Party shall reasonably request to be removed.

          (c) Notwithstanding the foregoing, the Parties have agreed on language of a press release
announcing the collaboration, attached hereto as Exhibit H, to be issued promptly after the
execution of this Agreement by both Parties.

          (d) During the Term, each Party shall have the right to issue press release or make a public
announcement concerning the material terms of this Agreement or the Development or
Commercialization of the Product under this Agreement, such as announcing the commencement and
completion of clinical studies for the Products in countries of the NK Territory, the filing and
obtaining of Regulatory Approvals for the Products in countries of the NK Territory, the First
Commercial Sale of the Products in countries of the NK Territory, and the publication of data and
results in accordance with Section 12.3, by providing the other Party with reasonable advance
notice of the content thereof. Such other Party shall have the right to review and comment on such
proposed press release or announcement and the Party seeking such disclosure shall take into
consideration and incorporate when appropriate the comment from the other Party.

          (e) The Parties agree that after a disclosure pursuant to Sections 12.4(a) or (b) has been
reviewed and approved by the other Party, the disclosing Party may make subsequent public
disclosures or issue a press release disclosing the same content without having to obtain the other
Party’s prior consent and approval.

          (f) The Parties agree that NK may publish or disclose any data, results and other
information generated from or obtained by the Development hereunder to the extent reasonably
necessary or helpful for the Development or Commercialization of the Product under this Agreement,
subject to Section 12.3.

     12.5 Equitable Relief. Each Party and its Affiliates acknowledge that a breach of this
Article 12 cannot reasonably or adequately be compensated in damages in an action at law and

37.

 

that
such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each
Party and its Affiliates agree that the other Party shall be entitled, in addition to any other
remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and
other equitable relief to prevent or curtail any breach of the obligations relating to Confidential
Information set forth herein by the other Party.

     12.6 Obligation Period. The obligations of the Parties under this Article 12 shall continue
for a period of [***] ([***]) years after the expiration or termination of this Agreement.

ARTICLE 13

TERM AND TERMINATION

     13.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier
terminated pursuant to this Article 13, shall remain in effect, on a country-by-country basis,
until the expiration of the Royalty Term of the Product in such country (“Term”). Upon the
expiration of the Term in a particular country, the license granted to NK under the Spectrum
Technology in such country shall become fully-paid, royalty-free and non-exclusive.

     13.2 Termination for Breach or for Other Reasons.

          (a) Notice. If either Party believes that the other Party is in material breach of this
Agreement, then the Party holding such belief (the “Non-breaching Party”) may deliver notice of
such breach to the other Party (the “Notified Party”). The Notified Party shall have [***] to cure
such breach to the extent involving non-payment of amounts due hereunder, and [***] to either cure
such breach for all other material breaches, or, if cure of such breach other than non-payment
cannot reasonably be effected within such [***] period, to deliver to the Non-breaching Party a
plan reasonably calculated to cure such breach within a timeframe that is reasonably prompt in
light of the circumstances then prevailing but in no event longer than an additional [***].
Following delivery of such a plan, the Notified Party shall carry out the plan and cure the breach
within the timeframe set forth in the plan and the failure of the Notified Party to cure the breach
within such timeframe shall be result in the immediate and automatic termination of this Agreement
upon the expiration of such timeframe.

          (b) Failure to Cure. If the Notified Party fails to cure a material breach of this Agreement
as provided for in Section 13.2(a), then the Non-Breaching Party may terminate this Agreement upon
written notice to the Notified Party.

          (c) Termination by NK. In the event NK determines at its sole discretion that further
Development or Commercialization of the Product is commercially, financially or otherwise not
advisable or reasonable due to the reasons of (i) efficacy, (ii) safety, (iii) infringement of
Third Party’s patent or other intellectual property or (iv) marketability, NK may terminate this
Agreement by giving to Spectrum nine (9)-month written notice to that effect.

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

38.

 

          (d) Disputes. If a Party gives notice of termination under this Section 13.2 and the
other Party disputes whether such termination is proper under this Section 13.2, then the issue of
whether this Agreement may properly be terminated upon expiration of the notice period (unless such
breach is cured as provided in Section 13.2(a)) shall be resolved in accordance with Article 14.
If as a result of such dispute resolution process it is determined that the notice of termination
was proper, then such termination shall be deemed to have been effective ninety (90) days following
the date of the notice of termination (or such other time period applicable pursuant to Section
13.2(a) or Section 13.2(c)). If as a result of such dispute resolution process it is determined
that the notice of termination was improper, then no termination shall have occurred and this
Agreement shall remain in effect.

     13.3 Spectrum Rights upon Termination of this Agreement. In the event this Agreement is
terminated, upon the early termination of this Agreement, the following shall apply (in addition to
any other rights and obligations otherwise under this Agreement with respect to such termination),
subject to Section 13.4 below:

          (a) Regulatory Filings; Data. To the extent permitted by applicable Laws, NK shall transfer
and assign to Spectrum all Regulatory Filings, Regulatory Approvals, and related preclinical,
analytical, and clinical data for the Products throughout the NK Territory.

          (b) NK License and Assignment. NK hereby grants to Spectrum, effective only in event of such
termination, an exclusive, royalty-free license, with the right to grant multiple tiers of
sublicenses if applicable, under NK Technology to Develop, make, have made, use, sell, offer for
sale, have sold, import and otherwise Commercialize the Products in the NK Territory, which license
shall be effective as of the date of such termination. NK hereby assigns to Spectrum, effective
only in the event of such termination, all of its rights and interests in and to the Product Marks
(other than the corporate names of NK) and NK shall provide such further assistance to Spectrum
promptly after the effective date of such termination to effect such assignment.

          (c) Revocation of Registration of License. NK shall, and shall cause its sublicensees to,
execute all documents and give all declarations regarding the licenses or sublicenses and
reasonably cooperate with Spectrum to the extent such documents, declarations and/or cooperation
are required for the revocation of record or registration of the licenses or sublicenses for the
benefit of NK or its sublicensees in the NK Territory made pursuant to Section 2.6.

          (d) Transition Assistance. NK shall provide such assistance, at no cost to Spectrum, as may
be reasonably necessary or useful for Spectrum to commence or continue, at Spectrums cost,
Developing or Commercializing Products in the NK Territory, to the extent NK is then performing or
having performed such activities, including without limitation transferring or amending as
appropriate, upon request of Spectrum, any agreements or arrangements with Third Party vendors to
sell Products in the NK Territory. To the extent that any such contract between NK and a Third
Party is not assignable to Spectrum, then NK shall reasonably cooperate with Spectrum to arrange to
continue to provide and provide such services from such entity.

39.

 

     13.4 Payment by Spectrum. In the event this Agreement is terminated by NK pursuant to Section
13.2 for Spectrum’s material breach of its material obligations under this Agreement, in order for
Sections 13.3(a) through (d) to take effect, Spectrum shall first agree in writing to reimburse NK,
in [***] equal monthly installments, for all reasonable and documented out-of-pocket and internal
costs (including labor costs) incurred by NK (or its sublicensees, to the extent NK’s assignment
and assistance obligations in Sections 13.3(a) through (d) above in the NK Territory outside of
Japan are fulfilled through such sublicensees) after the Effective Date and prior to the effective
date of such termination that are directly attributable to: (a) the conduct of preclinical,
analytical and clinical studies (including clinical studies in South Korea) using the Product for
the purpose of generating data to support Regulatory Approval for the Product in the Field in the
NK Territory; and (b) the preparation and filing for Regulatory Approval for the Product in the
Field in the NK Territory, including any filing fees associated therewith.

     13.5 Survival. The following provisions shall survive any expiration or termination of this
Agreement: Articles 1, 8 (solely with respect to payments that are due prior to or as of the
effective date of such expiration or termination), 11 (excluding Section 11.5), 12, 14, and 15, and
Sections 2.2 (other than subclause (a)), 9.1, 9.2, 9.3, 10.3, 10.4, 13.1, 13.3, 13.4 and 13.5.

ARTICLE 14

DISPUTE RESOLUTION

     14.1 Disputes. The Parties recognize that disputes as to certain matters may from time to
time arise during the Term which relate to either Party’s rights and/or obligations hereunder. It
is the objective of the Parties to establish procedures to facilitate the resolution of disputes
arising under this Agreement in an expedient manner by mutual cooperation and without resort to
litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in
this Article 14 to resolve any controversy or claim arising out of, relating to or in connection
with any provision of this Agreement, if and when a dispute arises under this Agreement.

     14.2 Internal Resolution. With respect to all disputes arising between the Parties under this
Agreement, including, without limitation, any alleged breach under this Agreement or any issue
relating to the interpretation or application of this Agreement, if the Parties are unable to
resolve such dispute within thirty (30) days after such dispute is first identified by either Party
in writing to the other, the Parties shall refer such dispute to the Chief Executive Officers or
the Managing Director of the Parties (or any senior executive reporting directly to either Party’s
Chief Executive Officer or Managing Director) for attempted resolution by good faith negotiations
within thirty (30) days after such notice is received.

     14.3 Binding Arbitration. If the Chief Executive Officers or the Managing Director or such
senior executive of the Parties are not able to resolve such disputed matter within thirty (30)
days and either Party wishes to pursue the matter, each such dispute, controversy or claim

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

40.

 

that is not an Excluded Claim (defined in Section 14.4 below) shall be finally resolved by
binding arbitration administered by JAMS pursuant to JAMS’ Streamlined Arbitration Rules and
Procedures then in effect (the “JAMS Rules”), and judgment on the arbitration award may be entered
in any court having jurisdiction thereof. The Parties agree that:

          (a) The arbitration shall be conducted by a panel of three persons experienced in the
pharmaceutical business: within thirty (30) days after initiation of arbitration, each Party shall
select one person to act as arbitrator and the two Party-selected arbitrators shall select a third
arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the
Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be
appointed by JAMS. The place of arbitration shall be Los Angeles, California, and all proceedings
and communications shall be in English.

          (b) Either Party may apply to the arbitrators for interim injunctive relief until the
arbitration award is rendered or the controversy is otherwise resolved. Either Party also may,
without waiving any remedy under this Agreement, seek from any court having jurisdiction any
injunctive or provisional relief necessary to protect the rights or property of that Party pending
the arbitration award. The arbitrators shall have no authority to award punitive or any other type
of damages not measured by a Party’s compensatory damage. Each Party shall bear its own costs and
expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative
fees of arbitration regardless of the outcome of such arbitration.

          (c) Except to the extent necessary to confirm an award or as may be required by law, neither a
Party nor an arbitrator may disclose the existence, content, or results of an arbitration without
the prior written consent of both Parties. In no event shall an arbitration be initiated after the
date when commencement of a legal or equitable proceeding based on the dispute, controversy or
claim would be barred by the applicable California statute of limitations.

     14.4 Excluded Claim. As used in Section 14.3, the term “Excluded Claim” shall mean a dispute,
controversy or claim that concerns (a) the scope, validity, enforceability, inventorship or
infringement of a patent, patent application, trademark or copyright; or (b) any antitrust,
anti-monopoly or competition law or regulation, whether or not statutory.

ARTICLE 15

MISCELLANEOUS

     15.1 Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, sets forth
the complete, final and exclusive agreement and all the covenants, promises, agreements,
warranties, representations, conditions and understandings between the Parties with respect to the
subject matter hereof and supersedes, as of the Effective Date, all prior agreements and
understandings between the Parties with respect to the subject matter hereof. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either
oral or written, between the Parties other than as are set forth herein and therein. No subsequent
alteration, amendment, change or addition to this Agreement shall be binding upon the Parties
unless reduced to writing and signed by an authorized representative of each Party.

41.

 

     15.2 Force Majeure. Each Party shall be excused from the performance of its obligations under
this Agreement to the extent that such performance is prevented by force majeure and the
nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse
shall be continued so long as the condition constituting force majeure continues and the
nonperforming Party takes reasonable efforts to remove the condition. For purposes of this
Agreement, force majeure shall include conditions beyond the reasonable control of the
nonperforming Party, including without limitation, an act of God or terrorism, involuntary
compliance with any regulation, law or order of any government, war, civil commotion, epidemic,
failure or default of public utilities or common carriers, destruction of production facilities or
materials by fire, earthquake, storm or like catastrophe. Notwithstanding the foregoing, a Party
shall not be excused from making payments owed hereunder because of a force majeure affecting such
Party. If a force majeure persists for more than ninety (90) days, then the Parties will discuss
in good faith the modification of the Parties’ obligations under this Agreement in order to
mitigate the delays caused by such force majeure.

     15.3 Notices. Any notice required or permitted to be given under this Agreement shall be in
writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate
Party at the address specified below or such other address as may be specified by such Party in
writing in accordance with this Section 15.3, and shall be deemed to have been given for all
purposes (a) when received, if hand-delivered or sent by confirmed facsimile or a reputable courier
service, or (b) five (5) business days after mailing, if mailed by first class certified or
registered airmail, postage prepaid, return receipt requested.

	 	 	 
	If to Spectrum:

	 	Spectrum Pharmaceuticals, Inc.
	 

	 	701 N. Green Valley Parkway Suite 265
	 

	 	Henderson, NV 89074
	 

	 	Attention: Legal Counsel
	 

	 	Fax: (702) 990-3001
	 
	 	 
	With copies to:

	 	Spectrum Pharmaceuticals, Inc.
	 

	 	157 Technology Drive
	 

	 	Irvine, CA 92618
	 

	 	Attention: Legal Counsel
	 

	 	Fax: (949) 788-6706
	 
	 	 
	and

	 	Cooley Godward Kronish LLP
	 

	 	5 Palo Alto Square
	 

	 	3000 El Camino Real
	 

	 	Palo Alto, CA 94306
	 

	 	Attention: Robert L. Jones, Esq.
	 

	 	Facsimile: (650) 849-7400

42.

 

	 	 	 
	If to NK:

	 	Nippon Kayaku Co., Ltd.
	 

	 	Tokyo Fujimi Bldg., 11-2,
	 

	 	Fujimi 1-chome, Chiyoda-ku
	 

	 	Tokyo 102-8172, Japan
	 

	 	Attention: General Manager of Licensing Division
	 

	 	Fax: +81-3-(3237)5920

     15.4 No Strict Construction; Headings. This Agreement has been prepared jointly and shall not
be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have authored the
ambiguous provision. The headings of each Article and Section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the
language contained in the particular Article or Section.

     15.5 Assignment. Neither Party may assign or transfer this Agreement or any rights or
obligations hereunder without the prior written consent of the other, except that a Party may make
such an assignment without the other Party’s consent to Affiliates or to a successor to
substantially all of the business of such Party to which this Agreement relates (whether by merger,
sale of stock, sale of assets or other transaction) (the “Acquisition”). Any permitted successor
or assignee of rights and/or obligations hereunder shall, in writing to the other Party, expressly
assume performance of such rights and/or obligations. Any permitted assignment shall be binding on
the successors of the assigning Party. Any assignment or attempted assignment by either Party in
violation of the terms of this Section 15.5 shall be null, void and of no legal effect.

     15.6 Performance by Affiliates. Each Party may discharge any obligations and exercise any
right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its
Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to
comply with the provisions of this Agreement in connection with such performance. Any breach by a
Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach
by such Party, and the other Party may proceed directly against such Party without any obligation
to first proceed against such Party’s Affiliate.

     15.7 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry
out the purposes and intent of this Agreement.

     15.8 Severability. If any one or more of the provisions of this Agreement is held to be
invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is
taken, the provision shall be considered severed from this Agreement and shall not serve to
invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable one such that the objectives
contemplated by the Parties when entering this Agreement may be realized.

     15.9 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as
to a particular default or other matter shall not constitute a waiver of such Party’s rights to the
future enforcement of its rights under this Agreement, except with respect to an express written
and signed waiver relating to a particular matter for a particular period of time.

43.

 

     15.10 Independent Contractors. Each Party shall act solely as an independent contractor, and
nothing in this Agreement shall be construed to give either Party the power or authority to act
for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the
relationship of partners, principal and agent, or joint-venture partners between the Parties.

     15.11 English Language. This Agreement was prepared in the English language, which language
shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. To the
extent this Agreement requires a Party to provide to the other Party Information, correspondence,
notice and/or other documentation, such Party shall provide such Information, correspondence,
notice and/or other documentation in the English language.

     15.12 Governing Law. This Agreement and all disputes arising out of or related to this
Agreement or any breach hereof shall be governed by and construed under the laws of the State of
California, without giving effect to any choice of law principles that would require the
application of the laws of a different state.

     15.13 Counterparts. This Agreement may be executed in one (1) or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

44.

 

Exhibit 10.36

EXECUTION COPY

     In Witness Whereof, the Parties have executed this Agreement in duplicate originals
by their duly authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	Spectrum Pharmaceuticals, Inc.	 	Nippon Kayaku Co., Ltd.
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Rajesh C. Shrotriya, M.D.	 	By:	 	/s/ Akira Mandai
	 	 	 	 	 	 	 
	 

	 	Name:
	 	Rajesh C. Shrotriya, M.D.	 	 	 	Name:	 	Akira Mandai
	 

	 	 	 	 
	 	 	 	 	 	 
	 

	 	Title:	 	Chairman & Chief Executive Officer	 	 	 	Title:	 	Managing Director
	 

	 	 	 	 
	 	 	 	 	 	 

45.

 

Exhibit A

Apaziquone

[***]

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

46.

 

Exhibit B

Spectrum Patents Existing as of the Effective Date

[***]

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

47.

 

Exhibit C

Target Product Profile (TPP)

[***]

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

48.

 

Exhibit D

Certain Spectrum Know-How

[***]

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

49.

 

Exhibit E

NK Development Plan

[***]

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

50.

 

Exhibit F

Outline of Adverse 

Reporting Requirements

[***]

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

51.

 

Exhibit G

Spectrum Manufacturing Know-How

[***]

 

			
	[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

52.

 

Exhibit H

Joint Press Release

[On 6 am of November 10 (PST) from Spectrum]

COMPANY CONTACTS

Paul Arndt

Senior Manager, Investor Relations

949-788-6700x216

SPECTRUM PHARMACEUTICALS AND NIPPON KAYAKU ENTER COLLABORATION

AGREEMENT FOR APAZIQUONE IN ASIAN TERRITORIES

	 	•	 	Total Potential Value Of Collaboration Exceeds $151 Million
	 
	 	•	 	Spectrum to Receive an Upfront Payment of $15 Million, up to $136 Million in Milestones,
and Royalties
	 
	 	•	 	Nippon Kayaku Responsible for 100% of Development and Commercial Expenses
	 
	 	•	 	Spectrum Retains Commercial Rights to South Korea

IRVINE, California — November 10, 2009 —Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a
commercial stage biotechnology company with a primary focus in oncology, and Nippon Kayaku today
announced an exclusive collaboration for the development and commercialization of apaziquone in
Asia. Apaziquone is an antineoplastic agent currently being investigated for the treatment of
non-muscle invasive bladder cancer by intravesical instillation. Spectrum Pharmaceuticals has
previously entered into a strategic collaboration with Allergan, Inc. (NYSE: AGN) for North
America, Europe, and other key markets. These two collaborations are representative of the
Company’s stated objective of achieving solid strategic partnerships that are aimed at fully
exploiting developmental goals for apaziquone on a worldwide basis.

“We are excited to partner apaziquone with a strong Japanese oncology company such as Nippon
Kayaku,” said Rajesh C. Shrotriya, Chairman of the Board and Chief Executive Officer of Spectrum
Pharmaceuticals, Inc. “Nippon Kayaku is one of the most established and reputable pharmaceutical
companies in Japan and has unparalleled experience in Asia in the field of non-muscle invasive
bladder cancer and prostate cancer. We believe that Nippon Kayaku is a terrific strategic partner
for apaziquone and for Spectrum.”

“Apaziquone is an ideal candidate to complement our portfolio of 24 anti-cancer products,”
said Akira Mandai, Head of Pharmaceuticals Group of Nippon Kayaku. “We look forward to working
with Spectrum in developing apaziquone for non-muscle invasive bladder cancer.”

Under the terms of the agreement, Nippon Kayaku will pay Spectrum an upfront payment of $15 million
and will make additional payments of up to $136 million based on the achievement of certain
regulatory and commercialization milestones. Nippon Kayaku received exclusive rights to apaziquone
for the treatment of non-muscle invasive bladder cancer in Asia, including Japan and China but
excluding South Korea. Nippon Kayaku will conduct the apaziquone clinical trials

53.

 

pursuant to a
development plan. Nippon Kayaku will be responsible for all expenses relating to the development
and commercialization of apaziquone in the Nippon Kayaku territory.

Spectrum is currently conducting two Phase 3 clinical trials to investigate apaziquone’s safety and
efficacy in non-muscle invasive bladder cancer. Spectrum’s goal is to complete enrollment in both
Phase 3 studies by year-end 2009.

About Non-Muscle Invasive Bladder Cancer

Non-muscle invasive bladder cancer is a form of bladder cancer localized in the surface layers of
the bladder and is commonly treated with intravesical therapies. Approximately 70% of all patients
newly diagnosed with bladder cancer have non-muscle invasive bladder cancer.1 More than
one million patients in the United States, Europe and Japan are estimated to be affected by the
disease, which is treated predominantly by urologists.2

About Apaziquone

Apaziquone is a drug currently being investigated for the treatment of non-muscle invasive bladder
cancer. Apaziquone, an anti-cancer agent that becomes activated by reductase enzymes found in
cancer cells, is formulated for administration directly into the urinary bladder. Phase 2 data has
confirmed anti-tumor activity in patients with multiple, recurrent non-muscle invasive bladder
cancer, as evidenced by 31 of 46 patients (67%) showing a complete response after receiving six
weekly treatments with 4 mg of apaziquone instilled into the urinary bladder in a marker lesion
study. In another Phase 2 study, apaziquone instilled into the bladder following surgery was well
tolerated and was not absorbed in any detectable amount from the bladder wall into the bloodstream
and therefore, is expected to carry a low risk of systemic toxicity, if any.

The apaziquone registration plan, which the U.S. Food and Drug Administration (FDA) concurred with
under a Special Protocol Assessment, calls for two double blind, placebo-controlled, randomized
Phase 3 clinical studies, each with 562 patients with Ta G1 or G2 low risk non-invasive bladder
cancer. Patients are randomized in a one-to-one ratio to apaziquone or placebo. Under the
protocol, the patients are given a single 4 mg dose following surgical removal of the tumors.
The primary endpoint is a statistically significant difference (p<0.05) in the rate of
tumor recurrence between the two treatment groups by year two. The FDA has granted Fast Track
Designation for the investigation of apaziquone for the treatment of non-muscle invasive bladder
cancer. Spectrum also received scientific advice from the European Medicines Agency
(EMEA) whereby the EMEA agreed that the two Phase 3 studies as designed should be sufficient for a
regulatory decision regarding European registration.

About Nippon Kayaku

Nippon Kayaku is a general chemical company focused on IT, health care and safety systems. The
Company’s Pharmaceuticals Group maintains extensive original expertise related to research and
development, production, sales, and aftermarket investigations of anti-cancer drugs. The Company’s
lineup of cancer-fighting drugs and cancer supportive products has reached 28 products. Nippon
Kayaku is also strengthening its licensing activities, and is

 

			
	1	 	Kirkali Z, et al. Bladder Cancer:
Epidemiology, Staging and Grading, and Diagnosis. Urology 66 (Suppl 6A): 4-34,
2005.
	 
	2	 	For U.S. see National Cancer Institute.
Bethesda, MD, http://seer.cancer.gov/statfacts/html/urinb.html accessed
10-23-2008; For Europe see Globocan 2002 database, http://www-dep.iarc.fr/
accessed 10-23-2008.

54.

 

introducing generic products in order
to expand its cancer-related business. For more information, please visit the Company’s website at
www.nipponkayaku.co.jp/english/.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a primary focus in
oncology. The Company’s strategy is comprised of acquiring and developing a broad and diverse
pipeline of late-stage clinical and commercial products; establishing a commercial organization for
its approved drugs; continuing to build a team with people who have demonstrated skills, passion,
commitment and have a track record of success in its areas of focus; and, leveraging the expertise
of partners around the world to assist it in the execution of its strategy. For more information,
please visit the Company’s website at www.sppirx.com.

Forward Looking Statements — This press release may also contain forward-looking statements
regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks
and uncertainties that could cause actual results to differ materially. These statements include
but are not limited to statements that relate to Spectrum’s business and its future, Spectrum’s
ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage
clinical and commercial products, establishing a commercial organization for Spectrum’s approved
drugs, continuing to build Spectrum’s team, leveraging the expertise of partners around the world
to assist Spectrum in the execution of its strategy, that apaziquone is expected to carry a low
risk of systemic toxicity, if any, the safety and efficacy of apaziquone and that enrollment in the
Phase 3 clinical trials will be completed by year-end 2009, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of
historical fact. Risks that could cause actual results to differ include the possibility that
Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that
Spectrum’s existing and new drug candidates may not receive approval from the FDA, and other
regulatory agencies in a timely manner or at all, the possibility that Spectrum’s existing and new
drug candidates, if approved, may not be more effective, safer or more cost efficient than
competing drugs, the possibility that Spectrum’s efforts to acquire or in-license and develop
additional drug candidates may fail, Spectrum’s lack of revenues, limited marketing experience,
dependence on third parties for clinical trials, manufacturing, distribution and quality control
and other risks that are described in further detail in Spectrum’s reports filed with the
Securities and Exchange Commission. Spectrum does not plan to update any such forward-looking
statements and expressly disclaim any duty to update the information contained in this press
release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum, TURNING INSIGHTS
INTO HOPETM and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals,
Inc.

Information
regarding Nippon Kayaku has been obtained from Nippon Kayaku and not independently verified by Spectrum.

© 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

55.

 

56.

 

57.exv10w37

EXHIBIT 10.37

CONFIDENTIAL

Execution Copy

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

LICENSE AND COLLABORATION AGREEMENT

by and between

SPECTRUM PHARMACEUTICALS, INC.

and

TOPOTARGET A/S

 

 

CONFIDENTIAL

	 	 	 	 	 	 	 
	ARTICLE 1
	 	DEFINITIONS	 	 	1	 
	 
	 	 	 	 	 	 
	ARTICLE 2
	 	GRANT OF RIGHTS	 	 	14	 
	2.1
	 	Rights to Spectrum	 	 	14	 
	2.2
	 	Sublicense Agreements	 	 	16	 
	2.3
	 	Mutual Exclusivity	 	 	16	 
	2.4
	 	Other HDAC Inhibitors	 	 	17	 
	2.5
	 	Right of Negotiation for China Territory	 	 	18	 
	2.6
	 	Backup Compound	 	 	19	 
	2.7
	 	No Other Licenses	 	 	22	 
	 
	 	 	 	 	 	 
	ARTICLE 3
	 	GOVERNANCE	 	 	22	 
	 
	 	 	 	 	 	 
	3.1
	 	Alliance Manager	 	 	22	 
	3.2
	 	Joint Development Committee	 	 	22	 
	3.3
	 	Meetings of the JDC	 	 	22	 
	3.4
	 	Responsibilities of the JDC	 	 	22	 
	3.5
	 	Areas Outside the JDC’s Authority; Other	 	 	23	 
	3.6
	 	JDC Decisions	 	 	23	 
	3.7
	 	Joint Commercialization Committee	 	 	24	 
	3.8
	 	Meetings of JCC	 	 	24	 
	3.9
	 	Responsibilities of the JCC	 	 	24	 
	3.10
	 	Areas Outside the JCC’s Authority; Other	 	 	25	 
	3.11
	 	JCC Decisions	 	 	25	 
	3.12
	 	Subcommittees	 	 	26	 
	3.13
	 	Appointment of Alliance Managers and Members of JDC and JCC	 	 	26	 
	 
	 	 	 	 	 	 
	ARTICLE 4
	 	DEVELOPMENT; REGULATORY	 	 	27	 
	 
	 	 	 	 	 	 
	4.1
	 	Development	 	 	27	 
	4.2
	 	Development Plan	 	 	27	 
	4.3
	 	Spectrum Development Obligations	 	 	30	 
	4.4
	 	Development Activities and Development Costs	 	 	31	 
	4.5
	 	Regulatory Matters	 	 	34	 
	4.6
	 	Rights of Reference to Regulatory Materials; Use of Clinical Data	 	 	35	 
	4.7
	 	Adverse Event Reporting and Safety Data Exchange	 	 	36	 
	4.8
	 	Communications with Regulatory Authorities	 	 	36	 
	4.9
	 	Regulatory Inspection or Audit	 	 	37	 
	4.10
	 	Product Withdrawals and Recalls	 	 	37	 
	 
	 	 	 	 	 	 
	ARTICLE 5
	 	COMMERCIALIZATION; MANUFACTURING	 	 	37	 
	 
	 	 	 	 	 	 
	5.1
	 	Commercialization by the Parties	 	 	37	 
	5.2
	 	Commercialization by Spectrum	 	 	37	 
	5.3
	 	Launch Efforts	 	 	39	 
	5.4
	 	Commercialization Reporting	 	 	39	 
	5.5
	 	Cross-Territory Sales	 	 	39	 
	5.6
	 	Manufacture and Supply of Product	 	 	40	 
	5.7
	 	Promotional Materials	 	 	43	 

 

 

	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	ARTICLE 6
	 	TOPOTARGET CO-PROMOTION RIGHT	 	 	44	 
	 
	 	 	 	 	 	 
	6.1
	 	Option Exercise	 	 	44	 
	6.2
	 	Grant of Co-Promotion Right	 	 	44	 
	 
	 	 	 	 	 	 
	ARTICLE 7
	 	FINANCIALS	 	 	47	 
	 
	 	 	 	 	 	 
	7.1
	 	License Fee	 	 	47	 
	7.2
	 	Development Milestone Payments	 	 	47	 
	7.3
	 	Sales Milestone Payments	 	 	49	 
	7.4
	 	Royalties	 	 	49	 
	7.5
	 	Sublicense Revenue	 	 	50	 
	7.6
	 	Spectrum Payments and Reports	 	 	51	 
	7.7
	 	Taxes	 	 	51	 
	7.8
	 	No Setoff	 	 	51	 
	7.9
	 	Late Payments	 	 	51	 
	7.10
	 	Records; Audits	 	 	52	 
	 
	 	 	 	 	 	 
	ARTICLE 8
	 	INTELLECTUAL PROPERTY	 	 	52	 
	 
	 	 	 	 	 	 
	8.1
	 	Ownership of Inventions	 	 	52	 
	8.2
	 	Disclosure of Inventions	 	 	52	 
	8.3
	 	Prosecution of Patents	 	 	52	 
	8.4
	 	Enforcement of TopoTarget Technology	 	 	55	 
	8.5
	 	Patent Marking	 	 	56	 
	8.6
	 	Trademarks	 	 	56	 
	8.7
	 	Infringement of Third Party IP	 	 	57	 
	8.8
	 	The CREATE Act	 	 	58	 
	8.9
	 	License to TopoTarget	 	 	58	 
	 
	 	 	 	 	 	 
	ARTICLE 9
	 	REPRESENTATIONS, WARRANTIES AND COVENANTS	 	 	59	 
	 
	 	 	 	 	 	 
	9.1
	 	Mutual Representations and Warranties	 	 	59	 
	9.2
	 	TopoTarget Technology	 	 	60	 
	9.3
	 	TopoTarget Trademark Representations and Warranties	 	 	61	 
	9.4
	 	Compliance with Law	 	 	61	 
	9.5
	 	Representations regarding Debarment	 	 	61	 
	9.6
	 	Regulatory Matters	 	 	62	 
	9.7
	 	Representations regarding Spectrum NDA Shares	 	 	63	 
	9.8
	 	No Broker	 	 	64	 
	9.9
	 	Material Contracts	 	 	64	 
	9.10
	 	No Other Representations or Warranties	 	 	64	 
	 
	 	 	 	 	 	 
	ARTICLE 10
	 	INDEMNIFICATION	 	 	64	 
	 
	 	 	 	 	 	 
	10.1
	 	General Indemnification by TopoTarget	 	 	64	 
	10.2
	 	General Indemnification by Spectrum	 	 	65	 
	10.3
	 	Product Liability Indemnification	 	 	65	 
	10.4
	 	Indemnification Procedures	 	 	66	 
	10.5
	 	Limitation of Liability	 	 	67	 
	10.6
	 	Insurance	 	 	68	 

-ii-

 

	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	ARTICLE 11
	 	CONFIDENTIALITY	 	 	68	 
	 
	 	 	 	 	 	 
	11.1
	 	Confidentiality	 	 	68	 
	11.2
	 	Authorized Disclosure	 	 	69	 
	11.3
	 	Publicity; Terms of Agreement	 	 	70	 
	11.4
	 	Publications	 	 	70	 
	11.5
	 	Clinical Trial Registries	 	 	71	 
	 
	 	 	 	 	 	 
	ARTICLE 12
	 	TERM AND TERMINATION	 	 	71	 
	 
	 	 	 	 	 	 
	12.1
	 	Term	 	 	71	 
	12.2
	 	Termination by Spectrum at Will	 	 	71	 
	12.3
	 	Termination by Spectrum for Breach by TopoTarget	 	 	71	 
	12.4
	 	Alternate Remedies for Breach by TopoTarget	 	 	72	 
	12.5
	 	Termination by TopoTarget	 	 	73	 
	12.6
	 	Termination Upon Bankruptcy	 	 	74	 
	12.7
	 	Effect of Termination of the Agreement	 	 	75	 
	12.8
	 	Accrued Liabilities; Other Remedies	 	 	76	 
	12.9
	 	Rights in Bankruptcy	 	 	76	 
	12.10
	 	Survival	 	 	77	 
	 
	 	 	 	 	 	 
	ARTICLE 13
	 	DISPUTE RESOLUTION	 	 	77	 
	 
	 	 	 	 	 	 
	13.1
	 	Disputes	 	 	77	 
	13.2
	 	Injunctive Relief	 	 	78	 
	 
	 	 	 	 	 	 
	ARTICLE 14
	 	MISCELLANEOUS	 	 	78	 
	 
	 	 	 	 	 	 
	14.1
	 	Entire Agreement; Amendment	 	 	78	 
	14.2
	 	Force Majeure	 	 	78	 
	14.3
	 	Notices	 	 	79	 
	14.4
	 	No Strict Construction; Headings; Interpretation	 	 	79	 
	14.5
	 	Assignment	 	 	80	 
	14.6
	 	Records Retention	 	 	80	 
	14.7
	 	Governing Law	 	 	80	 
	14.8
	 	No Third Party Beneficiaries	 	 	80	 
	14.9
	 	Performance by Affiliates	 	 	81	 
	14.10
	 	Further Assurances and Actions	 	 	81	 
	14.11
	 	Compliance with Applicable Law	 	 	81	 
	14.12
	 	Severability	 	 	81	 
	14.13
	 	No Waiver	 	 	81	 
	14.14
	 	Independent Contractors	 	 	82	 
	14.15
	 	Counterparts	 	 	82	 

-iii-

 

CONFIDENTIAL

LICENSE AND COLLABORATION AGREEMENT

     This License and Collaboration Agreement (the “Agreement”) is entered into as of the
2nd day of February, 2010 (the “Effective Date”) by and between TopoTarget A/S,
a Danish corporation having its principal offices at Symbion Science Park, Fruebjergvej 3, 2100
København, Denmark (“TopoTarget”), and Spectrum Pharmaceuticals, Inc, a Delaware
corporation having a place of business at 701 N. Green Valley Parkway, Henderson, Nevada 89074
U.S.A. (“Spectrum”). TopoTarget and Spectrum are sometimes referred to herein individually as a
“Party” and collectively as the “Parties”.

Recitals

TopoTarget owns certain intellectual property rights relating to belinostat (PXD 101), including
the TopoTarget Patents (as defined herein).

Spectrum and TopoTarget desire to establish a collaboration for the continued development and
commercialization of belinostat worldwide.

TopoTarget desires to grant, and Spectrum desires to accept, an exclusive license to develop and
commercialize Compounds and Products in the Territory (as such terms are defined herein).

Now Therefore, in consideration of the foregoing premises and the mutual promises,
covenants and conditions contained in this Agreement, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as
follows:

ARTICLE 1

DEFINITIONS

As used in this Agreement, the following initially capitalized terms, whether used in the singular
or plural form, shall have the meanings set forth in this Article 1.

     1.1 “Acquiring Group” has the meaning set forth in Section 1.13.

     1.2 “Acquisition” means (a) any consolidation or merger of a Third Party corporation or other
entity or person with or into a Party, or any other corporate reorganization in which the
shareholders holding capital stock of the Third Party immediately prior to such consolidation,
merger or reorganization represents less than fifty percent (50%) of the voting power of the
surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately
after such consolidation, merger or reorganization or (b) any transaction or series of related
transactions, as a result of which a Party shall have become, directly or indirectly, the
beneficial owner of the securities of the Third Party representing fifty percent (50%) or more of
the Third Party’s voting power, or (c) the consummation of a sale of all or substantially all of
the assets of the Third Party in any transaction or series of related transactions to a Party.

     1.3 “Additional Indication” has the meaning set forth in Section 7.2(e).

 

 

     1.4 “Affiliate” means, with respect to a particular Person, any person, firm, trust,
corporation, company, partnership, or other entity or combination thereof that directly or
indirectly controls, is controlled by or is under common control with such Person. For the
purposes of this definition, the word “control” (including, with correlative meaning, the terms
“controlled by” or “under the common control with”) means (a) ownership of fifty percent (50%) or
more, including ownership by trusts with substantially the same beneficial interest, of the voting
and equity rights of such person, firm, trust, corporation, company, partnership or other entity or
combination thereof, or (b) the power to direct the management of such person, firm, trust,
corporation, company, partnership, or other entity or combination thereof.

     1.5 “Alliance Manager” has the meaning set forth in Section 3.1.

     1.6 “ANDA” means an Abbreviated New Drug Application, as described in Section 505(j) of the
FD&C Act, or any similar procedure in any country in the Territory.

     1.7 “Applicable Law” means any and all statutes, ordinances, regulations or rules of any kind
whatsoever and any and all requirements under permits, orders, decrees, judgments or directives and
requirements of applicable Governmental Authorities, in each case pertaining to any of the
activities contemplated by this Agreement, including any regulations promulgated by any Regulatory
Authority in the Territory, all as amended from time to time.

     1.8 “Backup Compound” means any one, but only one, of either an Other HDAC Inhibitor or the
Preliminary Backup Compound that is designated by Spectrum pursuant to Section 2.6(b) for
Development and Commercialization in place of Belinostat, all in accordance with Section 2.6.

     1.9 “Backup Facility” has the meaning set forth in Section 5.6(c)(v)(1).

     1.10 “Belinostat” has the meaning set forth in Section 1.19.

     1.11 “Business Day” means each day of the week excluding Saturday, Sunday or a day on which
banking institutions in New York, New York USA or Copenhagen, Denmark are closed.

     1.12 “Cancer Field” means the detection, treatment and/or prevention of cancer.

     1.13 “Change of Control” means, with respect to a Party, any of the following events: (a) any
Third Party (or group of Third Parties acting in concert) acquires, directly or indirectly, shares
of such Party representing fifty percent (50%) or more of the voting shares (where voting refers to
being entitled to vote for the election of directors) then outstanding of such Party; (b) such
Party consolidates with or merges into another corporation or entity which is a Third Party, or any
corporation or entity which is a Third Party consolidates with or merges into such Party, in either
event pursuant to a transaction in which more than fifty percent (50%) of the voting shares of the
acquiring or resulting entity outstanding immediately after such consolidation or merger is not
held by the holders of the outstanding voting shares of such Party preceding such consolidation or
merger; or (c) such Party conveys, transfers or leases all or substantially all of its assets to a
Third Party. Such Third Party or group of Third Parties, and its and/or their

2

 

respective Affiliates (other than the Party and its Affiliates at the time of the Change of
Control of such Party), are hereinafter referred to as the “Acquiring Group”.

     1.14 “China Exclusivity Period” has the meaning set forth in Section 2.5.

     1.15 “China Territory” means the widely recognized territory of the People’s Republic of
China, including Hong Kong, and Macau. For the purpose of this Agreement, “China Territory” will
include the disputed region of Taiwan, but not include territories disputed by India.

     1.16 “Commercialization” means the marketing, Promotion, sale, offering for sale, importation
and/or distribution of Products for use anywhere in the world, including activities directed to
obtaining pricing or reimbursement approval. “Commercialize” has a correlative meaning.

     1.17 “Commercially Reasonable Efforts” means, with respect to a Party’s obligations under this
Agreement, the reasonable and good faith efforts normally used by a company in the pharmaceutical
industry for a product (regardless of whether the product is owned by the company or the company
has obtained rights to such product), which is of similar market potential at a similar stage in
its development or product life, which level of effort is at least commensurate with the level of
effort that a Party would devote to its own internally discovered compounds or products that are of
most closely comparable market potential at a most closely comparable stage in their development or
product life, taking into account regulatory requirements of safety and efficacy, product profile,
the competitiveness of the marketplace, the proprietary position of the product, and the cost of
scaling up a manufacturing process (including facility costs) and the market potential of the
applicable product.

     1.18 “Common Stock” has the meaning set forth in Section 7.2(a).

     1.19 “Compound” means (a) any compound that  [***] that is Controlled by TopoTarget or its
Affiliates either prior to the Effective Date or during the Term and/or (b) any salt, free acid,
free base, clathrate, solvate, hydrate, hemihydrate, anhydride, ester, chelate, conformer,
congener, crystal form, crystal habit, polymorph, amorphous solid, homolog, isomer, stereoisomer,
enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex
or mixture of any of the foregoing. For clarity, Compound includes the active pharmaceutical
ingredient known as belinostat (PXD-101), together with any salt, free acid, free base, clathrate,
solvate, hydrate, hemihydrate, anhydride, ester, chelate, conformer, congener, crystal form,
crystal habit, polymorph, amorphous solid, homolog, isomer, stereoisomer, enantiomer, racemate,
prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture thereof
(“Belinostat”).

     1.20 “Confidential Information” means, with respect to a Party, all proprietary Information of
such Party that is disclosed to or accessed by the other Party under this Agreement.

     1.21 “Control” means, with respect to any material, Information, or intellectual

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

3

 

property right, that an entity owns or has a license, right or covenant to such material,
Information, or intellectual property right and has the ability to grant to another entity access,
a license, or a sublicense right or covenant (as applicable) to such material, Information, or
intellectual property right on the terms and conditions set forth herein without (a) violating the
terms of any then-existing agreement or other arrangement with any Third Party or (b) increasing at
any time the amount of any payments required under any such agreement or arrangement executed after
the Effective Date. Notwithstanding anything to contrary herein, in the event of a Change of
Control of a Party, any material, Information or intellectual property of any Person within the
Acquiring Group shall not be included in any of the licenses or other rights granted under this
Agreement by such Party, and the term “Control” shall not include such material, Information or
intellectual property, except to the extent any material, Information or intellectual property is
conceived, reduced to practice, authored, developed, generated or otherwise made by any Person
within the Acquiring Group as part of the activities under this Agreement.

     1.22 “Co-Promotion Agreement” has the meaning set forth in Section 6.2.

     1.23 “Co-Promotion Commencement Date” has the meaning set forth in Section 6.2(a).

     1.24 “Co-Promotion Option” has the meaning set forth in Section 5.2(b)(iii).

     1.25 “Co-Promotion Option Period” has the meaning set forth in Section 5.2(b)(iii).

     1.26 “Co-Promotion Right” has the meaning set forth in Section 6.2.

     1.27 “Co-Promotion Term” has the meaning set forth in Section 6.2(a).

     1.28 “Cost of Goods” means (a) with respect to any Product or a component thereof
manufactured, packaged, transferred, validated, sterilized and/or quality-tested, in part or
solely, by a Third Party or Third Parties, the sum of: [***]; and

          (b) if a Product is manufactured, packaged, transferred, validated, sterilized and quality
tested solely by TopoTarget and/or its Affiliates, the sum of: [***].

     1.29 “Covering” means, with respect to a TopoTarget Patent and the subject matter at issue,
that, but for a license granted to Spectrum, its Affiliates or sublicensees under a Valid Claim
included in the TopoTarget Patent, the manufacture, use, sale or importation by Spectrum of the
subject matter at issue would infringe such Valid Claim.

     1.30 “CUP Indication” means cancer of unknown primary origin.

     1.31 “Detail” or "Detailing” means each separate face-to-face contact by a professional sales
representative with a physician or other professional with authority to write prescriptions during
which time the promotional message involving a Product is presented and is a topic of discussion.
When used as a verb, “Detail” shall mean to engage in a Detail.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

4

 

     1.32 “Development” means all activities worldwide that relate to obtaining, maintaining
or expanding Regulatory Approval of Product. This includes (a) research, preclinical testing,
toxicology, chemical process, formulation, manufacturing and clinical studies of Product; (b)
preparation, submission, review, and development of data or information for the purpose of
submission to a Governmental Authority to obtain, maintain and/or expand Regulatory Approval of
Product; and (c) post-Regulatory Approval product support for Product (including laboratory and
clinical efforts directed toward the further understanding of the safety and efficacy of Product).
“Develop” and “Developed” have correlative meanings.

     1.33 “Development Costs” means all direct and indirect expenditures actually incurred by the
Parties after the Effective Date in connection with the Development of a Product for any indication
in the Field in accordance with the Development Plan, to the extent such direct expenditures are
directly related to the Development Program and such indirect expenditures are allocated based upon
the proportion of such expenditures directly attributable to the support of the applicable
activity, including expenditures for FTEs at the FTE Rate and the following expenditures to the
extent such items are customary under industry practices: (a) expenditures for Development
activities incurred by a Party or paid by such Party to subcontractors or other Third Parties; (b)
FTEs engaged in planning Publications related to Development activities; (c) expenditures for
safety and pharmacovigilance activities; and (d) other expenditures mutually agreed to by the
Parties during the Term in connection with the Development of any Product.

     The Parties agree that the following expenditures shall not be considered Development Costs:
(i) any expenditures associated with manufacturing Product used after the Effective Date in
clinical trials and non-clinical studies in support of Development of a Product, including costs
associated with chemical, pharmaceutical and other process development pursuant to Section 5.6(b),
(ii) expenditures associated with the conduct of Phase 4 Clinical Trials of Products; (iii)
Regulatory Costs; (iv) amortization and depreciation expenses; (v) deductions, credits, interest
expenses including taxes and extraordinary or nonrecurring losses customarily deducted by a Party
in calculating and reporting consolidated net income; (vi) manufacturing facility capital costs,
capital expenditures, including purchases of facilities, property or equipment (unless such
equipment is exclusively used in the Development Program); and (vii) property taxes and any other
taxes not related to Development of Products in the Field.

     1.34 “Development Plan” has the meaning set forth in Section 4.2(b).

     1.35 [***].

     1.36 “Eligible HDAC Inhibitors” has the meaning set forth in Section 2.6(a).

     1.37 “Exclusivity Period” has the meaning set forth in Section 2.3.

     1.38 “Existing Confidentiality Agreement” means the confidentiality agreement between the
Parties dated October 9, 2009.

     1.39 “FDA” means the United States Food and Drug Administration or its successor.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

5

 

     1.40 “FD&C Act” means the United States Federal Food, Drug and Cosmetic Act.

     1.41 “Field” means all uses of any Compound or Product, alone or in combination with any other
drug or pharmaceutical product.

     1.42 “Field Personnel” means a Spectrum FTE not based at Spectrum’s principal place of
business who is a sales representative, MSL or account manager working in the field visiting
physicians and other customers or potential customers to educate them or market and Promote the
Products.

     1.43 “First Commercial Sale” means, with respect to a Product, the first sale for use or
consumption by any person of such Product in a country after Regulatory Approval has been granted
by the governing Regulatory Authority of such country, provided that sale of Product for clinical
or other research or compassionate use shall not constitute a First Commercial Sale.

     1.44 “First Indication” means, with respect to a Product, the first indication for which
Regulatory Approval is received from the FDA for such Product, whether or not the PTCL Indication.

     1.45 “First Non-PTCL Indication” means, with respect to a Product, the first indication for
which Regulatory Approval is received from the FDA for such Product, excluding the PTCL Indication.

     1.46 “FTE Rate” means an initial annual rate of [***] Dollars ($[***]) per FTE. The FTE Rate
for each FTE shall include compensation and all employee benefits, allocated travel costs (not
including travel costs budgeted for clinical trials and included as a separate line item in the
Development Plan budget and reimbursed as such), allocated equipment maintenance costs, utilities,
waste removal, and facilities expenses, including allocated building operating costs, allocated
depreciation, utilities, telephone, and repairs and maintenance, regardless of whether the same are
considered allocable overhead, and there shall be no additional charge for such items or any other
general and administrative costs; but shall not include any costs described above specifically and
forming a part of the independent line items of the Development Plan budget and reimbursed as such.
The FTE Rate shall be adjusted annually to reflect any percentage increase or decrease (as the
case may be) in the Consumer Price Index for the US City Average (all times) (“CPI”) (based on the
cumulative change in the CPI index from the Effective Date to the index most recently available at
the time of any such adjustment).

     1.47 “Full Time Equivalent” or “FTE” means one or more individuals at Spectrum or TopoTarget
or their respective Affiliates who spend time and effort working on a specific project or task
pursuant to the Development Plan or otherwise as contemplated by this Agreement whose time and
effort is equivalent to the time and effort of one (1) employee devoted exclusively to the project
or task based on 1,860 person-hours or greater per year.

     1.48 “GAAP” has the meaning set forth in Section 1.73.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

6

 

     1.49 [***].

     1.50 “Generic Product” means, on a country-by-country basis, any pharmaceutical product sold
by a Third Party which (a) contains a Compound which is the same active ingredient (or any salt,
free acid, free base, clathrate, solvate, hydrate, hemihydrate, anhydride, ester, chelate,
conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, homolog, isomer,
stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite,
conjugate, complex or mixture of any of the foregoing) as an approved Product of Spectrum, its
sublicensee and their respective Affiliates and (b) is approved under an ANDA or under 505(b)(2) of
the FD&C Act or any similar abbreviated route of approval in any country in the Territory.

     1.51 “Governmental Authority” means any multi-national, federal, state, county, local,
municipal or other government authority or self regulating organization of any nature (including
any governmental division, subdivision, department, agency, bureau, branch, office, commission,
council, court or other tribunal), including the United States Securities and Exchange Commission,
The NASDAQ Stock Market, Inc. and the Copenhagen Stock Exchange.

     1.52 “HDAC Inhibitor” means any compound that inhibits one or more histone deacetylase enzymes
or activity.

     1.53 “HDAC Inhibitor Information” has the meaning set forth in Section 2.6(a).

     1.54 “IND” means an Investigational New Drug Application, as defined in the FD&C Act.

     1.55 “Indemnification Claim Notice” has the meaning set forth in Section 10.4.

     1.56 “Indemnified Party” has the meaning set forth in Section 10.4.

     1.57 “Indemnifying Party” has the meaning set forth in Section 10.4.

     1.58 “Information” means any data, results, and information of any type whatsoever, in any
tangible or intangible form, including know-how, trade secrets, practices, techniques, methods,
processes, inventions, developments, specifications, formulations, formulae, software, algorithms,
marketing reports, expertise, stability, technology, data including pharmacological, biological,
chemical, biochemical, toxicological, and clinical test data, analytical and quality control data,
stability data, studies and procedures.

     1.59 “Initial Development Plan” has the meaning set forth in Section 4.2(a).

     1.60 “Initial Funding Cap” has the meaning set forth in Section 4.4(d).

     1.61 “Initial Funding Period” has the meaning set forth in Section 4.4(d).

     1.62 “Issuance Date” has the meaning set forth in Section 7.2(a).

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

7

 

     1.63 “IST” has the meaning set forth in Section 4.2(a).

     1.64 “Joint Inventions” has the meaning set forth in Section 8.1.

     1.65 “Joint Patent” has the meaning set forth in Section 8.3(b).

     1.66 “Joint Commercialization Committee” or “JCC” means the joint commercialization committee
formed by the Parties as described in Section 3.7.

     1.67 “Joint Development Committee” or “JDC” means the joint development committee formed by
the Parties as described in Section 3.2.

     1.68 [***].

     1.69 “NCI” has the meaning set forth in Section 4.2(a).

     1.70 “NCI Trial” has the meaning set forth in Section 4.2(c).

     1.71 “NDA” means a New Drug Application or supplemental New Drug Application, as defined in
the FD&C Act.

     1.72 “Negotiation Period” has the meaning set forth in Section 2.4(b) or Section 2.5, as
applicable.

     1.73 “Net Sales” means, for any period, the aggregate of the gross amounts invoiced or
otherwise billed by Spectrum, its Affiliates and sublicensees (“Selling Party”) for arm’s length
sales or other commercial disposition of a Product to a Third Party purchaser, less the following
to the extent specifically related to the Product and actually allowed, incurred or paid during
such period (collectively, “Net Sales Deductions”):

          (a) discounts, including cash, trade and quantity discounts, price reduction or incentive
programs, retroactive price adjustments with respect to sales of such Product, charge-back
payments, and rebates granted to managed health care organizations or to federal, state and local
governments (or their respective agencies, purchasers and reimbursers) or to trade customers,
including wholesalers and chain and pharmacy buying groups;

          (b) credits or allowances taken upon rejections or returns of Products, including for recalls
or damaged goods;

          (c) freight, postage, shipping and insurance charges for delivery of such Product actually
paid;

          (d) customs duties, surcharges and other governmental charges incurred in connection with the
exportation or importation of such Product;

          (e) bad debts relating to sales of Products that are actually written off by the

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

8

 

Selling Party (it being understood that “Net Sales” will include all amounts received for any
bad debts at a subsequent date);

          (f) taxes, duties or other governmental charges levied on, absorbed or otherwise imposed on
sale of such Product, including value-added taxes, or other governmental charges otherwise measured
by the billing amount, as adjusted for rebates and refunds, but specifically excluding taxes based
on net income of the Selling Party; and

          (g) the amount of any TopoTarget Margin (as defined in Section 5.6(c)(ii)) paid by Spectrum to
TopoTarget as part of the Commercial Supply Price pursuant to the Commercial Supply Agreement;

provided that all of the foregoing deductions are incurred in the ordinary course and calculated in
accordance with then-current generally accepted accounting principles in the United States,
consistently applied (“GAAP”) during the applicable calculation period throughout the Selling
Party’s organization.

Notwithstanding the foregoing, in the event a Product is (i) sold in the form of a combination
product containing one or more active ingredients which are not Products or (ii) sold under a
bundled or capitated arrangement with one or more products which are not Compounds or Products or
(iii) sold under an arrangement whereby the sale of Product is only available with or conditioned
upon the purchase of other products (a “Combination Product”), then Net Sales for such Combination
Product shall be calculated, on a country-by-country basis, by multiplying actual Net Sales of such
Combination Product by the fraction A/(A+B), where A is the average invoiced sales amount of the
Product if sold separately by the Selling Party in finished form, and B is the average invoiced
sales amount of all other active ingredients or products in finished form in such country, less the
Net Sales Deductions.

If, on a country-by-country basis, either the Product or the other active ingredients or products
of the Combination Product are not sold separately in finished form in such country, Net Sales of
the Combination Product shall be determined by the Parties in good faith based on the relative fair
market value for the Product and each active ingredient or product in finished form, as applicable.

For sake of clarity and avoidance of doubt, the transfer of Product by a Selling Party or one of
its Affiliates to another Affiliate of such Selling Party or to a sublicensee of such Selling Party
for resale shall not be considered a sale; in such cases, Net Sales shall be determined based on
the amount invoiced or otherwise billed by such Affiliate or sublicensee to an independent Third
Party, less the Net Sales Deductions allowed under this Section. Notwithstanding the foregoing,
sales of Product by Spectrum to a bona fide Third Party distributor in an arms length transaction
shall be considered a sale to a Third Party customer and Net Sales shall be determined based on all
amounts invoiced or otherwise billed to, or other consideration paid by, the distributor, less the
Net Sales Deductions allowed under this Section. Any Products used (but not sold for more than
nominal consideration) for Promotional, advertising or humanitarian purposes or used (but not sold
for more than nominal consideration) for clinical or other research purposes shall not be
considered in determining Net Sales hereunder.

9

 

     1.74 “Net Sales Deductions” has the meaning set forth in Section 1.73.

     1.75 “NSCLC Indication” means non small cell lung cancer.

     1.76 “Permitted Encumbrances” means (i) assessments and other governmental charges not yet due
and payable; (ii) mechanics’, workmen’s, repairmen’s, warehousemen’s, carriers’ or other like liens
arising or incurred in the ordinary course of business or other encumbrances that are a matter of
public record; and (iii) all notices, orders, demands, proposals or requirements of any
governmental authority which, in the case of each of (i) through (iii), individually are not
material and which do not individually materially adverse affect the use of such property in the
manner currently being utilized by the Products. The Permitted Encumbrances as of the Effective
Date are listed on Exhibit H.

     1.77 “Person” means an individual, partnership, joint venture, corporation, limited liability
company, trust, unincorporated organization or other similar entity or governmental authority.

     1.78 “Phase 4 Clinical Trial” means a human clinical trial or other study of a Product in a
particular indication conducted after Regulatory Approval of such Product for such indication has
been obtained from an appropriate Regulatory Authority, which trial or study is (a) conducted
voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b)
conducted due to a request or requirement of a Regulatory Authority.

     1.79 “Preliminary Backup Compound” has the meaning set forth in Section 2.6(a).

     1.80 “Product” means any and all pharmaceutical preparations that contain a Compound in any
formulation and any dosage strength, including Belinostat and all line extensions thereof.

     1.81 “Product Liability” means any product liability claims asserted or filed by Third Parties
(without regard to their merit or lack thereof), seeking damages or equitable relief of any kind,
relating to personal injury, wrongful death, medical expenses, an alleged need for medical
monitoring, consumer fraud or other alleged economic losses, allegedly caused by any Product, and
including claims by or on behalf of users of any Product (including spouses, family members and
personal representatives of such users) relating to the use, sale, distribution or purchase of any
Product sold by a Party or its distributors or sublicensees, or any Affiliate thereof, including,
but not limited to claims by third party payers, such as insurance carriers and unions.

     1.82 “Promote” means those activities, including Detailing and distributing samples of a
product, normally undertaken by a pharmaceutical company’s sales force to implement marketing plans
and strategies aimed at encouraging the appropriate use of a particular prescription pharmaceutical
product. When used as a verb, “Promote” shall mean to engage in such activities. “Promotion” and
“Promotional” have correlative meanings.

     1.83 “Promotional Materials” means all training materials and all written, printed, graphic,
electronic, audio or video matter, including advertisements, sales visual aids, leave items,
formulary binders, reprints, direct mail, Internet postings and broadcast advertisements, in

10

 

each case created by Spectrum or on its behalf, and used or intended for use by the Sales
Forces in connection with any Promotion of any Product in the Territory under this Agreement.

     1.84 “PTCL Indication” means peripheral T-cell lymphoma disease.

     1.85 “Publication” has the meaning set forth in Section 11.4.

     1.86 “Registration Rights and Stockholder Agreement” means the Registration Rights and
Stockholder Agreement being executed as of the date hereof between Spectrum and TopoTarget relating
to the Spectrum NDA Shares.

     1.87 “Regulatory Approval” means all approvals necessary for the manufacture, marketing,
importation and sale of a Product for one or more indications in a country or regulatory
jurisdiction, which may include satisfaction of all applicable regulatory and notification
requirements, but which shall exclude any pricing and reimbursement approvals.

     1.88 “Regulatory Authority” means, in a particular country or regulatory jurisdiction, any
applicable Governmental Authority involved in granting Regulatory Approval and/or, to the extent
required in such country or regulatory jurisdiction, governmental pricing or reimbursement approval
of a Product in such country or regulatory jurisdiction, including the FDA and the United States
Drug Enforcement Administration or its successor.

     1.89 “Regulatory Costs” means all costs and expenses incurred in connection with preparing,
submitting, amending and supplementing any applications for Regulatory Approvals for a Product in
the Field, including meetings with any relevant Regulatory Authority.

     1.90 “Regulatory Materials” means regulatory applications, submissions, notifications,
registrations, Regulatory Approvals and/or other filings made to or with a Regulatory Authority
that are necessary or reasonably desirable in order to Develop, manufacture, market, sell or
otherwise commercialize a Product in a particular country or regulatory jurisdiction and all
internal contact reports of agency interactions. Regulatory Materials include INDs and NDAs.

     1.91 “Sales Force” means each Party’s respective sales employees Promoting Product in the
Territory.

     1.92 “Sales Year” means the twelve (12) month period commencing with the first full calendar
month after First Commercial Sale, and each subsequent twelve (12) month period. The first Sales
Year is referred to herein as “Sales Year 1,” the second Sales Year is referred to herein as “Sales
Year 2,” and so on.

     1.93 “Second Non-PTCL Indication” means, with respect to a Product, the next indication after
the First Non-PTCL Indication for which Regulatory Approval is received from the FDA for such
Product, excluding the PTCL Indication.

     1.94 “Selling Party” has the meaning set forth in Section 1.73.

     1.95 “Sole Inventions” has the meaning set forth in Section 8.1.

11

 

     1.96 “Spectrum Indemnitees” has the meaning set forth in Section 10.1.

     1.97 “Spectrum NDA Shares” has the meaning set forth in Section 7.2(a).

     1.98 “Spectrum Overpayment” has the meaning set forth in Section 4.4(d).

     1.99 “Spectrum Repayment Amount” has the meaning set forth in Section 4.4(d).

     1.100 “Spectrum Term Sheet” has the meaning set forth in Section 2.4(b) or Section 2.5, as
applicable.

     1.101 “Spectrum Trademarks” has the meaning set forth in Section 8.6(a).

     1.102 “Statutory Exchange” has the meaning set forth in Section 7.2(a).

     1.103 “Sublicense Revenue” shall mean all income and payments received by Spectrum from a
sublicensee, in consideration of the grant of a sublicense under the TopoTarget Patents to make,
use, sell, or import Products including upfront license fees, annual maintenance fees and milestone
payments, but excluding (a) royalties based on Net Sales by or on behalf of sublicensees, (b)
payments made in consideration of the issuance of securities of Spectrum, but only up to the fair
market value of such securities, and (c) payments made by a sublicensee to Spectrum that are for
the provision (after the effective date of Spectrum’s sublicense agreement with such sublicensee)
of goods and services related to the research and/or development of Compounds or Products by
Spectrum to the sublicensee, but only up to the fair market value of such goods and services.

     1.104 “Supply Disruption” has the meaning set forth in Section 5.6(c)(v)(2).

     1.105 “Target Product Profile” or “TPP” means the target product profile that is mutually
agreed by the Parties and attached hereto as Exhibit B as of the Effective Date, as such
target product profile may be revised pursuant to Section 4.1(b).

     1.106 “Technical Failure” means, with respect to Belinostat, (i) the material failure of
Belinostat to meet any primary clinical study endpoint, (ii) material safety or efficacy issues of
Belinostat, or (iii) any other material failure of Belinostat to satisfy requirements necessary to
obtain Regulatory Approval from FDA, as reasonably determined by Spectrum for use in the Cancer
Field.

     1.107 “Term” has the meaning set forth in Section 12.1.

     1.108 “Territory” means (a) the U.S. Territory, (b) Canada and all of its territories and
possessions, (c) Mexico and all of its territories and possessions, (d) India and all of its
territories and possessions, and (e) if included pursuant to Section 2.5, the China Territory.

     1.109 “Third Party” means any Person other than TopoTarget, Spectrum or an Affiliate of either
Party.

12

 

     1.110 “Third Party Cost” is the amount actually paid by TopoTarget to a Third Party or Third
Parties for costs related to the third-party manufacturing, packaging, transfer, validation,
sterilization and/or quality testing of any Product or any component thereof.

     1.111 “Third Party Manufacturer Costs” has the meaning set forth in Section 5.6(c)(vi).

     1.112 “Third Party Term Sheet” has the meaning set forth in Section 2.4(b) or Section 2.5, as
applicable.

     1.113 “TLDs” has the meaning set forth in Section 2.1(c).

     1.114 “TopoTarget Indemnitees” has the meaning set forth in Section 10.2.

     1.115 “TopoTarget Know-How” means all Information (excluding any TopoTarget Patents or Joint
Inventions) that (a) is Controlled as of the Effective Date by TopoTarget or its Affiliates and
which relates to a Product or researching, developing, methods of manufacturing, using, importing
or selling a Product (including without limitation, all Product-related data) or (b) becomes
Controlled by TopoTarget or its Affiliates after the Effective Date and during the Term and which
relates to a Product or researching, developing, methods of manufacturing, using, importing or
selling a Product (including without limitation, all Product-related data).

     1.116 “TopoTarget Overpayment” has the meaning set forth in Section 4.4(e).

     1.117 “TopoTarget Patents” means (a) (i) all patents and patent applications that are
Controlled as of the Effective Date by TopoTarget or its Affiliates and that claim, disclose or
cover a Compound or Product or the manufacture, use, or sale of a Compound or Product and (ii) all
patents and patent applications (excluding Joint Inventions) that become Controlled by TopoTarget
or its Affiliates after the Effective Date and during the Term (including Sole Inventions) and that
claim, disclose or cover a Compound or Product or the manufacture, use, or sale of a Compound or
Product, (b) all divisions, continuations, continuations-in-part (to the extent directed to the
subject matter disclosed in a patent or patent application described in (a)) and requests for
continued examination of any of the foregoing, (c) all patents claiming priority to any of the
foregoing, (d) all reissues, registrations, re-examinations, and extensions (and equivalents
thereof) of any of the foregoing, in each case, in the Territory. Solely for purposes of the
manufacturing license granted in Section 2.1(a)(ii), TopoTarget Patents shall also include any and
all patents and patent applications outside the Territory that fall within the scope of subsection
(a), (b), (c), or (d) above (including any foreign equivalents of the categories described
therein). As of the Effective Date, the TopoTarget Patents include the patents and patent
applications set forth on Exhibit C.

     1.118 “TopoTarget Repayment Amount” has the meaning set forth in Section 4.4(e).

     1.119 “TopoTarget Technology” means the TopoTarget Patents and TopoTarget Know-How.

     1.120 “TopoTarget Territory” means the entire world other than the Territory.

13

 

     1.121 “TopoTarget Trademarks” means, in the Territory, the mark of or on Belinostat and any
mark associated with Product, together with any registrations or applications for registration
therefor, that are Controlled by TopoTarget as of the Effective Date, as listed on Exhibit
D. For avoidance of doubt, notwithstanding anything to the contrary herein, “TopoTarget
Trademarks” does not include the name “TOPOTARGET” or any confusingly similar variation thereof.

     1.122 “U.S. Territory” means the United States and all of its territories and possessions.

     1.123 “Valid Claim” means a claim of an issued and unexpired patent or pending patent
application included within the TopoTarget Patents to the extent such claim has not been revoked,
held invalid or unenforceable by a patent office, court or other governmental agency of competent
jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken
within the allowable time period) and which claim has not been disclaimed, denied or admitted to be
invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; provided that,
on a country-by-country basis, a patent application pending for more than five (5) years from the
date of filing of such application as a utility, non-provisional application shall not be
considered to have any Valid Claim for purposes of this Agreement from and after such five (5) year
date unless and until a patent with respect to such application issues.

ARTICLE 2

GRANT OF RIGHTS

     2.1 Rights to Spectrum.

          (a) License under TopoTarget Technology. Subject to the terms and conditions of this
Agreement, TopoTarget hereby grants to Spectrum a royalty-bearing license, with the right to
sublicense (subject to Section 2.2), under the TopoTarget Technology and TopoTarget’s interest in
the Joint Patents and Joint Inventions, to (i) research, develop, use, distribute, import, Promote,
market, sell, and offer for sale Products in the Territory in the Field, and (ii) subject to
Section 5.6, make and have made Product anywhere in the world for sale solely in the Territory.
The foregoing license shall be exclusive (even as to TopoTarget and its Affiliates) with respect to
the rights granted under clause (i) above, and non-exclusive with respect to the rights granted
under clause (ii) above; provided that such exclusive license shall not preclude TopoTarget or its
Affiliates from engaging in activities in the Territory to Develop Products pursuant to the
Development Plan subject to the terms of this Agreement.

     TopoTarget shall disclose to Spectrum any TopoTarget Technology, if in written form, that has
not already been disclosed to Spectrum within [***] ([***]) days after the Effective Date and on a
reasonably periodic (but not less than [***]) basis during the Term.

          (b) Assignment of TopoTarget Trademarks. Subject to the terms and conditions of this
Agreement, TopoTarget agrees to assign and hereby assigns to Spectrum the TopoTarget Trademarks,
together with the goodwill appurtenant thereto, in all respects free and

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

14

 

clear of any and all liens, hypothecations, mortgages, charges, security interests, pledges
and other encumbrances and claims of any nature. On the Effective Date, TopoTarget shall execute
and deliver to Spectrum an Assignment of Trademark suitable for recordation in the United States
Patent and Trademark Office (“USPTO”) in the form attached as Exhibit E hereto, and
thereafter shall take all reasonable actions requested by Spectrum to perfect Spectrum’s rights in
the TopoTarget Trademarks in the Territory at the expense of Spectrum, including the execution and
delivery of any additional documents of assignment. For the avoidance of doubt, Spectrum’s and its
Affiliates’ right to use the TopoTarget Trademarks in connection with the Products is limited to
the Territory, and TopoTarget shall own all rights to the TopoTarget Trademarks outside of the
Territory, and shall be free to register or apply for registration of the TopoTarget Trademarks
outside of the Territory and to use such TopoTarget Trademarks in connection with Products outside
of the Territory.

          (c) Domain Names. Spectrum shall have the sole right to register country-level domain names
for the Territory (e.g., .us, .ca, .mx) containing the assigned TopoTarget Trademarks, Spectrum
Trademarks or otherwise related to the Product in the Territory, and to enforce its rights in such
country-level domain names anywhere in the world. TopoTarget shall have the sole right to register
country-level domain names for the TopoTarget Territory (e.g., .eu, .uk,) containing the TopoTarget
Trademarks, Spectrum Trademarks or otherwise related to the Product in the TopoTarget Territory,
and to enforce its rights in such country-level domain names anywhere in the world. Spectrum shall
have the sole right to register the top-level domain names (e.g., .com, .net. and .org) containing
the assigned TopoTarget Trademarks, Spectrum Trademarks or otherwise related to the Product, in
consultation with TopoTarget (the “TLDs”). The Parties agree that the TLDs shall be used solely
for the purpose of hosting “jump pages” from which users may link to country specific websites
located at country-level domains registered in accordance with this Section 2.1(c). The TLDs and
“jump pages” shall be hosted and operated by Spectrum The content for all “jump pages” residing at
the TLDs (including any sub-pages) shall be discussed in good faith and mutually agreed to by the
Parties and shall comply with the terms of this Agreement. Either Party shall have the right to
initiate discussions at any time regarding the content of the “jump pages” by providing written
notice to the other Party, and promptly thereafter each of the Parties shall appoint a
representative to commence such discussions and develop such content. For avoidance of doubt,
content on the “jump pages” shall be amended only upon mutual written agreement of the Parties,
such agreement not to be unreasonably withheld, delayed or conditioned. Spectrum shall have the
initial right (at its cost) to take all actions reasonably necessary to protect the TLDs from
cybersquatting, infringement or other misappropriation by a Third Party anywhere in the world, and
in such case Spectrum shall consult with TopoTarget on the strategy for such actions and
considering in good faith TopoTarget’s comments regarding such actions. If Spectrum does not,
within ninety (90) days of learning of the cybersquatting, infringement or other misappropriation
of the TLDs by a Third Party, commence action to cause such Third Party to cease such unlawful
activity, or sooner if Spectrum declines in writing to commence such action, TopoTarget shall have
the right, but not the obligation, to commence such action, at its cost, against such Third Party,
and in such case TopoTarget shall consult with Spectrum on the strategy for such actions and
consider in good faith Spectrum’s comments regarding such actions. TopoTarget shall assign to
Spectrum any TLDs or country-level domain names for the Territory containing the assigned
TopoTarget Trademarks, Spectrum Trademarks or otherwise related to the Product (excluding the name

15

 

“TOPOTARGET” and any confusingly similar variation thereof) that TopoTarget has registered
prior to the Effective Date.

     2.2 Sublicense Agreements. The licenses granted by TopoTarget to Spectrum in Section 2.1 may
be sublicensed by Spectrum to any Affiliate or Third Party, provided that any sublicense to a Third
Party shall require the prior written consent of TopoTarget, which consent shall not be
unreasonably withheld, delayed or conditioned. Any sublicense under the licenses granted by
TopoTarget to Spectrum in Section 2.1 shall be consistent with the terms of this Agreement and
shall include confidentiality and non-use obligations no less stringent than those set forth in
Article 11.

     2.3 Mutual Exclusivity. Except for its activities with respect to Compounds and Products
under this Agreement and as set forth below, TopoTarget and Spectrum each hereby covenants that
neither it nor its Affiliates will, directly or indirectly through any Third Party, without the
other Party’s consent, such consent not to be unreasonably withheld, conditioned or delayed,
conduct research, development or commercialization activities with respect to any HDAC Inhibitor
(in any class) in the Cancer Field during the Exclusivity Period; provided however:

          (a) TopoTarget shall be free to itself (but not with any Third Party directly or indirectly)
conduct research and development activities (but not commercialization activities) with respect to
any HDAC Inhibitor that is not a Compound or Product solely in the furtherance of obtaining data to
demonstrate human proof of concept in the Cancer Field, subject to the terms of Section 2.4 below;
and

          (b) the foregoing restriction shall not apply to any HDAC Inhibitor (in any class) in the
Cancer Field which is (i) not owned or Controlled by a Party prior to a Change of Control of such
Party but is owned or Controlled by such Party after a Change of Control of such Party or (ii)
owned or Controlled by a Third Party at the time of Acquisition of such Third Party by a Party (in
either case, a “Third Party HDAC Inhibitor”); and

          (c) notwithstanding anything to the contrary herein, (i) Spectrum shall not utilize any
proprietary Information of TopoTarget, TopoTarget Know-How or TopoTarget Patents in the research or
development of any Third Party HDAC Inhibitor or any HDAC Inhibitor that is not a Product or
Compound, and shall establish procedures within Spectrum to ensure compliance with the foregoing;
and (ii) TopoTarget shall not utilize any proprietary Information of Spectrum, Spectrum Sole
Inventions, and all patents and intellectual property claiming or covering the Spectrum Sole
Inventions, in the research or development of any Third Party HDAC Inhibitor or any HDAC Inhibitor
that is not a Product or Compound, and shall establish procedures within TopoTarget to ensure
compliance with the foregoing.

     Nothing in this Agreement shall be construed as restricting the right of each Party to
research, develop and commercialize one or more HDAC Inhibitors (other than Compounds or Products)
outside the Cancer Field.

16

 

     As used herein, the term “Exclusivity Period” means the period commencing on the
Effective Date and continuing until such time as TopoTarget has itself developed data that
demonstrates human proof of concept for an HDAC Inhibitor in the Cancer Field.

     2.4 Other HDAC Inhibitors. In the event TopoTarget or its Affiliate demonstrates human proof
of concept with an HDAC Inhibitor that is not a Compound or Product in the Cancer Field (such HDAC
Inhibitor, an “Other HDAC Inhibitor”), TopoTarget shall provide all material data demonstrating
human proof of concept of such Other HDAC Inhibitor in writing to Spectrum and all other material
information in TopoTarget’s possession relevant to an evaluation of the development and
commercialization potential of such Other HDAC Inhibitor. For avoidance of doubt, Other HDAC
Inhibitor excludes all Third Party HDAC Inhibitors.

          (a) Spectrum Opt-In. Upon receipt of such data, Spectrum shall determine within [***] ([***])
days whether it is interested in participating in the development and commercialization of the
Other HDAC Inhibitor in the Cancer Field in the Territory. If Spectrum determines that it is
interested in such Other HDAC Inhibitor, then it shall provide written notice thereof to TopoTarget
within such [***] ([***]) day period, and the Parties will engage in good faith negotiations for
[***] ([***]) days from the date of Spectrum’s notice to determine the commercially reasonable
terms and conditions specific to such Other HDAC Inhibitor, including that the development costs
for the development of such Other HDAC Inhibitor shall be shared equally unless otherwise agreed.
The Parties acknowledge and agree that, in the event Spectrum provides written notice as set forth
above, it is the intention of the Parties to execute in a timely manner an agreement providing
rights to such Other HDAC Inhibitor in the Cancer Field in the Territory to Spectrum. If Spectrum
fails to provide written notice of its interest within the [***] ([***]) day period or if the
Parties fail to come to an agreement within such [***] ([***]) day period, or such longer period as
the Parties may mutually agree, then TopoTarget may pursue the development and commercialization of
the Other HDAC Inhibitor for any purpose worldwide at its own expense or in collaboration with a
Third Party, subject to subsection (b) below; provided that nothing in this Section 2.4(a) shall be
construed as granting TopoTarget any license or right under any intellectual property right or
Technology of Spectrum or any right to use or reference any Regulatory Approval of Spectrum (except
to the extent such right of use or reference to any Regulatory Approval is generally available to
Third Parties without consent or approval of Spectrum), unless Spectrum and TopoTarget first agree
in writing to the terms and conditions for such license or use; provided that the foregoing shall
not be deemed to restrict TopoTarget’s rights with respect to its owned share of Joint Inventions
or Joint Patents as set forth in this Agreement.

          (b) Right of Negotiation. If, at any time after the demonstration of human proof of concept
of an Other HDAC Inhibitor in the Cancer Field, TopoTarget or any of its Affiliates desires to
enter into an agreement or arrangement with a Third Party granting to such Third Party rights to
develop or commercialize an Other HDAC Inhibitor in the Cancer Field in the Territory, TopoTarget
first shall inform Spectrum in writing and provide any material information in TopoTarget’s
possession relevant to an evaluation of the development and commercialization potential of such
Other HDAC Inhibitor that was not previously provided to Spectrum. Spectrum shall have a period of
[***] ([***]) days from its receipt of such notice and

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

17

 

information in which to notify TopoTarget in writing that it wishes to enter into negotiations
with respect to such Other HDAC Inhibitor in the Cancer Field in the Territory.

     During the [***] ([***]) day period from TopoTarget’s receipt of such notice, the Parties
shall exclusively negotiate a term sheet setting forth the material terms upon which the Parties
would be willing to enter into a definitive license or other arrangement with respect to such Other
HDAC Inhibitor in the Cancer Field in the Territory (the “Spectrum Term Sheet”). Upon the
conclusion of such [***] ([***]) day period or such longer period as the Parties may agree (such
period, the “Negotiation Period”), TopoTarget shall be free to negotiate a term sheet with a Third
Party setting forth the material terms upon which the Third Party and TopoTarget would be willing
to enter into a definitive license or other arrangement with respect to such Other HDAC Inhibitor
in the Cancer Field in the Territory (the “Third Party Term Sheet”). If during the [***] ([***])
month period after the end of the Negotiation Period, TopoTarget negotiates a Third Party Term
Sheet, TopoTarget shall present both the Spectrum Term Sheet and Third Party Term Sheet to an
independent consultant selected by TopoTarget and approved by Spectrum, such approval not to be
unreasonably withheld, delayed or conditioned, and the independent consultant shall determine
whether the Spectrum Term Sheet or the Third Party Term Sheet, taken as whole, is more favorable to
TopoTarget, which decision the Parties agree shall be final and non-appealable.

     If the consultant determines that Third Party Term Sheet is more favorable to TopoTarget,
TopoTarget shall be free to enter into a transaction with the Third Party on terms consistent with
the Third Party Term Sheet. If the consultant determines that the Spectrum Term Sheet is more
favorable to TopoTarget, TopoTarget shall not be permitted to enter into a transaction with the
Third Party on the terms of the Third Party Term Sheet and, if TopoTarget does not enter into an
transaction with Spectrum on the terms of the Spectrum Term Sheet, then TopoTarget shall be
prohibited from entering into a transaction with any Third Party on any terms for a period of [***]
([***]) months after the date of the determination by the consultant. Thereafter, TopoTarget shall
be free to enter into an agreement or arrangement with any Person granting to such Person rights to
develop or commercialize an Other HDAC Inhibitor in the Cancer Field in the Territory under any
terms.

     2.5 Right of Negotiation for China Territory. Notwithstanding any provision of this
Agreement, in no event shall Spectrum or TopoTarget, directly or indirectly through any Third
Party, Develop or Commercialize any Product in the China Territory other than as expressly
permitted pursuant to this Section 2.5. Spectrum may not Develop, and neither Spectrum nor
TopoTarget may Commercialize, any Product in the China Territory, nor grant any rights to,
collaborate with or otherwise sell or transfer to any Third Party any rights in the China Territory
to any Product during the period commencing with the Effective Date and continuing until receipt of
Regulatory Approval for the Product for the First Indication in the U.S. Territory (“China
Exclusivity Period”).

     If, during the [***] ([***]) month period after the end of the China Exclusivity Period,
TopoTarget desires to Commercialize Products in the ChinaTerritory or desires to enter into an
agreement or arrangement with a Third Party granting to such Third Party rights to Develop or

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

18

 

Commercialize Products in the China Territory, TopoTarget shall provide Spectrum with written
notice thereof, and Spectrum shall have a period of [***] ([***]) days from its receipt of such
notice in which to notify TopoTarget in writing that it wishes to enter into negotiations with
TopoTarget to Develop and Commercialize the Products in the China Territory. During the [***]
([***]) day period from TopoTarget’s receipt of such notice, the Parties shall exclusively
negotiate a term sheet setting forth the material terms upon which the Parties would be willing to
enter into a definitive license or other arrangement with respect to the Development and
Commercialization of the Products in the China Territory (the “Spectrum Term Sheet”). Upon the
conclusion of such [***] ([***]) day period or such longer period as the Parties may agree (such
period, the “Negotiation Period”), TopoTarget shall be free to itself Develop and Commercialize the
Products in the China Territory, or to negotiate a term sheet with a Third Party setting forth the
material terms upon which the Third Party and TopoTarget would be willing to enter into a
definitive license or other arrangement with respect to the Development and Commercialization of
the Products in the China Territory (the “Third Party Term Sheet”). If during the [***] ([***])
month period after the end of the Negotiation Period TopoTarget negotiates a Third Party Term
Sheet, TopoTarget shall present both the Spectrum Term Sheet and Third Party Term Sheet to an
independent consultant selected by TopoTarget and approved by Spectrum, such approval not to be
unreasonably withheld, delayed or conditioned, and the independent consultant shall determine
whether the Spectrum Term Sheet or the Third Party Term Sheet, taken as whole, is more favorable to
TopoTarget, which decision the Parties agree shall be final and non-appealable. If the consultant
determines that Third Party Term Sheet is more favorable to TopoTarget, TopoTarget shall be free to
enter into a transaction with the Third Party on terms consistent with the Third Party Term Sheet,
and the China Territory shall be deemed included in the TopoTarget Territory. If the consultant
determines that the Spectrum Term Sheet is more favorable to TopoTarget, TopoTarget shall not be
permitted to enter into a transaction with the Third Party on the terms of the Third Party Term
Sheet and, if TopoTarget does not enter into an transaction with Spectrum on the terms of the
Spectrum Term Sheet, then TopoTarget shall be prohibited from entering into a transaction for the
China Territory with any Third Party on any terms for a period of [***] ([***]) months after the
date of the determination by the consultant. Thereafter, TopoTarget shall be free to enter into an
agreement or arrangement with any Person granting to such Person rights to Develop or Commercialize
Products in the China Territory under any terms. For avoidance of doubt, if the Parties cannot
agree upon the terms of the Spectrum Term Sheet during the Negotiation Period, TopoTarget shall be
free to itself Develop and Commercialize the Products in the China Territory.

     2.6 Backup Compound.

          (a) Promptly after the Effective Date, TopoTarget shall provide Spectrum with a list of all
HDAC Inhibitors (other than Belinostat and [***]) that are Controlled by TopoTarget as of the
Effective Date (the “Eligible HDAC Inhibitors”), together with chemical structure information and
any and all pre-clinical data in TopoTarget’s possession and Control that is directly related to
such HDAC Inhibitors (collectively, the “HDAC Inhibitor Information”). Spectrum shall have the
right to review the HDAC Inhibitor Information for the sole purpose of selecting from among the
Eligible HDAC Inhibitors one (1) compound (“Preliminary Backup Compound”) for use as a Backup
Compound pursuant to this Section

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

19

 

2.6. Within [***] ([***]) days of the receipt of such data from TopoTarget, Spectrum shall
notify TopoTarget in writing of its selection of one, but only one Preliminary Backup Compound, and
promptly after the delivery of such notice to TopoTarget, Spectrum shall return to TopoTarget all
HDAC Inhibitor Information. TopoTarget agrees that until Spectrum’s right to use a Designated
Backup Compound terminates pursuant to Section 2.6(d), TopoTarget shall not sell, license or
otherwise encumber the right to make, have made, use or sell the Preliminary Backup Compound for
use in the Cancer Field in the Territory in a manner that would deprive Spectrum of its rights
under this Section 2.6.

          (b) In the event that, prior to the First Commercial Sale of any Product containing Belinostat
as the active pharmaceutical ingredient, Spectrum has reasonably determined that Belinostat has
experienced a Technical Failure, Spectrum may provide TopoTarget with written notice of such
Technical Failure, along with reasonable supporting data for Spectrum’s determination, and that
Spectrum elects to designate any one, but only one, of the following as the Backup Compound: (i)
any Other HDAC Inhibitor that TopoTarget is then-developing for use in the Cancer Field as
contemplated by Section 2.4, or (ii) the Preliminary Backup Compound.

          (c) If Spectrum has elected to designate a Backup Compound pursuant to Section 2.6(b),
effective upon such election the Parties understand and agree that:

               (i) the Backup Compound (and any salt, free acid, free base, clathrate, solvate, hydrate,
hemihydrate, anhydride, ester, chelate, conformer, congener, crystal form, crystal habit,
polymorph, amorphous solid, homolog, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic
or radiolabeled equivalent, metabolite, conjugate, complex or mixture of any of the foregoing)
shall be deemed a “Compound” for all purposes under this Agreement;

               (ii) the TopoTarget Patents shall be amended to include any patents and patent applications
that claim, disclose or cover the Backup Compound or Product or the manufacture, use, or sale of
such Backup Compound or Product (and all divisions, continuations, continuations-in-part (to the
extent directed to the subject matter disclosed in any such patent or patent application) and
requests for continued examination of any of the foregoing, all patents claiming priority to any of
the foregoing, and all reissues, registrations, re-examinations, and extensions (and equivalents
thereof) of any of the foregoing;

               (iii) Spectrum shall have the same license to the Backup Compound as it had to the Compound
under Section 2.1 prior to such election, except that (1) Spectrum’s rights under this Agreement,
including Section 2.1, with respect to the Backup Compound, the Compound and the Product shall be
limited solely to the Cancer Field and (2) Spectrum shall not be subject to the diligence
obligations set forth in Section 4.3;

               (iv) TopoTarget shall provide to Spectrum all information and data, if

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

20

 

any, for the Backup Compound as and to the same extent that it was required to provide the
same to Spectrum for Belinostat;

               (v) Spectrum’s Development and Commercialization of the Backup Compound shall be subject to
all of the royalty, development milestone and sales milestone obligations set forth in this
Agreement to the same extent as applicable to Belinostat, except that Spectrum shall not be
obligated to pay any development milestone that was previously paid for Belinostat;

               (vi) Belinostat shall not be deemed a Compound or Product, and all rights of Spectrum under
this Agreement relating to Belinostat shall immediately revert to TopoTarget, as follows:

                    (1) the licenses granted to Spectrum under Section 2.1 shall terminate solely with respect to
Belinostat;

                    (2) all Regulatory Materials and Regulatory Approvals of Spectrum relating to Belinostat shall
be assigned to TopoTarget;

                    (3) a copy of all data and other information relating to Belinostat, to the extent not
previously disclosed, shall be provided to TopoTarget;

                    (4) TopoTarget shall have the sole right to conduct any and all future clinical trials
relating to Belinostat, including all NCI studies and ISTs, and Spectrum shall use Commercially
Reasonable Efforts to assign and transition any existing clinical trials to TopoTarget;

                    (5) all TopoTarget Trademarks, Spectrum Trademarks and domain names specific to Belinostat
(but not TopoTarget Trademarks, Spectrum Trademarks and domain names that could be used for the
Backup Compound) shall be assigned to TopoTarget;

                    (6) Spectrum shall assign to TopoTarget, for no additional consideration, any and all of
Spectrum’s Sole Inventions and Joint Inventions that claim only Belinostat or its manufacture, use
or sale;

                    (7) Spectrum shall grant TopoTarget a non-exclusive, royalty-free, irrevocable, non-terminable
and perpetual license, with the right to sublicense, under any and all of Spectrum’s Sole
Inventions and Joint Inventions that claim Belinostat or its manufacture, use or sale (other than
the Sole Inventions and Joint Inventions in subsection (6) above) to research, develop, make, have
made, use, distribute, import, Promote, market, sell, and offer for sale Belinostat anywhere in the
world;

                    (8) Spectrum shall use Commercially Reasonable Efforts to assign to TopoTarget any agreement
with a Third Party solely to the extent such agreement is for the manufacture and supply of
Belinostat in the Backup Facility; and

21

 

                    (9) nothing in this Agreement shall be deemed to restrict TopoTarget or its Affiliates or
licensees from prosecuting or enforcing the TopoTarget Patents in the Territory or elsewhere with
respect to Belinostat;

               (vii) TopoTarget shall be free to Develop and Commercialize Belinostat, whether alone or with
Third Parties, whether or not in the Field or in the Territory, such Development and
Commercialization to be outside the scope of the Development Plan, the JDC and the JCC;

               (viii) the Parties promptly shall discuss and negotiate in good faith a new Development Plan
for the Backup Compound, provided that the allocation of costs between the Parties with respect to
activities to be undertaken the Development Plan shall be as set forth in Section 4.4(c)(i) and
(ii); and

               (ix) the Parties reasonably shall cooperate with each other to effect the intent of the
Parties as contemplated by this Section 2.6, including by discussing and negotiating any reasonably
necessary amendments to this Agreement.

          (d) Spectrum’s rights under this Section 2.6 shall terminate immediately upon the First
Commercial Sale of any Product containing Belinostat as the active pharmaceutical ingredient.

     2.7 No Other Licenses. Neither Party grants to the other Party any rights, licenses or
covenants in or to any intellectual property, whether by implication, estoppel, or otherwise, other
than the license rights that are expressly granted under this Agreement.

ARTICLE 3

GOVERNANCE

     3.1 Alliance Manager. Each Party shall appoint one (1) employee representative who possesses
a general understanding of clinical, regulatory, manufacturing, and marketing issues to act as its
respective alliance manager for this relationship (“Alliance Manager”). The Alliance Managers will
be responsible for the day-to-day interactions between the Parties related to the Development of
Products in the Field.

     3.2 Joint Development Committee. As of the Effective Date, TopoTarget and Spectrum have
formed a joint development committee (“JDC”) consisting of three (3) representatives from
TopoTarget and three (3) representatives from Spectrum, which representatives are listed on
Exhibit F. Each Party may replace its JDC representatives with another employee of such
Party at any time upon prior written notice to the other Party. A representative designated by
Spectrum shall serve as the chairperson of the JDC and shall be responsible for calling meetings of
the JDC, establishing the agenda for each meeting and initiating the drafting of minutes of the
meetings for approval and finalization by the JDC.

     3.3 Meetings of the JDC. The JDC shall meet within [***] ([***]) days after the Effective
Date and at least once every calendar quarter thereafter, unless otherwise agreed by

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

22

 

the Parties, in each case unless a particular meeting is waived by mutual consent. In
addition, each Party shall have the right to call a meeting of the JDC on reasonable notice to the
other Party. Subject to the foregoing, the JDC shall meet on such dates and at such times as
agreed by the JDC and shall meet via teleconference or videoconference or, if mutually agreed by
the Parties, at a location determined by the JDC. Upon prior written notice to, and approval of,
the JDC, each Party may permit visitors to attend meetings of the JDC, provided that any approved
visitor shall be subject to confidentiality and non-use obligations no less stringent than the
terms of Article 11. Each Party shall be responsible for its own expenses for participating in the
JDC. Meetings of the JDC shall be effective only if at least two (2) representatives of each Party
are present or participating.

     3.4 Responsibilities of the JDC. The JDC shall have the responsibility and authority to:

          (a) discuss, plan, and inform of any further Development of Product in all indications in the
Field in the Territory and TopoTarget Territory, including manufacturing of Products in support of
such activities;

          (b) use Commercially Reasonable Efforts to align each Party’s strategy for the Development of
the Product on a worldwide basis;

          (c) no less frequently than on an annual basis, review, amend and approve any updates to the
Development Plan, including the activities, budget and timeline for Development;

          (d) review and approve proposed Publications in scientific journals resulting from Development
activities;

          (e) establish subcommittees pursuant to Section 3.12 on an as-needed basis, oversee the
activities of all subcommittees so established, and address disputes or disagreements arising in
all such subcommittees; and

          (f) perform such other functions as the Parties may agree in writing.

     3.5 Areas Outside the JDC’s Authority; Other. The JDC shall not have any authority other than
that expressly set forth in Section 3.4 and, specifically, shall have no authority to (a) amend or
interpret this Agreement, or (b) determine whether or not a breach of this Agreement has occurred.
Notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that:
(i) TopoTarget shall be entitled to conduct the Development of the Product in the TopoTarget
Territory as it solely determines, subject to Section 4.4(f)(iii), and (ii) Spectrum shall be
entitled to conduct the Development of the Product in the Territory as it solely determines,
subject to Section 4.3.

     3.6 JDC Decisions.

          (a) Consensus; Good Faith; Action Without Meeting. All decisions of the JDC shall be made by
a unanimous vote, with each Party having one collective vote. The members of the JDC shall act in
good faith to cooperate with one another and to reach agreement with respect to issues to be
decided by the JDC. Action that may be taken at a meeting of the

23

 

JDC also may be taken without a meeting if a written consent setting forth the action so taken
is signed by one (1) duly authorized representative of each Party.

          (b) Failure to Reach Consensus. In the event that the members of the JDC cannot come to
consensus within ten (10) days with respect to any matter over which the JDC has authority and
responsibility, the matter shall be resolved as follows:

               (i) with respect to any matter pertaining to the CUP Clinical Trial and any matter pertaining
to the Development of the Product conducted in the TopoTarget Territory (subject to Section
4.4(f)(iii)), the JDC shall submit the respective positions of the Parties with respect to such
matter to the respective chief executive officers of TopoTarget and Spectrum for resolution. If
such chief executive officers are not able to mutually agree upon the resolution to such matter
within ten (10) days after submission to them, TopoTarget’s chief executive officer shall have the
right to decide such matter reasonably, taking into account and seeking to reasonably accommodate
Spectrum’s legitimate interest under this Agreement, except that in no event can TopoTarget’s chief
executive officer unilaterally decide such matter in a manner (1) that is contrary to the express
terms of this Agreement or (2) that would result in the budget for the Development Plan during the
Initial Funding Period to exceed the Initial Funding Cap or (3) during the period commencing with
the Effective Date and continuing for [***] ([***]) [***] after the Effective Date, that would
result in the performance of Development activities inconsistent with the then current TPP; and

               (ii) with respect to Development of the Product in the Territory, other than the matters set
forth in subsection (i) above (subject to Section 4.3), the JDC shall submit the respective
positions of the Parties with respect to such matter to the respective chief executive officers of
TopoTarget and Spectrum for resolution. If such chief executive officers are not able to mutually
agree upon the resolution to such matter within [***] after submission to them, Spectrum’s chief
executive officer shall have the right to decide such matter reasonably, taking into account and
seeking to reasonably accommodate TopoTarget’s legitimate interest under this Agreement, except
that in no event can Spectrum’s chief executive officer unilaterally decide such matter in a manner
(1) that is contrary to the express terms of this Agreement or (2) that would result in the budget
for the Development Plan during the Initial Funding Period to exceed the Initial Funding Cap or (3)
during the period commencing with the Effective Date and continuing for [***] ([***]) [***] after
the Effective Date, that would result in the performance of Development activities inconsistent
with the then current TPP.

     3.7 Joint Commercialization Committee. Not later than six (6) months prior to the anticipated
First Commercial Sale of Product, Spectrum and TopoTarget shall form a joint commercialization
committee (“JCC”) consisting of two (2) representatives from Spectrum and two (2) representatives
from TopoTarget. Each Party may replace its JCC representatives with another employee of such
Party at any time upon prior written notice to the other Party. A representative designated by
Spectrum shall serve as the chairperson of the JCC and shall be responsible for calling meetings of
the JCC, establishing the agenda for each

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

24

 

meeting and initiating the drafting of the minutes of the meetings for approval and
finalization by the JCC.

     3.8 Meetings of JCC. The JCC shall meet at least once each calendar year, in each case
unless a particular meeting is waived by mutual consent. Subject to the foregoing, the JCC shall
meet on such dates and at such times as agreed by the JCC and shall meet via teleconference or
videoconference or, if mutually agreed by the Parties, at a location determined by the JCC. Upon
prior written notice to, and approval of, the JCC, each Party may permit visitors to attend
meetings of the JCC, provided that any approved visitor shall be subject to confidentiality and
non-use obligations no less stringent than the terms of Article 11. Each Party shall be
responsible for its own expenses for participating in the JCC. Meetings of the JCC shall be
effective only if at least two (2) representatives of each Party are present or participating.

     3.9 Responsibilities of the JCC. The JCC shall have the responsibility and authority to:

          (a) review the Commercialization of Products worldwide and the manufacturing of Products in
support of such activities;

          (b) use Commercially Reasonable Efforts to align each Party’s strategy for the Promotion of
the Product on a worldwide basis;

          (c) establish subcommittees pursuant to Section 3.12 on an as-needed basis, review the
activities of all subcommittees so established, and address disputes or disagreements arising in
all such subcommittees; and

          (d) perform such other functions as the Parties may agree in writing.

     3.10 Areas Outside the JCC’s Authority; Other. The JCC shall not have any authority other
than that expressly set forth in Section 3.9 and, specifically, shall have no authority to (a)
amend or interpret this Agreement, or (b) determine whether or not a breach of this Agreement has
occurred. In addition, notwithstanding anything to the contrary in this Agreement, the Parties
acknowledge and agree that TopoTarget’s manufacturing of the Product shall be outside the decision
making authority of the JCC. Notwithstanding anything to the contrary in this Agreement, the
Parties acknowledge and agree that: (i) TopoTarget shall be entitled to conduct the
Commercialization of the Product in the TopoTarget Territory as it solely determines, and (ii)
Spectrum shall be entitled to conduct the Commercialization of the Product in the Territory as it
solely determines.

     3.11 JCC Decisions.

          (a) Consensus; Good Faith; Action Without Meeting. All decisions of the JCC shall be made by
a unanimous vote, with each Party having one collective vote. The members of the JCC shall act in
good faith to cooperate with one another and to reach agreement with respect to issues to be
decided by the JCC. Action that may be taken at a meeting of the JCC also may be taken without a
meeting if a written consent setting forth the action so taken is signed by one (1) duly authorized
representative of each Party.

25

 

          (b) Failure to Reach Consensus. In the event that the members of the JCC cannot come to
consensus within  [***] [(***)] with respect to any matter over which the JCC has authority and
responsibility, the matter shall be resolved as follows:

               (i) with respect to any matter pertaining to the Commercialization of the Product in the
Territory, the JCC shall submit the respective positions of the Parties with respect to such matter
to the respective chief executive officers of TopoTarget and Spectrum for resolution. If such
chief executive officers are not able to mutually agree upon the resolution to such matter within
[***] [(***)] after submission to them, then Spectrum’s chief executive officer shall have the right to
reasonably decide such matter taking into account and seeking to reasonably accommodate
TopoTarget’s legitimate interest under this Agreement, except that in no event can Spectrum’s chief
executive officer unilaterally decide such matter in a manner that is contrary to the express terms
of this Agreement; and

               (ii) with respect to any matter pertaining to the Commercialization of the Product in the
TopoTarget Territory, the JCC shall submit the respective positions of the Parties with respect to
such matter to the respective chief executive officers of TopoTarget and Spectrum for resolution.
If such chief executive officers are not able to mutually agree upon the resolution to such matter
within [***] [(***)] after submission to them, then TopoTarget’s chief executive officer shall have the
right to reasonably decide any matter concerning Commercialization of the Product in the TopoTarget
Territory, taking into account and seeking to reasonably accommodate Spectrum’s legitimate interest
under this Agreement, except that in no event can TopoTarget’s chief executive officer unilaterally
decide such matter in a manner that is contrary to the express terms of this Agreement.

     3.12 Subcommittees. The JDC and JCC shall each have the right, upon unanimous agreement of
the representatives thereof (Sections 3.6(b) and 3.11(b), respectively, shall not apply) to
establish subcommittees and to delegate certain of its powers and responsibilities thereto.
Subcommittees established by the JDC and JCC shall operate under the same rules as the JDC and JCC
respectively, except that any disputes that cannot be resolved by a subcommittee in a reasonable
time period shall be submitted to the JDC or JCC for resolution in accordance with Section 3.6 or
3.11, respectively.

     The Parties agree that, within thirty (30) days after the first meeting of the JDC, the JDC
shall establish a joint CMC subcommittee (“JCS”) to review and oversee CMC for the Product
worldwide. A representative designated by TopoTarget shall serve as the chairperson of the JCS and
shall be responsible for calling meetings of the JCS, establishing the agenda for each meeting and
initiating the drafting of minutes of the meetings for approval and finalization by the JCS.

     The Parties agree that, within thirty (30) days after the first meeting of the JCC, the JCC
shall establish a joint manufacturing subcommittee (“JMS”) to review and discuss manufacture and
supply of the Product worldwide. A representative designated by Spectrum shall serve as the
chairperson of the JMS and shall be responsible for calling meetings of the JMS, establishing

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

26

 

the agenda for each meeting and initiating the drafting of minutes of the meetings for
approval and finalization by the JMS.

     3.13 Appointment of Alliance Managers and Members of JDC and JCC. The appointment of members
of the JDC and JCC and the Alliance Managers is a right of each Party and not an obligation and
shall not be a “deliverable” as defined in EITF Issue No. 00-21. Each Party shall be free to
determine not to appoint members to the JDC and JCC and not to appoint an Alliance Manager, and at
any time during the Term and for any reason, either Party shall have the right to withdraw from
participation in the JDC and JCC and to remove its Alliance Managers upon written notice to the
other Party, which notice shall be effective immediately upon receipt. If a Party (“Appointing
Party”) does not appoint members of the JDC or JCC or an Alliance Manager, or withdraws from the
JDC or JCC or removes its Alliance Manager, it shall not be a breach of this Agreement, nor shall
there be any associated penalty due nor shall there be any impact on the consideration otherwise
provided for or due to the Appointing Party under this Agreement, and unless and until such persons
are again appointed: (a) the other Party, without regard to the provisions of this Article 3 with
respect to voting, quorum or dispute resolution, may discharge the roles of the JDC or JCC and the
Alliance Manager for which appointments were not made or with respect to which a withdrawal or
removal has occurred by the Appointing Party (including, where the Appointing Party has not made
appointments to the JDC or JCC or has withdrawn from the JDC or JCC, making all decisions within
the decision-making authority of the JDC or JCC, which decisions shall be binding thereafter) and
(b) where the Appointing Party has not made appointments to the JDC or JCC or has withdrawn from
the JDC or JCC, the Appointing Party shall not participate in any meetings of the JDC or JCC and
shall not have the right to approve the minutes of any JDC or JCC meeting. If, at any time
following the Effective Date, a Party has not appointed or has pursuant to this Section withdrawn
from the JDC or JCC or removed its Alliance Manager, and such Party wishes to resume participating
in the JDC or JCC or re-appoint its Alliance Manager, such Party shall notify the other Party in
writing and, thereafter, such notifying Party’s designees shall be entitled to attend any
subsequent meeting of the JDC and JCC and to participate in the activities of, and decision-making
by, the JDC and JCC, and such Party’s Alliance Manager shall resume their duties, in each case as
provided in this Article 3 as if a failure to appoint or submitting the withdrawal notice had not
occurred.

ARTICLE 4

DEVELOPMENT; REGULATORY

     4.1 Development.

          (a) By the Parties. Subject to the terms and conditions of this Agreement including Section
3.6, Spectrum shall be solely responsible for the Development of Products in the Field for
Regulatory Approval in the Territory and TopoTarget shall be solely responsible for the Development
of Products in the Field for Regulatory Approval in the TopoTarget Territory, in each case in
accordance with the Development Plan and TPP. Each Party shall reasonably cooperate with and
provide reasonable support to the other Party in such Party’s conduct of Development activities for
the Product in its respective territory. The Development of Products in the Field shall be
conducted by the Parties in accordance with the terms of this Agreement, including without
limitation the Development Plan and TPP, in good scientific manner and in

27

 

compliance with all applicable good laboratory practices, applicable cGMPs and/or other
Applicable Laws. Neither Party shall on its own or with or for the benefit of any Third Party
engage in any Development activity with respect to Products other than as set forth in this
Agreement or otherwise agreed by the Parties. The Parties will cooperate and use Commercially
Reasonable Efforts to implement a clinical trial program for the Product that is satisfactory to
Regulatory Authorities worldwide and to prepare protocols and coordinate the conduct of such
clinical trials in a manner intended to result in the Parties filing for and obtaining Regulatory
Approval from the FDA, the European Medicines Agency or its successor (“EMEA”) and other Regulatory
Authorities within a reasonably proximate time frame.

     [***].

          (b) The TPP. The TPP shall not be amended, revised or updated except (i) as mutually agreed
by the Parties, (ii) by TopoTarget solely with respect to the Development and Commercialization of
the Product in the TopoTarget Territory, and (iii) by Spectrum solely with respect to the
Development and Commercialization of the Product in the Territory.

     4.2 Development Plan.

          (a) Initial Development Plan. As of the Effective Date, Spectrum and TopoTarget have
established an initial comprehensive plan for a research and development program for obtaining
Regulatory Approval for the Product in the Territory and in the TopoTarget Territory and
manufacturing of the Product worldwide for purposes of obtaining Regulatory Approval for the
Product in the Territory and the TopoTarget Territory (the “Initial Development Plan”). The
Initial Development Plan is attached hereto as Exhibit A and is incorporated herein by
reference. The Initial Development Plan includes a description of the activities to be conducted
by each Party, [***]. Within thirty (30) days after the first meeting of the JDC after the
Effective Date, the Initial Development Plan shall be updated to include a budget and timeline for
such activities. Any existing or future studies conducted with the National Cancer Institute
(“NCI”) or any investigator sponsored trials (“ISTs”) shall be part of the Development Plan. As
set forth in this Article 4, the Development Plan shall designate which Development activities
(including clinical trials which may be worldwide) are to be conducted by the Parties for the
primary purpose of obtaining Regulatory Approval of the Product in the Territory (“Spectrum
Development Activities”) and which Development activities (including clinical trials which may be
worldwide) are to be conducted by TopoTarget for the primary purpose of obtaining Regulatory
Approval of the Product in the TopoTarget Territory (“TopoTarget Development Activities”).

          (b) Development Plan. Periodically throughout the Term as needed and in no event less
frequently than once per calendar year, the JDC shall review, amend and update in writing the
Initial Development Plan for the conduct of Development activities in the Territory

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

28

 

and TopoTarget Territory and manufacturing activities worldwide, and a budget and timeline for
such activities, with respect to Products in the Field in a manner consistent with the TPP (each
such updated plan, along with the Initial Development Plan, referred to as the “Development Plan”).
The Development Plan shall be amended or updated on at least an annual basis no later than October
1 of each calendar year during the term of the Development Program, and more often as the JDC may
reasonably determine, for so long as there is a Product in active Development or mutually agreed to
be Developed. The JDC shall determine which Party shall take the lead in preparing the first draft
of the updated or amended Development Plan. All updated or amended Development Plans shall be
filed with the minutes of the JDC upon approval by the JDC in accordance with Section 3.2. Until
an amended Development Plan is approved by the JDC pursuant to this Section, the previous
Development Plan shall remain in effect. For the avoidance of doubt, any decision regarding the
Development Program made by the JDC pursuant to Section 3.6 shall be deemed to be an update to the
Development Plan and shall be deemed incorporated in the Development Plan as reflected in the JDC
minutes; provided that the JDC shall incorporate all such updates reflected in minutes in a
comprehensive restatement of the Development Plan as part of each annual update cycle of the
Development Plan.

          (c) NCI/IST Studies.

               (i) [***].

               (ii) [***].

               (iii) [***].

          (d) No Activities Outside Development Plan. Prior to undertaking any Development work for the
Product that is not included in the then current Development Plan or engaging or supporting any
Third Parties to conduct such Development activities (including studies with the NCI or ISTs), each
Party shall provide the JDC with its overall plan (including clinical trial design if applicable)
in sufficient time for review and comment by the JDC. The JDC shall then determine whether to
include such Development work in the Development Plan; provided however that, in accordance with
Section 3.6:

               (i) TopoTarget shall have the right to determine whether TopoTarget shall conduct Development
activities in the TopoTarget Territory (subject to Section 4.4(f)(iii)),

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

29

 

and if so, such Development activities shall be added to the Development Plan and be subject
to Section 4.4(c)(ii);

               (ii) TopoTarget shall have the right to determine whether or not to permit Development
activities to be conducted by Spectrum in the TopoTarget Territory, and if permitted, such
Development activities shall be added to the Development Plan and be subject to Section 4.4(c)(i)
and if not permitted, such Development activities shall not be conducted by Spectrum in the
TopoTarget Territory;

               (iii) Spectrum shall have the right to determine whether Spectrum shall conduct Development
activities in the Territory (subject to Section 4.3) and if so, such Development activities shall
be added to the Development Plan and be subject to Section 4.4(c)(i); and

               (iv) Spectrum shall have the right to determine whether or not Development activities may be
conducted by TopoTarget in the Territory, and if permitted, such Development activities shall be
added to the Development Plan and be subject to Section 4.4(c)(ii) and if not permitted, such
Development activities shall not be conducted by TopoTarget in the Territory.

     In addition, each Party may conduct at its sole expense any Phase 4 Clinical Trial of the
Product that is a requirement of, or otherwise requested by, a Regulatory Authority in its
respective territory, and either Party may manufacture Product subject to Section 5.6. Neither
Party shall be obligated to pay for any Development activities outside the scope of the activities
specified in the Development Plan.

     4.3 Spectrum Development Obligations. Spectrum shall use Commercially Reasonable Efforts to
Develop the Products in accordance with the Development Plan and TPP, as such documents may be
amended, which will include Commercially Reasonable Efforts to meet the targeted activity timelines
set forth below, as they may be amended:

          (a) Spectrum will be responsible for (i) finalizing any protocol for any clinical trial to be
conducted to obtain Regulatory Approval of the Product in the Territory, (ii) identifying all sites
and investigators to perform such clinical trials and (iii) obtaining IRB approval for any such
clinical trial;

          (b) Spectrum will assign clinical research associates (“CRAs”) and medical scientific liaisons
(“MSLs”) to the Product, who shall be committed to spending a majority of their time on activities
related to the Development of the Compound or Product;

          (c) Except as otherwise agreed by the JDC, [***] subject to Section 4.4(c)(i), Spectrum shall
commence at least [***] ([***]) randomised clinical trials of the Product within [***] ([***])
months after the Effective Date, subject to the following:

               (i) Spectrum shall be ready to dose, without further delay, the first

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

30

 

(1st) patient in a clinical trial of the Product for any indication within [***]
([***]) days of IRB approval;

               (ii) at least [***] ([***]) clinical trial is expected to be a pivotal registration study;

               (iii) Spectrum shall ensure that the [***] ([***]) clinical trial site for a randomized
clinical trial for the Product for Regulatory Approval in the Territory of the NSCLC Indication
(the “NSCLC Clinical Trial”) is then ready to dose the first (1st) patient, without
further delay, within [***] ([***]) months after the Effective Date, subject to Section 4.4(c)(i),
[***]. [***], provided that the JDC has agreed on the following in advance: (1) protocol design,
(2) a development plan with regulatory options, including FDA guidance (possible Special Protocol
Assessment (SPA) or end of Phase II meeting), (3) comprehensive budget, (4) identification of
principal investigators, and (5) a feasibility study to determine number of sites, geographical
location of sites (Territory vs. TopoTarget Territory), specific Key Opinion Leader (KOL)
involvement, academic vs. community practice and other relevant considerations in advance of study
initiation; and

               (iv) [***] ([***]) patients shall be enrolled by Spectrum in [***] ([***]) or more clinical
trials of the Product during the [***] ([***]) year period commencing with the Effective Date,
which is based on the clinical trials contemplated by the Development Plan and TPP. Patients
included in NCI trials and/or ISTs shall not be counted for purposes of the foregoing [***] ([***])
patient requirement.

          (d) For clarity, the Parties agree that Spectrum’s obligation to perform the foregoing shall
be subject to commercially reasonable conditions being met, such as relevant supportive clinical
study endpoints, safety considerations, achievement of development timelines, successful end of
Phase 2 meetings (if required for progression into the pivotal registration study), approval of the
protocol design by the FDA and, where necessary, approval of an SPA. Notwithstanding the
foregoing, Spectrum shall not be deemed to have failed to perform the foregoing obligations, if it
is using its Commercially Reasonably Efforts, in the event one or more of the following events or
circumstances is attributable to a failure or delay in performance by Spectrum that is outside of
Spectrum’s reasonable control: (i) the occurrence of adverse events or health or safety issues such
that the JDC determines to hold or delay a study, (ii) any regulatory hold, constraint or
restriction imposed or raised by a Regulatory Authority; (iii) process development, manufacture or
supply delays or failures, (iv) any Force Majeure event, or (v) a Third Party alleges that the
manufacture, use or sale of the Product infringes its intellectual property. For the avoidance of
doubt, Spectrum’s failure to meet one of the milestones set forth in this Section 4.3 for a Product
shall not automatically establish Spectrum’s failure to use Commercially Reasonable Efforts to
Develop Products.

     4.4 Development Activities and Development Costs.

          (a) PTCL Indication Clinical Trial. Promptly after the Effective Date, the control of the
ongoing clinical trial of the Product in the PTCL Indication (referred to as the

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

31

 

PXD101-CLN-19 trial or “Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma”)
(this specific trial, the “PTCL Clinical Trial”) at all sites will be transferred to Spectrum and
Spectrum shall be responsible for, and shall have the sole right to conduct, the PTCL Clinical
Trial including clinical trial monitoring, site selection and contract research organization use,
provided that Spectrum shall consider in good faith any input provided by TopoTarget through the
JDC. TopoTarget shall use Commercially Reasonable Efforts to ensure a smooth, orderly and timely
transition of control of the PTCL Clinical Trial to Spectrum. Spectrum shall use Commercially
Reasonable Efforts to complete the PTCL Clinical Trial in a timely manner.

     Spectrum will pay one hundred percent (100%) of the Development Costs associated with the PTCL
Clinical Trial that are accrued by the Parties commencing with the Effective Date; provided that
Spectrum shall not be responsible for any costs accrued under any agreement between TopoTarget and
any Third Party related to the PTCL Clinical Trial unless such agreement is listed on Schedule
4.4(a). For avoidance of doubt, as part of such Development Costs, Spectrum agrees to
reimburse TopoTarget at the FTE Rate for [***] ([***]) TopoTarget FTEs who will be dedicated to the
performance of PTCL Clinical Trial, including the reporting activities for the PTCL Clinical Trial
as set forth in Section 4.7, as directed by Spectrum; provided that, upon written notice to
TopoTarget, Spectrum shall have the right based upon the contribution of such TopoTarget FTEs to
increase or decrease the number of such TopoTarget FTEs on a quarterly basis.

          (b) CUP Indication Clinical Trial. TopoTarget shall be responsible for, and have the sole
right to conduct, the ongoing clinical trial of the Product in the CUP Indication (referred to as
PXD101-CLN-17 — a randomized Phase 2 clinical trial in previously untreated carcinoma of unknown
primary site) (this specific trial, the “CUP Clinical Trial”), provided that TopoTarget shall
consider in good faith any input provided by Spectrum through the JDC. TopoTarget will pay one
hundred percent (100%) of the Development Costs associated with the CUP Clinical Trial that are
accrued by the Parties after the Effective Date.

          (c) Other Development Activities and Costs.

               (i) Except as set forth in Sections 4.4(a) and (b) and subject to Sections 3.6 and 4.2(c), and
subsections (c)(iii), (d) (e) and (f) below, all Development Costs accrued by the Parties after the
Effective Date in the performance of Spectrum Development Activities shall be shared as follows:
Spectrum shall be responsible for seventy percent (70%) and TopoTarget shall be responsible for
thirty percent (30%).

               (ii) TopoTarget shall be responsible for all Development Costs accrued by TopoTarget in the
performance of TopoTarget Development Activities and by Spectrum in the performance of any
TopoTarget Development Activities specifically requested and authorized in advance by TopoTarget.

               (iii) Neither Party may incur costs or expenses that exceed the budget for Development Costs
in the Development Plan by more than [***] percent ([***]%) on a calendar year basis without the
prior written approval of the JDC. In the event either Party

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

32

 

incurs costs or expenses that exceeds the budget by more than [***] percent ([***]%), such
Party shall be solely responsible for such excess costs and expenses.

               (iv) Each Party shall provide the other Party with an accounting in writing of the Development
Costs actually incurred by such Party in the performance of the Development Plan on a monthly
basis, as follows: each Party shall provide a preliminary accounting within ten (10) days after
the end of each calendar month and a final accounting within thirty (30) days after the end of each
calendar month. The Party that has expended less than its percentage share of the Development
Costs under Section 4.4(c)(i) for the calendar month shall pay the amount required to satisfy its
percentage share for the relevant time period by cash or by offset against other amounts due to
such Party on a monthly basis at the time of each accounting for the applicable calendar month.
Notwithstanding the foregoing, the Parties agree that any Development Costs associated with the
start-up of any clinical trial (i.e., costs associated with setting up the clinical trial until
first patient-first visit) shall be paid on a monthly basis in advance and that the Parties
estimate that the maximum amount of Development Costs on a per patient basis for any clinical trial
of the Product in the Territory shall be between [***] Dollars (US$[***]) and [***] Dollars
(US$[***]), as such estimated amounts may be adjusted by the JDC. Spectrum shall use Commercially
Reasonable Efforts to keep per patient costs within such estimated range.

          (d) TopoTarget Failure to Fund Development Costs. TopoTarget commits to fully fund its
thirty percent (30%) share of the Development Costs set forth in Section 4.4(c)(i) above for the
period commencing with the Effective Date and continuing until [***] ([***]) months after the
Effective Date (the “Initial Funding Period”), provided that the total Development Costs incurred
by both Parties under the Development Plan during the Initial Funding Period do not exceed US
$[***] (or such greater amount as the Parties may agree in writing) (the “Initial Funding Cap”).

     In the event that, after the Initial Funding Period, TopoTarget does not pay its thirty
percent (30%) share of all Development Costs incurred by the Parties as described in Section
4.4(c)(i) up to the Initial Funding Cap, then Spectrum shall have the option to pay all or a
portion of such share of Development Costs during the remainder of the Initial Funding Period (such
costs, the “Spectrum Overpayment”). In the event Spectrum incurs any Spectrum Overpayment, then
Spectrum shall be reimbursed by TopoTarget in an amount equal to [***] (the “Spectrum Repayment
Amount”), as follows: Spectrum shall deduct the repayment amount from any payment due to
TopoTarget pursuant to Sections 7.2 (Development Milestone Payments), 7.3 (Sales Milestone
Payments) and 7.5 (Sublicense Revenue) and/or from any royalty payment due to TopoTarget pursuant
to Section 7.4, provided that in no event shall the royalty payment to TopoTarget after deductions
pursuant to this Section and any applicable reductions pursuant to Section 7.4 be reduced to less
than [***] percent ([***]%) of Net Sales of Product in any given calendar year. In the event of
termination of this Agreement for any reason pursuant to Section 12, any Spectrum Repayment Amount
not previously recouped by Spectrum shall be paid to Spectrum within [***] ([***]) days of the
effective date of termination.

          (e) Spectrum Failure to Fund Development Costs. Spectrum commits to

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

33

 

fully fund its seventy percent (70%) share of the Development Costs set forth in Section
4.4(c)(i) above during the Term.

     In the event that, during the Term, Spectrum does not pay its seventy percent (70%) share of
all Development Costs incurred by the Parties as described in Section 4.4(c)(i) up to the Initial
Funding Cap, then TopoTarget shall have the option to pay all or a portion of such share of
Development Costs during the remainder of the Term (such costs, the “TopoTarget Overpayment”). In
the event TopoTarget incurs any TopoTarget Overpayment, then TopoTarget shall be reimbursed by
Spectrum in an amount equal to [***] (the “TopoTarget Repayment Amount”), as follows: Spectrum
shall increase by [***] percent ([***]%) any royalty payment due to TopoTarget pursuant to Section
7.4 until the total TopoTarget Repayment Amount has been repaid. In the event of termination of
this Agreement for any reason pursuant to Section 12, any TopoTarget Repayment Amount not
previously paid by Spectrum shall be paid to TopoTarget within [***] ([***]) days of the effective
date of termination.

          (f) Phase 4 Clinical Trials.

               (i) Spectrum shall be responsible for, and shall have the sole right to conduct all Phase 4
Clinical Trials of the Product in the Field for any Regulatory Authority in the Territory, at
Spectrum’s sole cost and expense.

               (ii) TopoTarget shall be responsible for, and shall have the sole right to conduct all Phase 4
Clinical Trials of the Product in the Field for any Regulatory Authority in the TopoTarget
Territory, at TopoTarget’s sole cost and expense.

               (iii) Notwithstanding the foregoing, (1) if a randomized clinical trial is required by the FDA
for the PTCL Indication, such randomized clinical trial shall not be deemed a Phase 4 Clinical
Trial and shall be included in the Development Plan, subject to the cost allocation specified
Section 4.4(c)(i) and (2) if a randomized clinical trial is required solely by a Regulatory
Authority in the TopoTarget Territory for the PTCL Indication, such randomized clinical trial shall
be included in the Development Plan and be subject to Section 4.4(c)(ii), provided that TopoTarget
shall not conduct a randomized clinical trial for the PTCL Indication in the TopoTarget Territory
prior to Spectrum’s receipt of Regulatory Approval for the PTCL Indication from the FDA.

     4.5 Regulatory Matters.

          (a) Spectrum Responsibility. Promptly after the Effective Date, and subject to Section 4.7,
the IND for the Product shall be transferred to Spectrum. TopoTarget shall take all reasonably
necessary steps and execute all documents reasonably necessary to effectuate such transfer to
Spectrum, for no additional consideration. TopoTarget shall have the right to reference such IND
pursuant to Section 4.6. For avoidance of doubt, TopoTarget shall have an unrestricted, exclusive
and sublicensable right to use for the Development of the Product in the

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

34

 

TopoTarget Territory, all Information, data and results obtained in connection with
Development activities undertaken for obtaining Regulatory Approval for the Product in the
Territory.

     In addition, commencing with the Effective Date, Spectrum shall be responsible for preparing
and filing all Regulatory Materials and seeking all Regulatory Approvals for the Product in the
Field in the Territory, including preparing all reports necessary as part of an NDA. All such
Regulatory Materials for Products in the Territory shall be filed in the name of Spectrum, and
Spectrum alone shall be responsible for all communications and other dealings with Regulatory
Authorities relating to the Products in the Territory. As between the Parties, Spectrum shall be
the legal and beneficial owner of all Regulatory Materials and Regulatory Approvals for the Product
in the Field in the Territory. Spectrum shall use Commercially Reasonably Efforts to obtain
Regulatory Approval for the Products in each jurisdiction within the Territory. All Regulatory
Costs associated with the foregoing regulatory activities for obtaining Regulatory Approvals for
the Product in the Field in the Territory shall be shared as follows: Spectrum shall be
responsible for seventy percent (70%) and TopoTarget shall be responsible for thirty percent (30%),
provided that [***] Regulatory Costs relating to obtaining Regulatory Approval for the PTCL
Indication in the Territory shall be [***].

     Spectrum shall promptly notify TopoTarget of all material Regulatory Materials (including all
material written communications with the FDA) that it proposes to submit or receives and shall
promptly provide TopoTarget with a copy (which may be wholly or partly in electronic form) of such
material Regulatory Materials in the Territory for review by TopoTarget. Spectrum shall reasonably
consider and give due consideration to any comments provided by TopoTarget with respect to such
Regulatory Materials. Spectrum shall retain the right to make any final decisions with respect to
the content of any such communications, which shall be compliant with the Development Plan, this
Agreement and Applicable Law. Spectrum shall provide TopoTarget with reasonable advance notice of
any scheduled meeting with any Regulatory Authority relating to the Product and/or any Regulatory
Approval in the Territory, and TopoTarget shall have the right to have up to two (2) individuals
attend any such meeting as non-participating observers, to the extent practicable and permitted by
Applicable Law; provided that Spectrum will retain the lead role and responsibility in any such
meetings.

          (b) TopoTarget Responsibility. TopoTarget shall have the sole right, but not the obligation,
for preparing and filing all Regulatory Materials and seeking all Regulatory Approvals in the
TopoTarget Territory. All such Regulatory Approvals for Products in the TopoTarget Territory shall
be filed in the name of TopoTarget, and TopoTarget alone shall be responsible for all
communications and other dealings with Regulatory Authorities relating to the Products in the
TopoTarget Territory. As between the Parties, TopoTarget shall be the legal and beneficial owner
of all Regulatory Materials and Regulatory Approvals in the TopoTarget Territory. TopoTarget shall
be responsible for all Regulatory Costs incurred by TopoTarget that are associated with the
foregoing regulatory activities for the Product in the TopoTarget Territory. For avoidance of
doubt, Spectrum shall have an unrestricted, exclusive and sublicensable right to use for the
Development of the Product in the Territory, all Information,

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

35

 

data and results obtained in connection with Development activities undertaken for obtaining
Regulatory Approval for the Product in the Territory.

     TopoTarget shall promptly notify Spectrum of all material Regulatory Materials (including all
material written communications with the EMEA) for the Product in the TopoTarget Territory that it
submits or receives, and shall promptly provide Spectrum with a copy (which may be wholly or partly
in electronic form) of such material Regulatory Materials for review by Spectrum. TopoTarget shall
retain the right to make any final decisions with respect to the content of any such
communications. TopoTarget will provide Spectrum with reasonable advance notice of any scheduled
meeting with any Regulatory Authority relating to the Product and/or any Regulatory Approval in the
TopoTarget Territory, and Spectrum shall have the right to have up to two (2) individuals attend
any such meeting as non-participating observers, to the extent practicable and permitted by
Applicable Law, provided that TopoTarget will retain the lead role and responsibility in any such
meetings.

     4.6 Rights of Reference to Regulatory Materials; Use of Clinical Data. TopoTarget shall
provide Spectrum with a copy of, or access in a reasonably acceptable form to, all Regulatory
Materials that have not already been disclosed to Spectrum, within [***] ([***]) days after the
Effective Date. TopoTarget hereby grants to Spectrum an exclusive, sublicenseable right of
reference to all Regulatory Materials and Regulatory Approvals owned or Controlled by TopoTarget
solely for the purpose of obtaining Regulatory Approval for Product in the Field in Territory
during the Term.

     Spectrum hereby grants to TopoTarget an exclusive, sublicenseable right of reference to all
Regulatory Materials (including the IND) and Regulatory Approvals owned or Controlled by Spectrum
solely for the purpose of obtaining Regulatory Approval for Product in the TopoTarget Territory
during the Term, including to perform the CUP Clinical Trial.

     As between the Parties, each Party shall own all data developed by such Party or its
Affiliates relating to any Compound or Product. Notwithstanding the terms of Article 2, each Party
shall have the right, without any additional payment, to access and use any data, Information or
results developed or acquired by the other Party and its Affiliates relating to any Compound or
Product solely (a) for purposes of Developing the Compounds and Products in accordance with this
Agreement, including for avoidance of doubt TopoTarget’s Development of the Compounds and Product
in the TopoTarget Territory, (b) to support the Regulatory Approval of Products in such Party’s
territory and (c) for Promotional, marketing, and medical education purposes in support of the
Commercialization of Product in such Party’s territory, which right may be sublicensed by such
Party (with the consent of the other Party, not to be unreasonably withheld, conditioned or
delayed) to any Third Party collaborator or licensee that agrees to allow any Product-related
clinical data developed by such collaborator to be used by the other Party for such purposes in a
reciprocal manner in such other Party’s territory.

     For clarity, the rights of reference and use granted by this Section shall be in addition to
the licenses and other rights granted under this Agreement and shall be independent of the

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

36

 

ownership of the Regulatory Materials and Regulatory Approvals as allocated or transferred by
this Agreement.

     4.7 Adverse Event Reporting and Safety Data Exchange. At any time after the Effective Date,
any adverse event (any unwanted or unintended experience in a person that is associated with the
use of a drug, whether or not that experience is caused by that drug, including any known side
effects) or any Product complaint received by either Party regarding a Product will be forwarded to
the other Party as soon as possible, but no later than two (2) calendar days after the Party
receives such adverse event or complaint, by telephone, facsimile or secure e-mail, and shall
promptly provide the other Party with such other information reasonably requested by the other
Party to comply with its reporting obligations in connection with the Development of Product in
support of Regulatory Approval. The Parties agree that TopoTarget shall be responsible for all
safety reporting to Regulatory Authorities under the IND pertaining to the CUP Clinical Trial, and
Spectrum shall be responsible for all safety reporting to Regulatory Authorities under the IND for
the PTCL Clinical Trial and all other clinical trials. Without limiting the allocation of
responsibility set forth in the immediately preceding sentence, TopoTarget shall, on behalf of
Spectrum, provide reporting to Regulatory Authorities for the PTCL Clinical Trial, using the
TopoTarget FTEs dedicated to the PTCL Clinical Trial as determined by Spectrum pursuant to Section
4.4(a) to perform such reporting activities.

     Within [***] ([***]) days after the Effective Date, Spectrum and TopoTarget shall enter into a
pharmacovigilance agreement containing specific terms, conditions and obligations of the Parties
with respect to collection, reporting and monitoring of all adverse drug reactions, adverse events,
product complaints, medical inquiries and other relevant drug safety matters relating to the
Product, sufficient to enable each Party to comply with its reporting obligations and regulatory
submissions in its respective territory with respect to the Product.

     4.8 Communications with Regulatory Authorities.

          (a) General. Each Party shall keep the other Party informed, in a timely manner compliant
with the reporting requirements of Regulatory Authorities in the other Party’s territory, of
notification of any action by, or notification or other information which it receives (directly or
indirectly) from any Regulatory Authority in such Party’s territory with respect to the Product and
which may have a material impact on Regulatory Approval or the continued Commercialization of the
Product in the other Party’s territory.

          (b) Other Communications. Except as may be required by Applicable Law, TopoTarget shall not,
subsequent to final approval by the FDA of the NDA for the Product, communicate regarding the
Product with any Regulatory Authority having jurisdiction in the Territory unless explicitly
requested or permitted in writing to do so by Spectrum or unless so ordered by such Regulatory
Authority in the Territory, in which case TopoTarget shall immediately provide notice of such order
to Spectrum. Except as may be required by Applicable Law, Spectrum shall not communicate with any
Regulatory Authority having jurisdiction in the TopoTarget Territory regarding any Product unless
explicitly requested or permitted in writing to

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

37

 

do so by TopoTarget, or unless so ordered by such Regulatory Authority, in which case Spectrum
shall immediately provide notice of such order to TopoTarget.

     4.9 Regulatory Inspection or Audit. If a Regulatory Authority desires to conduct an
inspection or audit of either Party’s facility or a facility under contract with either Party with
regard to the Product in the Territory, such Party shall cooperate and use Commercially Reasonable
Efforts to cause the contract facility to cooperate with such Regulatory Authority during such
inspection or audit. Following receipt of the inspection or audit observations of such Regulatory
Authority (a copy of which such Party will immediately provide to the other Party), such Party will
prepare the response to any such observations. Such Party agrees to conform its activities under
this Agreement to any commitments made in such a response, except to the extent it believes in good
faith that such commitments violate Applicable Laws.

     4.10 Product Withdrawals and Recalls. Spectrum shall have the right and responsibility, at
its expense, to control any product recall, field correction, or withdrawal of any Product in the
Territory, provided however that Spectrum shall be reimbursed by TopoTarget for expenses of any
recall to the extent provided in the Commercial Supply Agreement. As between the Parties,
TopoTarget shall have the right, at its expense, to control all recalls, field corrections, and
withdrawals of any Product in the TopoTarget Territory. To the extent practicable, the Parties
shall discuss the circumstances of any potential product recall, field correction or withdrawal of
any Product and possible appropriate courses of action. Each Party shall maintain complete and
accurate records of any recall in its territory for such periods as may be required by Applicable
Laws, but in no event for less than [***] ([***]) years.

ARTICLE 5

COMMERCIALIZATION; MANUFACTURING

     5.1 Commercialization by the Parties. Subject to the terms of this Agreement, (a) Spectrum
shall have responsibility and decision-making authority for Commercialization activities with
respect to any Product in the Territory and, except as otherwise provided herein, Spectrum shall be
responsible for [***] and (b) TopoTarget shall have responsibility and decision-making authority
for Commercialization activities for Products in the TopoTarget Territory and TopoTarget shall be
responsible for [***].

     5.2 Commercialization by Spectrum. Spectrum, itself or through its Affiliates or
sublicensees, shall use Commercially Reasonable Efforts to Commercialize Products for which
Regulatory Approval has been received in the Territory. Without limiting the generality of the
foregoing, unless otherwise agreed by the Parties, Spectrum shall satisfy each of the following
requirements:

          (a) Commercially Reasonable Efforts. Spectrum shall use Commercially Reasonable Efforts to
Promote the Product in the Territory by committing FTEs and resources for Promotion activities
consistent with industry standards at least [***] ([***]) year prior to the anticipated date of
Regulatory Approval for the Product for the First Indication;

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

38

 

          (b) Spectrum Sales Force.

               (i) Sales Year [***]. Spectrum will provide at least [***] ([***]) Field Personnel for the
Promotion of the Product for the First Indication in the U.S. Territory (the “Spectrum Sales
Force”) for Sales Year [***]. The Spectrum Sales Force shall be comprised of qualified Field
Personnel who have at least [***] ([***]) years work experience in oncology. The Product will be
the primary focus of the Detailing efforts of the Spectrum Sales Force directed to appropriately
targeted physicians, provided, however, that in the event there are materially significant
differences between the TPP as of the Effective Date and the proposed labeling for the Product for
the First Indication or if the First Indication for the Product is not the PTCL Indication,
Spectrum will have the right to adjust its Commercialization efforts in a commercially reasonable
manner. Spectrum promptly will provide written notice to TopoTarget of any such differences
between the TPP and proposed labeling of which Spectrum becomes aware.

               (ii) Sales Year [***]. For [***], Spectrum will engage the Spectrum Sales Force for the
Promotion of the Product for any approved indication in the U.S. Territory, which Spectrum Sales
Force shall consist of at least [***] ([***]) Field Personnel (unless such number was adjusted
pursuant to subsection (i) above or is adjusted pursuant to subsection (iv) below or the Parties
agree in writing or it is determined by arbitration that it is commercially reasonable for the
Spectrum Sales Force to consist of less than [***] ([***]) Field Personnel) (the “Minimum Sales
Force Number”). Upon TopoTarget’s request from time to time, Spectrum shall provide TopoTarget
with a written statement reasonably identifying such FTEs.

               (iii) Disagreement. In the event that at any time during Sales Year [***], TopoTarget
determines in good faith that Spectrum’s number of FTEs for the Spectrum Sales Force for such Sales
Year is less than the Minimum Sales Force Number, then TopoTarget shall notify Spectrum in writing,
in which case TopoTarget shall have an option (the “Co-Promotion Option”) to Promote in the U.S.
Territory all Products that are being Commercialized by Spectrum under this Agreement as of or
subsequent to the date of exercise of the Co-Promotion Option on the terms set forth in Article 6,
unless Spectrum disputes TopoTarget’s assertion that it does not have the Minimum Sales Force
Number devoted to the Promotion of the Product. TopoTarget shall have the right to exercise the
Co-Promotion Option within [***] ([***]) Business Days of receipt of its notice (such [***] ([***])
Business Day period or the [***] period set forth in subsection (1) below, as applicable, the
“Co-Promotion Option Period”) in order to Co-Promote the Product in the U.S. Territory in
accordance with the terms of Article 6; unless Spectrum has disputed that it does not have the
Minimum Sales Force Number devoted to the Promotion of the Product, in which case Spectrum may
invoke an arbitration proceeding pursuant to Section 13.1(b) in order to have an arbitrator
determine whether or not it has Minimum Sales Force Number devoted to the Promotion of the Product.
Upon a determination by the arbitrator that Spectrum does not have the Minimum Sales Force Number
devoted to the Promotion of the Product, and provided that Spectrum does not increase the number of
Field Personnel to the Minimum Sales Force Number within [***] ([***]) days,

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

39

 

TopoTarget shall have a [***] ([***]) day period following such [***] ([***]) day period to
exercise the Co-Promotion Option in accordance Article 6.

               (iv) Adjustment. Notwithstanding the foregoing, the Parties agree that Spectrum shall have
the right to make commercially reasonable adjustments to its obligation with respect to its Sales
Force for Sales Year [***] and its obligation to launch the Product under Section 5.3 in the event
any of the following events occur outside of Spectrum’s reasonable control and which materially
affect Spectrum’s ability to Commercialize the Product in the U.S. Territory: (1) a Third Party
manufacturer fails to satisfy its supply obligations for the Product, including the obligation to
supply sufficient initial launch quantities of Product not less than ninety (90) days following the
date upon which Regulatory Approval for the Product is granted in the U.S. Territory, (2) market
related events outside of Spectrum’s control (e.g., physician access issues) occur, (3) adverse
events or health or safety issues have occurred or any regulatory hold, constraint or restriction
has been imposed or raised by a Regulatory Authority, (4) any Force Majeure event occurs or (5) a
Third Party alleges that the manufacture, use or sale of the Product infringes its intellectual
property.

     5.3 Launch Efforts. Subject to Section 5.2(b)(iv), Spectrum shall use Commercially Reasonable
Efforts to Commercially launch each Product in the Territory within [***] ([***]) days of receiving
Regulatory Approval therefor.

     5.4 Commercialization Reporting. Through the JCC, each Party shall keep the other Party
reasonably informed regarding the material progress and results of its Commercialization activities
in its territory and those of its Affiliates, sublicensees and Third Party contractors. Each Party
shall provide the JCC with a marketing plan describing such Party’s plans for Commercializing the
Product in its territory.

     5.5 Cross-Territory Sales. Each Party shall not, and shall use Commercially Reasonable
Efforts (consistent with any Applicable Law) to obligate its sublicensees, distributors or
wholesalers to not, deliver or cause to be delivered, including via the Internet or mail order,
Product outside each Party’s territory and to not sell any Product to a purchaser if in either case
such Party or its sublicensees, distributors or wholesalers knows, or has reason to believe, that
such purchaser intends to remove such Product from such Party’s territory for the purpose of sales
or use by patients of the Product in the other Party’s territory. In the event that, despite such
efforts, Product for sale in a Party’s territory is diverted or delivered or sold into the other
Party’s territory, then (a) if such Product were diverted by an identifiable customer, distributor,
employee, consultant or agent of a Party then, upon the request of the other Party, such Party
shall not sell Product to, or allow the sale of Product by, any such customer, distributor,
employee, consultant or agent for the remaining Term and shall use Commercially Reasonable Efforts
to buy back all such Product from such customer, distributor, employee, consultant or agent within
[***] ([***]) business days of such request from the other Party; or (ii) such Party shall use
Commercially Reasonable Efforts to investigate the location of such diverted Product and buy it
back; but, if and to the extent that, such Party elects not to, or is unable to, buy back the
applicable diverted Product, then the other Party may, in its sole discretion, buy back the

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

40

 

applicable diverted Product and such Party shall reimburse the other Party for all reasonable
costs incurred by the other Party in connection with the buy-back of any such diverted Product.

     5.6 Manufacture and Supply of Product.

          (a) Except as set forth below, TopoTarget shall have sole responsibility (either itself or
through one or more contract manufacturers) for manufacturing all clinical and commercial supplies
of Product for Development and Commercialization worldwide, in all formulations in bulk and
finished form, TopoTarget shall supply Spectrum’s requirements for Products for the Territory as
set forth in the Clinical Supply Agreement and Commercial Supply Agreement and, subject to Section
5.6(c)(v)(1), Spectrum (for itself and its sublicensees) shall purchase all of its requirements for
Product from TopoTarget. As of the Effective Date, TopoTarget’s agreements with any Third Party
contract manufacturer for the supply of Product in any formulation are listed on Exhibit G
(the “Manufacturing Agreements”). TopoTarget represents that the existing Manufacturing Agreements
do not contain any obligations for Spectrum to obtain all or part of its requirements from such
Third Parties and TopoTarget will take no action or inaction that would result in any such
obligation or that would adversely affect Spectrum’s rights under this Agreement. TopoTarget shall
not amend or terminate any Manufacturing Agreement without Spectrum’s consent if such amendment or
termination would materially and adversely affect TopoTarget’s obligations under the Clinical
Supply Agreement or Commercial Supply Agreement, which shall not be unreasonably withheld, delayed
or conditioned, and TopoTarget shall use Commercially Reasonable Efforts to comply in all material
respects with its obligations and enforce its rights under each such Manufacturing Agreement.

     Commencing with the Effective Date, TopoTarget shall consult with Spectrum with respect to any
new agreement between TopoTarget and any Third Party related to the manufacture and supply of
Product worldwide. TopoTarget shall not enter into any such new agreement unless Spectrum consents
to the terms for the Territory, such consent not to be unreasonably withheld, conditioned or
delayed; provided that in the event the Parties fail to agree, each Party may obtain supply from
any Third Party for its territory, and provided further that TopoTarget shall continue to supply
Products to Spectrum until such time as Spectrum or its manufacturer is producing Product. The
Parties acknowledge that it may be beneficial to negotiate worldwide supply arrangements with one
or more Third Parties in order to obtain the best pricing and delivery terms from Third Parties.
TopoTarget shall use Commercially Reasonable Efforts to obtain reasonably long term supply
obligations from Third Parties and to include terms and conditions limiting the ability of the
Third Party to increase the price of the Product other than in a commercially reasonable manner.

          (b) Spectrum and TopoTarget will each pay [***] percent ([***]%) of the costs for chemical,
pharmaceutical and other process development related to the manufacturing of the Product that are
incurred after the Effective Date in accordance with a mutually agreed upon budget in the
Development Plan; provided however, that in the event process development work is requested by
either Party as necessary or useful only in its own territory, such Party shall pay [***] percent
([***]%) of the costs. Any payments by a Party to satisfy its percentage share

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

41

 

of such process development costs shall be made in arrears on a monthly basis in a manner
consistent with Section 4.4(c)(iv). If a Party (the “Non-Paying Party”) wishes to use the results
of any particular chemical, pharmaceutical and other process development work paid for solely by
the other Party (the “Sole Paying Party”) in such Non-Paying Party’s own territory, the Non-Paying
Party shall be required to reimburse the Sole Paying Party for [***] percent ([***]%) of the Sole
Paying Party’s costs that it incurred in performing such chemical, pharmaceutical and other process
development work, and from and after such date the Non-Paying Party and Sole Paying Party shall
each pay [***] percent ([***]%) of any additional costs of such process chemical, pharmaceutical
and other process development work.

          (c) Within [***] ([***]) days after the Effective Date, Spectrum and TopoTarget shall
negotiate and execute in good faith an agreement for clinical supply of Product to Spectrum (the
“Clinical Supply Agreement”) and an agreement for commercial supply of Product to Spectrum (the
“Commercial Supply Agreement”). The Clinical Supply Agreement and Commercial Supply Agreement
shall include commercially reasonable terms and conditions, including the following:

               (i) [***];

               (ii) [***];

               (iii) With respect to clinical supply of Product to Spectrum, TopoTarget shall provide all of
Spectrum’s requirements for Product in finished form, labeled and packaged;

               (iv) With respect to commercial supply of Product to Spectrum, TopoTarget shall provide bulk
nested vials and oral bulk tablets (in each case with a certificate of analysis). TopoTarget shall
perform release testing of commercial supplies. Spectrum shall label and package the Product and
shall control its presentation and distribution. TopoTarget shall use its Commercially Reasonable
Efforts to manufacture or have manufactured Product having a shelf life of at least [***] ([***])
months, it being understood and agreed that the shelf life of the Products shall be as provided by
the TopoTarget’s Third Party manufacturers, but that in no event shall the Product supplied to
Spectrum have a remaining shelf life that is shorter than the remaining shelf life of Product
supplied to TopoTarget or its Affiliates, other licensees or distributors. Binding and non-binding
forecasts for the Product shall be consistent with the terms and conditions of the Manufacturing
Agreements;

               (v) [***]:

                    (1) [***].

                    (2) [***].

                    (3) Spectrum shall establish, at its cost, a safety stock of Products comprised of a quantity
of Products sufficient to satisfy Spectrum’s requirements for Products.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

42

 

               (vi) Within [***] ([***]) days after the Effective Date and thereafter periodically
throughout the Term, TopoTarget shall transfer to Spectrum, its Affiliate or the Third Party
manufacturer selected by Spectrum pursuant to Section 5.6(c)(v)(1), all Information, including the
specifications for the Product, Controlled by TopoTarget at such time that is necessary or useful
to enable Spectrum, its Affiliate or a Third Party manufacturer (as appropriate) to replicate the
process employed by or on behalf of TopoTarget to manufacture Product. The internal FTE costs and
expenses of each Party incurred in such transfer shall be borne by such Party. Any costs and
expenses payable to the Third Party manufacturer (“Third Party Manufacturer Costs”) and
TopoTarget’s third party manufacturers shall be borne solely by Spectrum. TopoTarget shall take
commercially reasonable steps to ensure the smooth and timely transfer of the manufacturing process
for Products to Spectrum, its Affiliate or Third Party manufacturer. Spectrum acknowledges and
agrees that TopoTarget may condition its agreement to transfer (or to permit Spectrum to transfer)
any TopoTarget manufacturing technology or Information to a Third Party manufacturer (other than
those Third Party manufacturers with which Spectrum has written agreements as of the Effective
Date) on the execution of a confidentiality agreement between such Third Party manufacturer and
Spectrum that contains obligations of confidentiality and non-use no less stringent than those of
Article 11 of this Agreement. TopoTarget represents, as of the Effective Date and as of the date
of execution of the Commercial Supply Agreement, that there are no contractual limitations or
restrictions under the Manufacturing Agreements with respect to Spectrum qualifying a back-up
supplier of Product and TopoTarget will take no action that would result in any such limitation or
restriction.

               (vii) [***].

               (viii) To the extent permitted by the Manufacturing Agreements, TopoTarget shall pass through
to Spectrum the benefit of any representations, warranties, and indemnities made by the Third Party
manufacturers under the Manufacturing Agreement and any other remedies TopoTarget may have against
such manufacturers. TopoTarget shall not have any liability to Spectrum or any other Person for
any liability solely to the extent attributable to a breach or other failure by any such
manufacturer, provided that Spectrum is a third party beneficiary entitled to enforce the
applicable Manufacturing Agreement against such manufacturer.

     5.7 Promotional Materials.

          (a) All uses of the TopoTarget Trademarks and Spectrum Trademarks shall comply in all material
respects with all Applicable Laws in the Territory. Spectrum may include its company name and
associated logos on all Product packaging and Promotional Materials for the Territory.

          (b) Spectrum shall be responsible, at its expense, for preparing and producing the Promotional
Materials for the Territory. Spectrum shall provide TopoTarget with a final copy of each version
of the Promotional Materials for the Territory promptly after completion thereof. Except as
specifically permitted by this Section 5.7, neither Party shall distribute or

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

43

 

have distributed any materials bearing the name or any trademarks of the other Party without
the prior written approval of such other Party. TopoTarget shall be responsible, at its expense,
for preparing and producing the Promotional Materials for the TopoTarget Territory. TopoTarget
shall provide Spectrum with a final copy of each version of the Promotional Materials for the
Territory promptly after completion thereof. Spectrum agrees that TopoTarget may use in
TopoTarget’s Promotional Materials in the TopoTarget Territory any content included within
Spectrum’s Promotional Materials. TopoTarget agrees that Spectrum may use in Spectrum’s
Promotional Materials in the Territory any content included within TopoTarget’s Promotional
Materials.

          (c) Upon the Co-Promotion Commencement Date, at TopoTarget’s cost, Spectrum shall provide
TopoTarget with the Promotional Materials then used by the Spectrum Sales Force to Promote the
Product in the Territory in quantities sufficient for TopoTarget to satisfy its obligations under
this Agreement, and subsequently shall provide TopoTarget with any updated Promotional Materials.
TopoTarget shall be responsible for distributing the Promotional Materials to the TopoTarget Sales
Force. Spectrum shall own all right, title and interest in the Promotional Materials, including
all intellectual property rights appurtenant thereto. Spectrum hereby grants to TopoTarget a
royalty-free license to use the Promotional Materials during the Term solely in connection with its
Promotion of the Product in the Territory and in accordance with this Agreement, the Co-Promotion
Agreement and Applicable Laws, subject to TopoTarget’s payment of costs as provided in this
Section.

          (d) Neither Party shall use or distribute in connection with Detailing the Product in the
Territory any promotional materials other than the Promotional Materials (branded or non-branded)
in the form(s) prepared and approved in accordance with this Section 5.7. Spectrum shall be solely
responsible for timely submitting, as applicable, any Promotional Materials to the FDA’s Division
of Drug Marketing, Advertising and Communications and to any applicable state Governmental
Authorities in the Territory. TopoTarget shall distribute the Promotional Materials in accordance
with the terms of this Agreement and the Co-Promotion Agreement and shall not distribute any
out-dated Promotional Materials to the extent it has received notice from Spectrum that such
Promotional Materials are out-dated. TopoTarget shall certify that any such out-dated Materials
have been returned to Spectrum or its designee or destroyed, in accordance with Spectrum’s written
policy delivered on the Co-Promotion Commencement Date, as such policies may be updated from time
to time by Spectrum.

ARTICLE 6

TOPOTARGET CO-PROMOTION RIGHT

     6.1 Option Exercise. TopoTarget may exercise the Co-Promotion Option by written notice to
Spectrum at any time during the Co-Promotion Option Period pursuant to Section 5.2(b)(iii),
provided that TopoTarget may not exercise the Co-Promotion Option if TopoTarget is in material
breach of this Agreement and has not cured such breach within the sixty (60) day period set forth
in Section 12.3. The Co-Promotion Option shall automatically and irrevocably expire in the event
(i) TopoTarget has not provided written notice to Spectrum of its exercise of the Co-Promotion
Option during the Co-Promotion Option Period or (ii) there is a Change of Control of TopoTarget
prior to the exercise by TopoTarget of the Co-Promotion Option, unless

44

 

Spectrum consents to the exercise of the Co-Promotion Option by the acquirer of TopoTarget,
which consent shall not be unreasonably withheld, delayed or conditioned.

     6.2 Grant of Co-Promotion Right. In the event TopoTarget exercises the Co-Promotion Option by
written notice to Spectrum pursuant to Section 6.1, then Spectrum hereby grants to TopoTarget the
co-exclusive (with Spectrum) right to Promote Products in the U.S. Territory during the
Co-Promotion Term, on the terms and subject to the conditions set forth herein (the “Co-Promotion
Right”). For clarity, TopoTarget shall have no right to Detail or Promote the Product in the U.S.
Territory prior to the Co-Promotion Commencement Date. Promptly upon the grant of the Co-Promotion
Right, the Parties shall enter into a co-promotion agreement (“Co-Promotion Agreement”) that will
contain commercially reasonable terms for the Promotion of the Product by TopoTarget in the U.S.
Territory, including the following:

          (a) Co-Promotion Term. The Co-Promotion Right shall commence on the date that is [***]
([***]) months after the date of exercise of the Co-Promotion Option (the “Co-Promotion
Commencement Date”) and shall continue in effect until [***] (the “Co-Promotion Term”).

          (b) Co-Promotion Sales. [***]. The Co-Promotion Agreement shall provide each Party with
audit rights with respect to the foregoing consistent with the audit right under this Agreement.

          (c) Sales Force.

               (i) During the Co-Promotion Term, TopoTarget shall Detail and Promote the Product in the U.S.
Territory in accordance with the Co-Promotion Agreement and this Agreement using a commercially
reasonable number of qualified sales representatives who have at least [***] ([***]) years work
experience in oncology (which number in no event shall be less than the Minimum Sales Force Number
minus the number of FTEs in the Spectrum Sales Force in the U.S. Territory) or the Co-Promotion
shall terminate. During the Co-Promotion Term, all Details and Promotion activities conducted by
TopoTarget shall be under the reasonable direction of Spectrum, shall be overseen by Spectrum and
shall be in accordance with Spectrum’s SOPs and in compliance with all Applicable Laws. TopoTarget
shall manage the TopoTarget Sales Force and shall implement Spectrum’s sales strategies and plans.
TopoTarget shall use Commercially Reasonable Efforts to provide the TopoTarget Sales Force with the
level of oversight, management, direction and sales support with respect to the Promotion of
Product to effectively and efficiently Promote the Product in accordance with the terms of this
Agreement. During any period in which the TopoTarget Sales Force is Co-Promoting the Product, the
Parties will use Commercially Reasonable Efforts at the local level to coordinate Details by the
Spectrum Sales Force with Details by the TopoTarget Sales Force in a manner intended to increase
effective coverage of the target audience and to decrease non-productive efforts. Except as set
forth in Section 6.2(b) and Section 6.2(d), TopoTarget shall bear all of the costs and expenses
incurred by TopoTarget or its employees, consultants, service providers, or agents in connection
with the Co-Promotion Agreement and shall indemnify and defend the

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

45

 

Spectrum Indemnitees from and against any and all claims, damages, liabilities, costs
and expenses resulting from TopoTarget’s Promotion of the Product, except to the extent such
claims, damages, liabilities, costs and expenses arise out of or relate to compliance with
Spectrum’s SOPs, directions, Promotional Materials or Spectrum’s breach of this Agreement or
Applicable Laws. Spectrum shall bear all of the costs and expenses incurred by Spectrum or its
employees, consultants, service providers, or agents in connection with the Co-Promotion Agreement
and shall indemnify and defend the TopoTarget Indemnitees from and against any and all claims,
damages, liabilities, costs and expenses resulting from TopoTarget’s compliance with Spectrum’s
SOPs, directions, Promotional Materials or from Spectrum’s breach of this Agreement or Applicable
Laws, except to the extent such claims, damages, liabilities, costs and expenses arise out of or
relate to TopoTarget’s failure to comply with Spectrum’s SOPs, directions, Promotional Materials or
TopoTarget’s breach of this Agreement or Applicable Laws. Except as set forth in Section 6.2(b)
and Section 6.2(d), each Party shall be solely responsible for all costs and expenses of
recruiting, hiring, training, maintaining and compensating its Sales Force, including salaries,
benefits and incentive compensation, provided that such incentive compensation shall not be
structured in a manner that would reasonably be expected to inappropriately motivate such
individuals to engage in the improper Promotion or sales of Product.

               (ii) Each Party shall indemnify the other Party and Affiliates against any Losses for any
payment or obligation to make a payment to any of its employees or agents for the co-promotion of
Product relating in any way to any compensation or benefits or the payment or withholding of any
contributions, payroll taxes, or any other payroll-related item, even if it is subsequently
determined by any court or any other Governmental Authority that any such employee or agent may be
a common law employee of the other Party and/or its Affiliates, distributors or sublicensees or
otherwise entitled to such benefits.

               (iii) In no case shall TopoTarget be responsible for, or liable to Spectrum on account of, the
inaccurate or misleading content of any of Spectrum’s Promotional Material.

          (d) Samples; Training. Spectrum shall bear all costs related to the supply of Product samples
and promotional materials, the cost of creating and implementing the TopoTarget Sales Force
training programs, and all marketing costs and expenses, provided that expenses shall be limited to
expenses for the Reimbursed Sales Representatives only. Spectrum or its distributor(s) or
sublicensee(s), as applicable, shall develop and implement the training program for the respective
Sales Forces for the co-promotion of Products in the U.S. Territory, and TopoTarget agrees to
utilize such training program to assure a consistent, focused promotional strategy and message.

          (e) No Sales or Distribution; Returns. With respect to the U.S. Territory, Spectrum shall
sell all Product to each customer, and shall book each sale. The Parties recognize that TopoTarget
may from time to time receive orders for the Product directly from Third Parties for delivery in
the U.S. Territory. In such event, TopoTarget promptly shall advise such Third Party that
TopoTarget is not authorized to accept orders for the Product and shall immediately and accurately
forward such order to Spectrum, or its designee, which order Spectrum may accept or reject in its
sole discretion. Spectrum shall be responsible for handling all returns of

46

 

the Product with respect to the U.S. Territory. If any Product sold in the U.S. Territory is
returned to TopoTarget, TopoTarget shall either promptly destroy or ship such Product to Spectrum
or its designee, as directed by Spectrum, at Spectrum’s expense, and in accordance with Applicable
Laws.

ARTICLE 7

FINANCIALS

     7.1 License Fee. Not later than two (2) Business Days after Spectrum receives wire transfer
information from TopoTarget after the Effective Date, Spectrum shall pay to TopoTarget a
non-refundable, non-creditable license fee of Thirty Million Dollars (US $30,000,000) by wire
transfer of immediately available funds into an account designated by TopoTarget.

     7.2 Development Milestone Payments. Spectrum shall make development milestone payments to
TopoTarget as follows:

          (a) Acceptance of First NDA. Upon the acceptance by the FDA of the first NDA filed by
Spectrum or an Affiliate or sublicensee of Spectrum for a Product for the First Indication and in
accordance with the Registration Rights and Stockholder Agreement, Spectrum shall issue one million
(1,000,000) shares of Spectrum Common Stock (such 1,000,000 shares of Common Stock, as adjusted
from time to time on and after the Effective Date for any stock splits, stock dividends and other
similar adjustments, the “Spectrum NDA Shares”), to TopoTarget on a date to be determined upon the
mutual agreement of Spectrum and TopoTarget, but in no event later than the tenth (10th) Business
Day following such FDA acceptance (the “Issuance Date”). As used herein, “Common Stock” means
shares of Spectrum common stock, $0.001 par value per share. If any of the following events occur
prior to the issuance of the Spectrum NDA Shares, namely (i) any consolidation, merger or
combination of Spectrum with another person as a result of which holders of Common Stock shall be
entitled to receive stock, securities or other property or assets (including cash) with respect to
or in exchange for such Common Stock, (ii) any statutory exchange, as a result of which holders of
Common Stock generally shall be entitled to receive stock, securities or other property or assets
(including cash) with respect to or in exchange for such Common Stock (such transaction, a
“Statutory Exchange”), or (iii) any sale or conveyance of the properties and assets of Spectrum as,
or substantially as, an entirety to any other person as a result of which holders of Common Stock
shall be entitled to receive stock, securities or other property or assets (including cash) with
respect to or in exchange for such Common Stock, then Spectrum shall hold, set aside in an
unencumbered fund (free of liens) and, upon satisfaction of the condition described in the first
sentence of this Section 7.2(a), issue (and shall cause any successor or purchasing person, as the
case may be, to hold, set aside in an unencumbered fund (free of liens) and, upon satisfaction of
the condition described in the first sentence of this Section 7.2(a), issue), all of the kind and
amount of shares of stock and other securities or property or assets (including cash) receivable
upon such reclassification, change, consolidation, merger, combination, Statutory Exchange, sale or
conveyance by a holder of a number of shares of Common Stock equal to the number of Spectrum NDA
Shares immediately prior to such reclassification, change, consolidation, merger,

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

47

 

combination, Statutory Exchange, sale or conveyance assuming such holder of Common Stock did
not exercise his rights of election, if any, that holders of Common Stock who were entitled to vote
or consent to such transaction had as to the kind or amount of securities, cash or other property
receivable upon such consolidation, merger, combination, Statutory Exchange, sale or conveyance
(provided that, if the kind or amount of securities, cash or other property receivable upon such
consolidation, merger, combination, Statutory Exchange, sale or conveyance is not the same for each
share of Common Stock in respect of which such rights of election shall not have been exercised
(“non-electing share”), then for the purposes of this Section 7.2(a) the kind and amount of
securities, cash or other property receivable upon such consolidation, merger, combination,
Statutory Exchange, sale or conveyance for each non-electing share shall be deemed to be the kind
and amount so receivable per share by a plurality of the non-electing shares). The above
provisions of this Section 7.2(a) shall similarly apply to successive reclassifications, changes,
consolidations, mergers, combinations, Statutory Exchanges, sales and conveyances.

          (b) PTCL Indication.

               (i) [***] Dollars (US $[***]) upon acceptance by the FDA of the first NDA filed by Spectrum or
an Affiliate or sublicensee of Spectrum for a Product for use in the PTCL Indication; and

               (ii) [***] Dollars (US $[***]) upon receipt by Spectrum or an Affiliate or sublicensee of
Spectrum of Regulatory Approval from the FDA for a Product for use in the PTCL Indication.

          (c) First Non-PTCL Indication.

               (i) [***] Dollars (US $[***]) upon initiation by Spectrum or an Affiliate or sublicensee of
Spectrum of treatment of the first patient in a Phase III Clinical Trial of a Product for use in
the First Non-PTCL Indication.

               (ii) [***] Dollars (US $[***]) upon acceptance by the FDA of the first NDA or filed by
Spectrum or an Affiliate or sublicensee of Spectrum for a Product for use in the First Non-PTCL
Indication; and

               (iii) [***] Dollars (US $[***]) upon receipt by Spectrum or an Affiliate or sublicensee of
Spectrum of Regulatory Approval from the FDA for a Product for use in the First Non-PTCL
Indication.

          (d) Second Non-PTCL Indication.

               (i) [***] Dollars (US $[***]) upon acceptance by the FDA of the first NDA filed by Spectrum or
an Affiliate or sublicensee of Spectrum for a Product for use in the Second Non-PTCL Indication;
and

               (ii) [***] Dollars (US $[***]) upon receipt by Spectrum or an Affiliate

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

48

 

or sublicensee of Spectrum of Regulatory Approval from the FDA for a Product for use in the
Second Non-PTCL Indication.

          (e) Additional Milestone. In the event (i) of receipt by Spectrum or an Affiliate or
sublicensee of Spectrum of Regulatory Approval from the FDA for a Product for use in any indication
(other than the PTCL Indication, First Non-PTCL Indication or Second Non-PTCL Indication) (the
“Additional Indication”) and (ii) such Regulatory Approval for such Additional Indication was
obtained (1) through the use of efficacy and safety information and data generated solely by
TopoTarget at TopoTarget’s sole cost and expense for the purpose of obtaining Regulatory Approval
of the Product in the TopoTarget Territory for such Additional Indication and that was provided to
Spectrum pursuant to this Agreement but (2) without the use of any efficacy information or data
generated from any clinical trial of the Product for the Additional Indication performed by
Spectrum or an Affiliate or sublicensee of Spectrum, then Spectrum shall pay to TopoTarget a
milestone payment in an amount equal to [***] Dollars (US $[***]), [***].

     Each milestone payment in this Section 7.2 shall be paid only once regardless of the number of
Products (including Belinostat or a Backup Compound) that achieve such milestones, and shall be
non-refundable and non-creditable. The maximum total amount of payment to TopoTarget pursuant to
Sections 7.2(b) through (e) shall be $[***].

     7.3 Sales Milestone Payments. Spectrum shall make each of the sales milestone payments
indicated below to TopoTarget when cumulative, aggregate Net Sales from and after the Effective
Date of all Products by Spectrum, its Affiliates and sublicensees in the Territory reach the
specified dollar values:

	 	 	 	 	 
	Cumulative, Aggregate Net Sales in the Territory	 	Payment
	US $[***]
	 	US $[***]
	US $[***]
	 	US $[***]
	US $[***]
	 	US $[***]
	US $[***]
	 	US $[***]
	US $[***]
	 	US $[***]

Each milestone payment in this Section 7.3 shall be paid only once. The maximum total amount of
payment to TopoTarget pursuant to this Section 7.3 shall be $[***]. Spectrum shall notify and pay
to TopoTarget the amounts set forth in this Section 7.3 within [***] after the delivery due date of
the quarterly report pursuant to Section 7.6 for the calendar quarter in which the applicable event
was achieved. For clarity, in the event that more than one of the aggregate Net Sales thresholds
is achieved in a calendar year, Spectrum shall owe each of the corresponding payments. Each such
payment shall be made by wire transfer of immediately available funds into an account designated by
TopoTarget. Each such payment is nonrefundable and noncreditable against any other payments due
hereunder.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

49

 

     7.4 Royalties.

          (a) Royalty Rate. Subject to the terms of this Section 7.4 and 6.2(b), Spectrum shall pay to
TopoTarget a royalty of [***] percent ([***]%) on Net Sales of Products by it and its Affiliates
and sublicensees in the Territory, as adjusted pursuant to this Section.

          (b) Royalty Reduction — Generic Competition. In the event a Product is subject to Generic
Competition in a country in the Territory, then the royalty rate set forth in Section 7.4(a) (as
such rate may have been adjusted under Section 7.4(d)) shall be reduced by [***] percent ([***]%)
in such country, provided that if the royalty rate set forth in Section 7.4(a) has already
been reduced pursuant to Section 7.4(c), the amount of the reduction permitted to be taken under
this Section 7.4(b) shall be limited to [***] percent ([***]%) of the royalty rate prior to the
reduction being taken under Section 7.4(c). Such royalty reduction shall become effective on the
first day of the month after the month in which on such Generic Competition first occurs and shall
expire on the last day of the month in which such Generic Competition ceases to exist, subject to
the royalty duration provided for under Section 7.4(e).

          (c) Royalty Reduction — Patent Expiry. In the event the expiration of the last to expire
Valid Claim of a TopoTarget Patent in the U.S. Territory Covering a Product occurs prior to the
expiration of the [***] period set forth in Section 7.4(e), the royalty rate set forth in Section
7.4(a) (as such rate may have been adjusted under Section 7.5(d)) for such Product shall be reduced
by [***] percent ([***]%) for the remainder of the applicable royalty duration. Notwithstanding
the foregoing, (i) this Section 7.4(c) shall not apply during any time period that the royalty
rates are reduced pursuant to Section 7.4(b) and (ii) this Section 7.4(c) shall only apply during
such period that the payment of royalties set forth herein beyond the expiration of the last to
expire Valid Claim would render the TopoTarget Patent unenforceable (i.e., until such time as a
court of competent jurisdiction in the U.S. Territory holds in a final and non-appealable judgment
(or judgment from which no appeal was taken within the allowable time period) or a law or
administrative order explicitly provides that the payment of royalties beyond the expiration of the
last to expire Valid Claim does not render the TopoTarget Patent unenforceable).

          (d) Royalty Reduction — Anti-Stacking. In the event the manufacture, use or sale of any
Compound or Product in the Territory under this Agreement would infringe the intellectual property
rights of any Third Party absent a license thereunder, which manufacturing, use or sale activity,
as of the Effective Date, is also encompassed within any claim of the TopoTarget Patents, and
Spectrum reasonably obtains a license under such intellectual property rights, then Spectrum may
deduct from the royalties due to TopoTarget pursuant to this Section 7.4 [***] percent ([***]%) of
any payments actually paid to any such Third Party as consideration solely for any such license to
such intellectual property rights; provided that in no event shall the royalties due to TopoTarget
for a given calendar quarter be reduced under this Section 7.4(d) by more than [***] percent
([***]%) (but not any payments due under Section 4.4(e), which shall be paid in full)). Unused
credit amounts may be carried over into subsequent quarterly periods.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

50

 

          (e) Duration. Royalties shall be payable under this Section 7.4 on a
country-by-country and Product-by-Product basis during the period commencing with First Commercial
Sale of Product in the Territory and continuing until the later of: (i) [***] or (ii) [***].

     7.5 Sublicense Revenue. Without limitation of Spectrum’s obligations to pay the milestone
payments pursuant to Sections 7.2 and 7.3, whether achieved by Spectrum or its Affiliates or
sublicensees, or royalty payments pursuant to Section 7.4, Spectrum shall pay TopoTarget [***]
percent ([***]%) of any Sublicense Revenue received by Spectrum from any sublicensee under a
sublicense agreement entered into after the Effective Date.

     7.6 Spectrum Payments and Reports. Within sixty (60) days after the end of each calendar
quarter, Spectrum shall provide TopoTarget with a statement of (a) the amount of gross sales of
Product in the Territory by Spectrum, its Affiliates and sublicensees during the applicable
calendar quarter, (b) an itemized calculation of Net Sales showing Net Sales Deductions during such
calendar quarter, (c) a calculation of the amount of royalty payment due on such sales for such
calendar quarter pursuant to Section 7.4, (d) any milestone payment due pursuant to Section 7.2 or
7.3 and (e) Sublicense Revenue received by Spectrum and the percentage of Sublicense Revenue due
under Section 7.5. Concurrently with each statement, Spectrum shall pay to TopoTarget the royalty
payment for such calendar quarter pursuant to Section 7.4, any milestone payment due pursuant to
Section 7.2 or 7.3 and any percentage of Sublicense Revenue payment due pursuant to Section 7.5.
All amounts payable to TopoTarget under this Agreement shall be paid in United States dollars.

     7.7 Taxes. All payments required to be paid under this Agreement shall be paid without
deduction or withholding of any taxes, except as set forth in this Section 7.7. The Parties agree
to cooperate with one another and use reasonable efforts to minimize obligations for any and all
income or other taxes required by Applicable Law to be withheld or deducted from any of the royalty
and other payments made by or on behalf of a Party hereunder (“Withholding Taxes”). The applicable
paying Party under this Agreement (the “Paying Party”) shall, if required by Applicable Law, deduct
from any amounts that it is required to pay to the recipient Party hereunder (the “Recipient
Party”) an amount equal to such Withholding Taxes, provided that the Paying Party shall
give the Recipient Party reasonable notice prior to paying any such Withholding Taxes. Such
Withholding Taxes shall be paid to the proper taxing authority for the Recipient Party’s account
and, if available, evidence of such payment shall be secured and sent to recipient within one (1)
month of such payment. The Paying Party shall, at the Recipient Party’s cost and expense, do all
such lawful acts and things and sign all such lawful deeds and documents as the Recipient Party may
reasonably request to enable the Paying Party to avail itself of any applicable legal provision or
any double taxation treaties with the goal of paying the sums due to the Recipient Party hereunder
without deducting any Withholding Taxes. For the sake of clarity, in no event shall the Paying
Party be required to pay any additional amounts, whether in the nature of a “gross up” payment or
otherwise, to the Recipient Party on account of such Withholding Taxes.

     7.8 No Setoff. Except as provided in Section 4.4(c) or 7.4, all payments due to TopoTarget
under this Agreement shall be made without setoff or deduction of any kind if TopoTarget does not
dispute that it owes money to Spectrum, provided that this Section 7.8 shall not apply to any money
damages awarded to Spectrum in a final, non-appealable judgment (or

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

51

 

judgment from which no appeal was taken within the allowable time period) awarded against
TopoTarget.

     7.9 Late Payments. If a Party does not receive payment of any sum due to it on or before the
due date, simple interest shall thereafter accrue on the sum due to such Party from the due date
until the date of payment at [***] per annum or the maximum rate allowable by Applicable Law,
whichever is less.

     7.10 Records; Audits. Spectrum shall maintain complete and accurate books and records in
accordance with GAAP (to the extent appropriate) in sufficient detail to permit TopoTarget to
confirm the accuracy of [***] under this Agreement, and Spectrum’s compliance with the
Manufacturing Limitations, for a period of [***] ([***]) years from the creation of individual
records or any longer period required by Applicable Law. At TopoTarget’s request, such records
going back no more than [***] ([***]) years shall be available for review not more than once each
calendar year (during normal business hours on a mutually agreed date with reasonable advance
notice) by an independent Third Party auditor selected by TopoTarget and approved by Spectrum (such
approval not to be unreasonably withheld, conditioned, or delayed) and subject to confidentiality
and non-use obligations no less stringent than those set forth in Article 11 for the sole purpose
of verifying for TopoTarget the accuracy of the financial reports furnished by Spectrum pursuant to
this Agreement or of any payments made by Spectrum to TopoTarget pursuant to this Agreement. Any
such auditor shall not disclose Spectrum’s Confidential Information to TopoTarget, except to the
extent such disclosure is necessary to verify the accuracy of the financial reports furnished by
Spectrum or the amount of payments due by Spectrum under this Agreement. Any amounts shown to be
owed but unpaid or overpaid and in need of reimbursement shall be paid or refunded (as the case may
be) within thirty (30) days after the accountant’s report, plus interest (as set forth in Section
7.9) from the original due date. [***].

ARTICLE 8

INTELLECTUAL PROPERTY

     8.1 Ownership of Inventions. Each Party shall own all inventions and Information made solely
by the respective employees, agents, and independent contractors of it and its Affiliates in the
course of conducting such Party’s activities under this Agreement (collectively, “Sole
Inventions”). All inventions and Information that are conceived, reduced to practice, authored or
otherwise made jointly by employees, Affiliates, agents, or independent contractors of both Parties
in the course of performing activities under this Agreement (collectively, “Joint Inventions”)
shall be owned jointly by the Parties in accordance with joint ownership interests of co-inventors
under United States patent laws.

     8.2 Disclosure of Inventions. Each Party shall promptly disclose to the other all Sole
Inventions or Joint Inventions relating to Product or its manufacture or use, including all
invention disclosures or other similar documents submitted to such Party by its, or its
Affiliates’, employees, agents or independent contractors describing such Sole Inventions or Joint

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

52

 

Inventions. Such Party shall also respond promptly to reasonable requests from the other
Party for more Information relating to such inventions.

     8.3 Prosecution of Patents.

          (a) TopoTarget Patents.

               (i) In the Territory. Except as otherwise provided in this Section 8.3(a), as between the
Parties, Spectrum shall have the sole right and authority to prepare, file, prosecute (including
any interferences, reissue proceedings and reexaminations) and maintain, in TopoTarget’s name, the
TopoTarget Patents in the Territory and to retain counsel in its reasonable discretion in
connection therewith, all at [***], subject to TopoTarget’s approval of such counsel, such approval
not to be unreasonably withheld, delayed or conditioned, provided that, unless otherwise agreed in
writing by the Parties, Spectrum shall not knowingly file or prosecute any TopoTarget Patent in the
Territory in a manner materially detrimental to the TopoTarget Patents being prepared, filed,
prosecuted and maintained by TopoTarget in the TopoTarget Territory.

     Spectrum shall keep TopoTarget reasonably informed with respect to the preparation and
prosecution of the TopoTarget Patents in the Territory and shall provide TopoTarget with the right
to review and comment on such preparation and prosecution. Spectrum shall consider reasonable
comments by TopoTarget, but Spectrum shall have ultimate decision-making authority. If Spectrum
determines in its sole discretion that it is not interested in preparing, filing, prosecuting or
maintaining any TopoTarget Patent in the Territory, then Spectrum shall provide TopoTarget written
notice of such determination at least thirty (30) days before any deadline for taking action to
avoid abandonment and TopoTarget shall thereafter have the right and authority to prepare, file,
prosecute and maintain such former TopoTarget Patent in the Territory, at [***] and in consultation
with Spectrum, provided that TopoTarget shall not knowingly file or prosecute any such former
TopoTarget Patent in a manner that would be materially detrimental to the other TopoTarget Patents
being prepared, filed, prosecuted and maintained by Spectrum. Any such former TopoTarget Patent
shall be licensed to Spectrum and shall be considered in determining the royalties on Net Sales of
Products, provided that any such former TopoTarget Patent first prepared, filed, prosecuted and
maintained by TopoTarget after it has experienced a Change of Control shall not automatically be
licensed to Spectrum or considered in determining the royalties on Net Sales of Products unless
agreed to by Spectrum in writing. TopoTarget shall provide Spectrum with all documents (including
all office actions, communications from the relevant patent office and drafts of any filings or
responses thereto, and foreign filings and foreign search report) relevant to such preparation,
filing, prosecution and maintenance by TopoTarget for review and comment by Spectrum, and the
Parties shall discuss all such preparation, filing, prosecution and maintenance in the context of
the IP Committee. TopoTarget shall include reasonable comments by Spectrum.

               (ii) In the TopoTarget Territory. Except as otherwise provided in this Section 8.3(a), as
between the Parties, TopoTarget shall have the sole right and authority to prepare, file, prosecute
(including any interferences, reissue proceedings and reexaminations)

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

53

 

and maintain, in TopoTarget’s name, the TopoTarget Patents in the TopoTarget Territory and to
retain counsel in its sole discretion in connection therewith, all at [***]; provided that
TopoTarget shall not knowingly file or prosecute any TopoTarget Patent in the TopoTarget Territory
in a manner materially detrimental to the TopoTarget Patents being prepared, filed, prosecuted and
maintained by Spectrum in the Territory. To the extent feasible, TopoTarget shall use Commercially
Reasonable Efforts to keep Spectrum informed with respect to the preparation and prosecution of the
TopoTarget Patents in the TopoTarget Territory and shall provide Spectrum with the right to review
and comment on such preparation and prosecution. TopoTarget shall consider reasonable comments by
Spectrum, but TopoTarget shall have ultimate decision-making authority.

               (iii) In the China Territory. Until such time as the China Territory is included in the
Territory pursuant to Section 2.5 or such time that the China Territory is included in the
TopoTarget Territory pursuant to Section 2.5, whichever is earlier, TopoTarget shall have the sole
right and authority to prepare, file, prosecute (including any interferences, reissue proceedings
and reexaminations) and maintain, in TopoTarget’s name, the TopoTarget Patents in the China
Territory and to retain counsel in its sole discretion in connection therewith, all at [***]. To
the extent feasible, TopoTarget shall use Commercially Reasonable Efforts to keep Spectrum informed
with respect to the preparation and prosecution of the TopoTarget Patents in the China Territory
and shall provide Spectrum with the right to review and comment on such preparation and
prosecution. TopoTarget shall include reasonable comments by Spectrum.

          (b) Joint Patents. With respect to any potentially patentable Joint Invention, the Parties
shall meet and agree upon which Party, if any, shall prepare, file, prosecute (including any
interferences, reissue proceedings and reexaminations) and maintain patent applications covering
such Joint Invention (any such patent application and any patents issuing therefrom a “Joint
Patent”) in any jurisdictions throughout the world, as well as the manner in which patent expense
for such Joint Patent will be [***].

     The Party that prosecutes a patent application in the Joint Patents (the “Prosecuting Party”)
shall provide the other Party reasonable opportunity to review and comment on such prosecution
efforts regarding the applicable Joint Patents in the particular jurisdictions, and such other
Party shall provide the Prosecuting Party reasonable assistance in such efforts. The Prosecuting
Party shall provide the other Party with a copy of all material communications from any patent
authority in the applicable jurisdictions regarding the Joint Patent being prosecuted by such
Party, and shall provide drafts of any material filings or responses to be made to such patent
authorities a reasonable amount of time in advance of submitting such filings or responses. In
particular, each Party agrees to provide the other Party with all information necessary or
desirable to enable the other Party to comply with the duty of candor/duty of disclosure
requirements of any patent authority. The prosecuting Party shall consider comments by the
non-prosecuting Party, but each Party shall have ultimate decision-making authority in its own
territory.

     Either Party may determine that it is no longer interested in supporting the continued
prosecution or maintenance of a particular Joint Patent in a country or jurisdiction, in which case

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

54

 

the disclaiming Party shall provide the other Party with written notice of such determination
at least [***] ([***]) days before any deadline for taking action to avoid abandonment and shall
provide the other Party with the opportunity to have the disclaiming Party’s interest in such Joint
Patent in such country or jurisdiction assigned to the other Party, at no cost to the other Party.

     Subject to the license granted to Spectrum pursuant to Section 2.1(a), each Party shall have
the right to practice, license and exploit the Joint Patents worldwide, without consent of the
other Party (where consent is required by law, such consent is hereby deemed granted) and without a
duty of accounting to the other Party.

          (c) Cooperation in Prosecution. Each Party shall provide the other Party all reasonable
assistance and cooperation in the Patent prosecution efforts provided above in this Section 8.3,
including providing any necessary powers of attorney and executing any other required documents or
instruments for such prosecution.

          (d) IP Committee. It is the goal of the Parties to facilitate the exchange of information
between them regarding each Party’s performance of its responsibilities under this Article 8. To
this end, the Parties may from time to time during the Term convene an ad hoc advisory group of
individuals (the “IP Committee”) having the requisite expertise in order to (a) facilitate the
sharing of information between the Parties regarding the Parties’ activities under this Agreement
relating to the filing, prosecution, maintenance and enforcement of the TopoTarget Patents and
TopoTarget Know-How in the Territory and (b) provide a forum for discussing such matters. The IP
Committee shall not have any decision-making rights or responsibilities, and any failure or delay
in obtaining consensus with respect to any issue discussed by this group shall not preclude the
Party having control over a particular matter pursuant to this Article 8 from taking action with
respect to such matter.

     8.4 Enforcement of TopoTarget Technology.

          (a) Notification. If there is any infringement, threatened infringement, or alleged
infringement of the TopoTarget Patents or misappropriation of TopoTarget Know-How on account of a
Third Party’s manufacture, use or sale of a Product in the Territory (in each case, a “Product
Infringement”), then each Party shall promptly notify the other Party in writing of any such
Product Infringement of which it becomes aware, and shall provide evidence in such Party’s
possession demonstrating such Product Infringement. Each Party shall immediately, but in no case
more than five (5) Business Days, give written notice to the other Party of any certification of
which it becomes aware filed pursuant to 21 U.S.C. Sections 355(b)(2)(A)(iv) or
355(j)(2)(A)(vii)(IV) claiming any TopoTarget Patent covering Product is invalid or unenforceable,
or that infringement will not arise from the manufacture, use or sale of a product by a Third
Party.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

55

 

          (b) Enforcement Rights.

               (i) Subject to Section 8.4(d) and the remainder of this Section 8.4(b), during the Term,
Spectrum shall have the first right, but not the obligation, to bring an appropriate suit or other
action against any Person engaged in such Product Infringement of the TopoTarget Technology in the
Territory, at Spectrum’s expense. If Spectrum has not brought suit to enforce such TopoTarget
Technology against such Person within thirty (30) days after Spectrum’s receipt or delivery (as
applicable) of notice and information under Section 8.4(a), then TopoTarget shall have the right,
but not the obligation, to commence a suit or take action to enforce the applicable TopoTarget
Technology with respect to such Product Infringement in the Territory, TopoTarget’s expense.
Notwithstanding the foregoing, TopoTarget shall not, and shall not permit any other licensee of
TopoTarget under the TopoTarget Patents in the Territory to, proceed against an alleged infringer
of the TopoTarget Patents in the Territory (1) unless significant damages are reasonably expected
to be recovered from the infringer in such proceeding, and (2) without first consulting with
Spectrum regarding the strategy for such proceeding and considering in good faith Spectrum’s
comments regarding such proceeding, provided that TopoTarget shall not, nor shall it permit any
other licensee of TopoTarget under the TopoTarget Patents in the Territory to, proceed against an
alleged infringer of any claims of a TopoTarget Patent in the Territory that are directed solely to
the sulphonamide class of HDAC Inhibitors without Spectrum’s prior written consent.

     Each Party shall provide to the Party enforcing any such rights under this Section 8.4(b)
reasonable assistance in such enforcement, including using best efforts if required to establish
and maintain standing to join such action as a party plaintiff if required by Applicable Law to
pursue such action. The enforcing Party shall keep the other Party regularly informed of the
status and progress of such enforcement efforts, and shall reasonably consider the other Party’s
comments on any such efforts.

               (ii) Any recovery obtained by any enforcing Party as a result of any proceeding described in
this Section 8.4, by settlement or otherwise, shall be applied in the following order of priority:
[***].

          (c) Settlement. Without the prior written consent of the other Party, such consent not to be
unreasonably withheld, conditioned or delayed, neither Party shall settle any claim, suit or action
that it brought under this Section 8.4 involving TopoTarget Technology in any manner that would
negatively impact such intellectual property or that would limit or restrict the ability of
Spectrum or its Affiliates or licensees to sell Products in the Territory or the ability of
TopoTarget or its Affiliates or licensees to sell Products in the TopoTarget Territory.

          (d) TopoTarget Technology Licensed from Third Parties. Spectrum’s rights under this Section
8.4 with respect to any TopoTarget Technology licensed to TopoTarget by a Third Party shall be
subject and subordinated to the rights of such Third Party to enforce such TopoTarget Technology
and/or defend against any claims that such TopoTarget Technology is invalid or unenforceable, and
the rights of such Third Party to share in any recoveries.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

56

 

     8.5 Patent Marking. Both Parties shall, and shall require its Affiliates and
sublicensees, to mark Products sold by it hereunder with appropriate patent numbers or indicia to
the extent permitted by Applicable Law, in those countries in which such markings or such notices
impact recoveries of damages or equitable remedies available with respect to infringements of
patents.

     8.6 Trademarks.

          (a) Spectrum Trademarks. Spectrum shall be responsible for the selection, adoption,
registration, maintenance and defense of all Compound and Product related trademarks for use in
connection with the sale or marketing of Products in the Territory (the “Spectrum Trademarks”), as
well as all expenses associated therewith. Spectrum shall own all Spectrum Trademarks. All rights
arising from the use by Spectrum of the Spectrum Trademarks in the Territory during the Term shall
inure to Spectrum’s benefit. Spectrum shall have the sole right and discretion to bring
infringement or unfair competition proceedings anywhere in the world involving infringement of or
unfair competitive activities relating to the Spectrum Trademarks in the Territory.

     TopoTarget shall have the right, and is hereby granted an exclusive, royalty-free license, to
adopt, use, register and cause to be registered any of the Spectrum Trademarks solely for use in
connection with the sale, marketing and distribution of Products in the TopoTarget Territory. All
rights arising from the use by TopoTarget of the Spectrum Trademarks in the TopoTarget Territory
during the Term shall inure to TopoTarget’s benefit. TopoTarget shall have the sole right and
discretion to bring infringement or unfair competition proceedings anywhere in the world involving
infringement of or unfair competitive activities relating to the Spectrum Trademarks in the
TopoTarget Territory. TopoTarget shall properly designate the TopoTarget Trademarks on the
packaging of the final Product, to the extent required or permissible by the applicable Regulatory
Approvals and TopoTarget agrees that all Products with which the TopoTarget Trademarks are used
shall conform to all requirements of any Applicable Laws and any Regulatory Authorities in the
TopoTarget Territory.

          (b) TopoTarget Trademarks. Spectrum’s use of the TopoTarget Trademarks in the Territory shall
be limited to the marketing, sale and distribution of the Product. TopoTarget shall have all
rights to the TopoTarget Trademarks in the TopoTarget Territory, as set forth in Section 2.2.
Spectrum shall be responsible for maintaining in its own name the registrations for any or all of
the TopoTarget Trademarks in the Territory, and for defending the TopoTarget Trademarks in the
Territory, all at Spectrum’s sole expense. TopoTarget shall, as soon as practicable after
receiving notice of any potential infringement of the TopoTarget Trademarks in the Territory,
inform Spectrum of any such potential infringement. Spectrum shall have the sole right and
discretion to bring infringement or unfair competition proceedings anywhere in the world involving
infringement of or unfair competitive activities relating to the TopoTarget Trademarks in the
Territory. Spectrum agrees that, during the Term, it will not assign the TopoTarget Trademarks to
any Third Party, except pursuant to Section 14.5. Spectrum shall, as soon as practicable after
receiving notice of any potential infringement of the TopoTarget Trademarks in the TopoTarget
Territory, inform TopoTarget of

57

 

any such potential infringement. TopoTarget shall have the sole right and discretion to bring
infringement or unfair competition proceedings anywhere in the world involving infringement of or
unfair competitive activities relating to the TopoTarget Trademarks in the TopoTarget Territory.

     8.7 Infringement of Third Party IP. Each Party shall promptly notify the other in writing of
any allegation, claim or suit that the manufacture, use or sale of a Product infringes or
misappropriates a Third Party’s Patent or other intellectual property rights. Subject to Section
7.4(d), each Party shall have the sole right to control any defense of any such claim involving
alleged infringement of Third Party rights by such Party’s activities, at its own expense and by
counsel of its own choice.

     Spectrum shall be solely responsible for obtaining, at its sole expense and subject to Section
7.4(d), any agreements with Third Parties required in order to lawfully perform its manufacturing
and Commercialization responsibilities under this Agreement; provided however that, during the
Term, in the event TopoTarget enters into an agreement with a Third Party for the development or
commercialization of Products in the TopoTarget Territory or TopoTarget licenses any intellectual
property necessary or useful for the Development or Commercialization of the Products in the
Territory, TopoTarget shall use Commercially Reasonable Efforts to obtain the right to sublicense
such rights to Spectrum under this Agreement.

     8.8 The CREATE Act. Each Party acknowledges and agrees that: (a) the provisions herein are
intended to encompass and include a joint research agreement for the performance of experimental,
developmental and research work as contemplated by 35 U.S.C. § 103(c)(3), and that any invention
made in connection with the activities contemplated in this Agreement, whether made solely by or on
behalf of one Party or jointly by or on behalf of both Parties, is intended to and should have the
benefit of the rights and protections conferred by Public Law 108-453, the Cooperative Research and
Enhancement Act of 2004 as codified in 35 U.S.C. §103(c)(2) (the “CREATE Act”); (b) in the event
that a Party seeks to rely on the foregoing and invoke the CREATE Act with respect to any invention
that is the subject of a patent application filed by or on behalf of such Party, such Party will
give prior written notice(s) to the other Party of its intent to invoke the CREATE Act and of each
submission or disclosure such Party intends to make to the USPTO pursuant to the CREATE Act,
including: (i) any disclosure of or regarding the existence or contents of this Agreement to the
USPTO; (ii) the disclosure of any “subject matter developed by the other Party” (as such term is
used in the CREATE Act) in, without limitation, an information disclosure statement, or (iii) the
filing of any terminal disclaimer over the intellectual property of the other Party, it being
agreed that no such submission, disclosure or filing shall be made by such Party without the prior
written consent of the other Party, such consent not to be unreasonably withheld, conditioned or
delayed; (c) without limiting subsection (b) above (including the obligation to obtain a Party’s
prior approval), it shall not be a violation of confidentiality obligations hereunder for a Party,
as necessary in connection with the invocation of the CREATE Act, to disclose to the USPTO (i) the
intellectual property of the other Party in, without limitation, an information disclosure
statement or (ii) this Agreement, provided that such Party exercises reasonable efforts to limit
the scope of such disclosure as strictly necessary to invoke the CREATE Act, including by
reasonably redacting the material terms of this Agreement before any such disclosure; and (d)

58

 

without limiting subsection (b) above, each Party will provide reasonable cooperation to the
other Party in connection with such other Party’s efforts to invoke and rely on the CREATE Act.

     8.9 License to TopoTarget.

          (a) Spectrum hereby grants TopoTarget a royalty-free license to and under the Spectrum Sole
Inventions which relate to a [***]. The foregoing license shall be exclusive (even as to Spectrum
and its Affiliates) with respect to the rights granted under clauses (i) and (ii) above, and
non-exclusive with respect to the rights granted under clause (iii) above.

          (b) The licenses granted by Spectrum to TopoTarget in this Section may be sublicensed by
TopoTarget to any Affiliate or Third Party; provided that TopoTarget shall have the right to
sublicense the license granted by Spectrum under this Section only to sublicensees who agree in
advance to grant TopoTarget a license, with the right to sublicense to Spectrum on a royalty-free
basis, under any invention, data or information made by such sublicensee which relates to a [***].
Any sublicense under the licenses granted by Spectrum to TopoTarget in this Section shall be
consistent with the terms of this Agreement and shall include confidentiality and non-use
obligations no less stringent than those set forth in Article 11.

ARTICLE 9

REPRESENTATIONS, WARRANTIES AND COVENANTS

     9.1 Mutual Representations and Warranties. Each Party hereby represents, warrants, and
covenants (as applicable) to the other Party as follows, as of the Effective Date:

          (a) Corporate Existence and Power. It is a corporation or limited partnership, as applicable,
duly organized, validly existing, and in good standing under the laws of the jurisdiction in which
it is incorporated or formed, and has all requisite power and authority and the legal right to own
and operate its property and assets and to carry on its business as it is now being conducted and
as contemplated in this Agreement, including the right to grant the licenses granted by it
hereunder.

          (b) Authority and Binding Agreement. It has the requisite power and authority and the legal
right to enter into this Agreement and perform its obligations hereunder; it has taken all
necessary action on its part required to authorize the execution and delivery of this Agreement and
the performance of its obligations hereunder; and this Agreement has been duly executed and
delivered on its behalf, and constitutes a legal, valid, and binding obligation of such Party that
is enforceable against it in accordance with its terms, subject as to enforcement of remedies to
applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting generally
the enforcement of creditors’ rights and subject to a court’s discretionary authority with respect
to the granting of a decree ordering specific performance or other equitable remedies.

          (c) Consents. All necessary consents, approvals and authorizations of all Governmental
Authorities and any Third Parties required to be obtained by it in connection with the execution,
delivery and performance of this Agreement have been obtained by it.

 

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

59

 

          (d) No Conflict. The execution and delivery of this Agreement, the performance of such
Party’s obligations hereunder and the licenses and sublicenses to be granted pursuant to this
Agreement (i) to its knowledge, do not conflict with or violate any requirement of Applicable Law
existing as of the Effective Date, (ii) do not conflict with or violate the certificate of
incorporation, certificate of formation, by-laws, limited partnership agreement or other
organizational documents of such Party, and (iii) do not conflict with, violate, breach or
constitute a default under any contractual obligations of such Party or any of its Affiliates
existing as of the Effective Date, except as would not reasonably be expected to have a material
adverse effect on the transactions contemplated by this Agreement.

          (e) Notice of Infringement or Misappropriation. Such Party has not received any written notice
from any Third Party asserting or alleging that the research, Development, making or using of
Compounds or Products by such Party prior to the Effective Date or upon Commercialization,
infringed, misappropriated or diluted, or will infringe, misappropriate or dilute the intellectual
property rights of such Third Party.

     9.2 TopoTarget Technology. TopoTarget hereby represents and warrants to Spectrum as of the
Effective Date that:

          (a) TopoTarget is the sole owner of all right, title and interest in and to, or Controls, with
the right to sublicense, the TopoTarget Patents set forth in Exhibit C, free and clear of
any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien, lease,
sublease, option, or charge of any kind, limitations on transfer or any subordination arrangement
in favor of a Third Party (other than Permitted Encumbrances) and, except for the licenses and
sublicenses contemplated by Article 2 and the Material Contracts, as of the Effective Date it has
granted no other rights in favor of a Third Party under the TopoTarget Technology in the Territory;

          (b) [***].

          (c) as of the Effective Date, to TopoTarget’s knowledge, there are no materials, Information,
or intellectual property rights that TopoTarget has a license, right or covenant to and that, if
TopoTarget provided Spectrum with access, a license, or a sublicense right or covenant (as
applicable) to such materials, Information or intellectual property without violating the terms of
any then-existing agreement or other arrangement with any Third Party, would increase at any time
the amount of any payments required under any such agreement or arrangement;

          (d) no Third Party nor employee of TopoTarget has asserted or alleged in writing to TopoTarget
that it has an ownership interest in the TopoTarget Technology, and no Third Party has contested or
asserted in writing to TopoTarget that the TopoTarget Patents are not valid or enforceable in the
Territory;

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

60

 

          (e) to the knowledge of TopoTarget as of the Effective Date, the Development, manufacture
and Commercialization of the Compound or Product (in its current form) in the Territory does not
infringe any valid or enforceable claims of any Third Party issued patent or, if issued, any claims
of any Third Party pending patent applications;

          (f) TopoTarget has not received written notice of any interference or opposition proceeding
relating to the TopoTarget Patents in the Territory;

          (g) TopoTarget has made available to Spectrum all data, results or other information derived
from or regarding any preclinical or clinical study that would be reasonably expected to be
relevant to an evaluation of any material safety risks associated with the Product; and

          (h) The statements set forth in Schedule 9.2(h) accurately reflect the specifications
for Belinostat as of the Effective Date.

     9.3 TopoTarget Trademark Representations and Warranties. TopoTarget hereby represents and
warrants to Spectrum as of the Effective Date that:

          (a) to the knowledge of TopoTarget, there is no Third Party using or infringing any of the
TopoTarget Trademarks in the Territory in derogation of the rights granted to Spectrum in this
Agreement;

          (b) TopoTarget has not received notice of any opposition or cancellation action or litigation
pending or any communication which expressly threatens an opposition or cancellation action, or
other litigation, before any trademark office, court or any other governmental entity in the
Territory with respect to any of the TopoTarget Trademarks;

          (c) the TopoTarget Trademarks listed on Exhibit D attached hereto are the only
trademarks owned, held, Controlled, licensed or otherwise used (or intended to be used) by
TopoTarget or its Affiliates with respect to the Product in the Territory (other than the
“TOPOTARGET” trademark);

          (d) to the knowledge of TopoTarget, it has all rights necessary to use the TopoTarget
Trademarks with respect to the Product in the Territory and to assign to Spectrum the TopoTarget
Trademarks as set forth above and TopoTarget has not obtained any Third Party consents in
connection with the prosecution of the TopoTarget Trademarks in the Territory; and

          (e) to the knowledge of TopoTarget, it has not infringed, misappropriated, diluted or
otherwise violated any trademark of any Third Parties by registering or using the TopoTarget
Trademarks in the Territory.

     9.4 Compliance with Law. Each Party shall, and shall ensure that its Affiliates and
sublicensees shall, comply in all material respects with all Applicable Laws in exercising their
rights and fulfilling their obligations under this Agreement.

     9.5 Representations regarding Debarment. Each Party represents, warrants and covenants that
as of the Effective Date and during the Term, neither it nor its Affiliates nor any

61

 

of their respective directors, officers, or employees, and, to its knowledge based upon
reasonable inquiry, any Third Party (and its directors, officers, employees and consultants), in
each case who were responsible for the development or whose responsibilities involve the
Development or Commercialization of the Product as authorized by this Agreement or the Promotion of
the Product as authorized by the Co-Promotion Right:

          (a) are debarred under Section 306(a) or 306(b) of the FD&C Act;

          (b) have been charged with, or convicted of, any felony under Applicable Laws related to any
of the following: (A) the development or approval of any drug product or the regulation of any drug
product under the FD&C Act; (B) a conspiracy to commit, aid or abet the development or approval of
any drug product or regulation of any drug product; (C) health care program-related crimes
(involving Medicare or any State health care program); (D) patient abuse, controlled substances,
bribery, payment of illegal gratuities, fraud, perjury, false statement, racketeering, blackmail,
extortion, falsification or destruction of records; (E) interference with, obstruction of an
investigation into, or prosecution of, any criminal offense; or (F) a conspiracy to commit, aid or
abet any of these listed felonies or misdemeanors; and

          (c) is excluded, suspended or debarred from participation, or otherwise ineligible to
participate, in any Federal or State health care programs (including convicted of a criminal
offense that falls within the scope of 42 U.S.C. §1320a-7 but not yet excluded, debarred,
suspended, or otherwise declared ineligible), or excluded, suspended or debarred from
participation, or otherwise ineligible to participate, in any Federal procurement or nonprocurement
programs;

          (d) each Party will notify the other Party immediately, but in no event later than five (5)
days, after knowledge of any exclusion, debarment, suspension or other ineligibility occurring
during the Term.

     9.6 Regulatory Matters. TopoTarget hereby represents and warrants the following to Spectrum
as of the Effective Date:

          (a) TopoTarget has provided or made available, when requested by Spectrum to conduct its due
diligence review, any and all material documents and communications in its possession from and to
the FDA or any other Governmental Authority, or prepared by the FDA or any other Governmental
Authority, related to a Product, that may bear on compliance with the requirements of the FDA or
any other Governmental Authority in the Territory, including any notice of inspection, inspection
report, warning letter, deficiency letter, or similar communication;

          (b) Neither TopoTarget nor any of its Affiliates has received, with respect to a Product, any
oral or written communication (including any warning letter, untitled letter, or similar notices)
from the FDA and there is no action pending or, to TopoTarget’s knowledge, threatened (including
any prosecution, injunction, seizure, civil fine, suspension or recall), in each case alleging that
with respect to a Product, TopoTarget or any of its Affiliates is not currently materially in
compliance with any and all Applicable Laws implemented by the FDA. Neither TopoTarget nor any of
its Affiliates has received any written notice from any

62

 

Governmental Authority claiming that the research, development, manufacture, use, offer for
sale, sale, or import of a Product is materially noncompliant with any Applicable Laws;

          (c) To TopoTarget’s knowledge, none of TopoTarget, any of its Affiliates or any of their
respective officers, employees or agents has made, with respect to a Product, an untrue statement
of a material fact to the FDA or other Governmental Authority or failed to disclose a material fact
required to be disclosed to the FDA or other Governmental Authority;

          (d) To TopoTarget’s knowledge, all testing, research and manufacture of the Products by or on
behalf of TopoTarget and its Affiliates has been conducted in compliance with all Applicable Laws
as applicable and required at the time such activity was performed; and

          (e) There is no material matter known to TopoTarget as of the Effective Date which has not
been disclosed by TopoTarget to Spectrum concerning the safety or efficacy of any Product.

     9.7 Representations regarding Spectrum NDA Shares. TopoTarget hereby represents and warrants
the following to Spectrum as of each of the Effective Date and the Issuance Date:

          (a) Investment Intent. TopoTarget is acquiring the Spectrum NDA Shares for its own account
for investment purposes only and not with a view to or for distributing or reselling such
securities or any part thereof, without prejudice, however, to its right at all times to sell or
otherwise dispose of all or any part of such securities in compliance with applicable federal and
state securities laws and with such other restrictions as may apply, including the restrictions set
forth in the Registration Rights and Stockholder Agreement. TopoTarget does not have any agreement
or understanding, directly or indirectly, with any Person to distribute any of the Spectrum NDA
Shares.

          (b) Purchaser Status. TopoTarget meets one or more of the standards for an “accredited
investor” as defined in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities
Act”).

          (c) Access to Information. TopoTarget has been afforded (i) the opportunity to ask such
questions as it has deemed necessary of, and to receive answers from, representatives of Spectrum
concerning the terms and conditions of the issuance of the Spectrum NDA Shares and the merits and
risks of investing in such securities; (ii) access to information about Spectrum and its financial
condition, results of operations, business, properties, management and prospects sufficient to
enable it to evaluate its investment; and (iii) the opportunity to obtain such additional
information that is necessary to make an informed investment decision with respect to the Spectrum
NDA Shares.

          (d) Restrictions on Resale. TopoTarget understands that the Spectrum NDA Shares to be issued
upon the conditions outlined under Section 7.2(a) have not been and will not be registered under
the Securities Act upon issuance and must be held indefinitely unless or until a subsequent
disposition thereof is registered under the Securities Act (including under the registration
statement contemplated by the Registration Rights and Stockholder Agreement) or is exempt from such
registration, that the Spectrum NDA Shares will also be subject to the

63

 

restrictions on transfer set out in the Registration Rights and Stockholder Agreement, and
that the share certificate for such Spectrum NDA Shares will contain a restrictive legend
substantially as set forth in the Registration Rights and Stockholder Agreement.

     9.8 No Broker. No broker, finder, agent or similar intermediary has acted for or on behalf of
a Party or its Affiliates in connection with this Agreement or the transactions contemplated
hereby, and no broker, finder, agent or similar intermediary is entitled to any broker’s, finder’s
or similar fee or other commission in connection therewith based on any agreement, arrangement or
understanding with a Party or its Affiliates or any action taken by a Party or its Affiliates;
provided that a Party shall bear all liabilities associated with claims by any broker, finder,
agent or similar intermediary that it is entitled to any broker’s, finder’s or similar fee or other
commission in connection with this Agreement or the transactions contemplated hereby asserted
against such Party or its Affiliates.

     9.9 Material Contracts. Schedule 9.9 sets forth all of the agreements to which
TopoTarget or its Affiliates are a party as of the Effective Date that involve the manufacturing of
Products in bulk and finished form or otherwise directly relevant to the manufacture or supply of
Product for sale in the Territory (the “Material Contracts”). All of the Material Contracts have
been delivered or made available (in an acceptable format) to Spectrum (or where a contract or
agreement is other than in writing, Schedule 9.9 contains a true, accurate and complete
summary of the material terms of such contract or agreement) and, as of the Effective Date, to
TopoTarget’s knowledge, are valid, subsisting agreements, in full force and effect and binding upon
the parties thereto in accordance with their terms and TopoTarget or its Affiliate has paid in full
all amounts due thereunder and has satisfied in full all of its material accrued liabilities and
obligations thereunder, and is not in material default under any of them nor is any other party to
any such contract or other agreement in default thereunder, nor does any condition exist which with
notice or lapse of time or both would constitute a default thereunder.

     9.10 No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS
ARTICLE 9, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR
NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF
OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE,
ARE HEREBY EXPRESSLY EXCLUDED.

ARTICLE 10

INDEMNIFICATION

     10.1 General Indemnification by TopoTarget. TopoTarget shall defend, indemnify, and hold
harmless Spectrum, its Affiliates, and their respective officers, directors, employees, consultants
and authorized agents and their respective successors and assigns or heirs, as the case may be (the
“Spectrum Indemnitees”) from and against any and all claims, damages, liabilities, losses, costs
(including reasonable attorneys’ fees and expenses) and expenses (collectively “Losses”) to the
extent resulting from any claim of a Third Party against such Spectrum Indemnitee based on or
arising out of:

64

 

          (a) any misrepresentation or breach of any of TopoTarget’s representations, warranties,
covenants or obligations under this Agreement;

          (b) the gross negligence or willful misconduct of, or violation of Applicable Law by,
TopoTarget, its Affiliates, licensees, contractors, distributors, or their respective officers,
directors, employees, consultants or authorized agents under this Agreement;

          (c) Product Liability claims under Section 10.3(b).

     The foregoing indemnity obligations shall not apply to the extent that the Losses of such
Spectrum Indemnitee were caused by: (i) a breach of any of Spectrum’s representations, warranties,
covenants, or obligations under this Agreement; or (ii) the negligence or willful misconduct of, or
violation of Applicable Law by, such Spectrum Indemnitee.

     10.2 General Indemnification by Spectrum. Spectrum shall defend, indemnify and hold harmless
TopoTarget, its Affiliates, and their respective officers, directors, employees, consultants and
authorized agents and their respective successors and assigns or heirs, as the case may be (the
“TopoTarget Indemnitees”) from and against any and all Losses to the extent resulting from any
claim of a Third Party against such TopoTarget Indemnitee based on or arising out of:

          (a) any misrepresentation or breach of any of Spectrum’s representations, warranties,
covenants or obligations under this Agreement;

          (b) the gross negligence or willful misconduct of, or violation of Applicable Law by,
Spectrum, its Affiliates, licensees, distributors or their respective officers, directors,
employees, consultants or authorized agents under this Agreement; or

          (c) Product Liability claims under Section 10.3(a).

     The foregoing indemnity obligation shall not apply to the extent that the Losses of such
TopoTarget Indemnitee were caused by: (i) a breach of any of TopoTarget’s representations,
warranties, covenants, or obligations under the Agreement; or (ii) the negligence or willful
misconduct of, or violation of Applicable Law by, such TopoTarget Indemnitee.

     10.3 Product Liability Indemnification

          (a) Notwithstanding anything to the contrary herein, Spectrum shall be solely responsible for
all Losses from Product Liability claims brought in the Territory, other than to the extent covered
in clause (b) below, resulting directly from (i) Spectrum’s breach of its warranties, covenants or
agreements contained in this Agreement, (ii) the violation of any Applicable Laws by Spectrum, its
Affiliates, distributors or sublicensees (other than TopoTarget, its Affiliates, licensees or
contractors), (iii) Development Activities by Spectrum, its Affiliates or sublicensees (other than
TopoTarget, its Affiliates, licensees or contractors), (iv) the use, development, manufacture,
promotion, distribution, marketing, offering for sale, sale and commercialization of the Product by
or on behalf of Spectrum or its Affiliates, licensees or sublicensees (other than TopoTarget, its
Affiliates, licensees or contractors), (v) the conduct of clinical trials for the Product anywhere
by Spectrum, its Affiliates, licensees or sublicensees

65

 

(other than TopoTarget, its Affiliates, licensees or contractors) and/or (vi) inaccurate or
misleading content of any sales or promotional literature in connection with the marketing,
promotion and sale of the Product in the Territory.

          (b) Notwithstanding anything to the contrary herein, TopoTarget shall be solely responsible
for all Losses from Product Liability claims, other than to the extent covered in clause (a) above,
resulting directly from (i) TopoTarget’s breach of its warranties, covenants or agreements
contained in this Agreement, (ii) the violation of any Applicable Laws by TopoTarget, its
Affiliates or licensees (other than Spectrum, its Affiliates, licensees or contractors), (iii)
Development activities by TopoTarget, its Affiliates or licensees (other than Spectrum, its
Affiliates, licensees or contractors), (iv) the use, development, manufacture, promotion,
distribution, marketing, offering for sale, sale and commercialization of the Product by or on
behalf of TopoTarget or its Affiliates, licensees or sublicensees (other than Spectrum, its
Affiliates, licensees or contractors) inside or outside the Territory prior to the Effective Date
or during the Term, (v) the conduct of clinical trials for the Product anywhere by TopoTarget, its
Affiliates, licensees or sublicensees (other than Spectrum, its Affiliates, licensees or
contractors), and/or (vi) inaccurate or misleading content of any sales or promotional literature
in connection with the marketing, promotion and sale of the Product in the Territory that was not
approved by Spectrum.

     10.4 Indemnification Procedures.

          (a) Notice of Claim. All indemnification claims in respect of any indemnitee seeking
indemnity under this Agreement will be made solely by the corresponding Party seeking indemnity
under this Article 10 (the “Indemnified Party”). The Indemnified Party will give the indemnifying
Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any
Losses or the discovery of any fact upon which such Indemnified Party intends to base a request for
indemnification under this Article 10, as applicable. The failure to give such prompt written
notice shall not, however, relieve the Indemnifying Party of its indemnification obligations,
except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of
such failure. Each Indemnification Claim Notice must contain a description of the claim and the
nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at
such time). Together with the Indemnification Claim Notice, the Indemnified Party will furnish
promptly to the Indemnifying Party copies of all notices and documents (including court papers)
received by the Indemnified Party in connection with the Third Party claim.

          (b) Control of Defense. At its option, the Indemnifying Party may assume the defense of any
Third Party claim subject to indemnification as provided for in this Article 10 by giving written
notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of
an Indemnification Claim Notice, provided however that (i) the claim solely seeks monetary damages
and (ii) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party
and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and
discharge the claim in full (the matters described in (i) and (ii), the “Litigation Conditions”).
The Indemnified Party may, at any time, assume all such defense if the Litigation Conditions are
not satisfied at any time. Upon assuming the defense of a Third Party claim in accordance with
this Section 10.4, the Indemnifying Party shall be entitled to

66

 

appoint lead counsel in the defense of the Third Party claim. Should the Indemnifying Party
assume the defense of a Third Party claim, except as otherwise set forth in this Section 10.4(b),
the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses
subsequently incurred by such Indemnified Party in connection with the analysis, defense or
settlement of the Third Party claim.

          (c) Right to Participate in Defense. Without limiting Section 10.4(b), any Indemnified Party
will be entitled to participate in, but not control, the defense of a Third Party claim for which
it has sought indemnification hereunder and to employ counsel of its choice for such purpose;
provided, however, that such employment will be at the Indemnified Party’s own expense unless (i)
the employment thereof has been specifically authorized by the Indemnifying Party in writing, (ii)
the Indemnifying Party has failed to assume and actively further the defense and employ counsel in
accordance with Section 10.4(b) (in which case the Indemnified Party will control the defense), or
(iii) the Indemnifying Party no longer satisfies the Litigation Conditions.

          (d) Settlement. Notwithstanding any other provision of this Agreement, the Indemnifying Party
shall not enter into settlement of any Third Party claim without the prior written consent of the
Indemnified Party, except as provided in this Section 10.4(d). If a firm offer is made to settle a
Third Party claim without leading to liability or the creation of a financial or other obligation
on the part of the Indemnified Party and provides, in customary form, for the unconditional release
of each Indemnified Party from all liabilities and obligations in connection with such Third Party
claim and the Indemnifying Party desires to accept and agree to such offer, the Indemnifying Party
shall give written notice to that effect to the Indemnified Party. If the Indemnified Party fails
to consent to such firm offer within ten (10) days after its receipt of such notice, the
Indemnified Party may continue to contest or defend such Third Party claim and in such event, the
maximum liability of the Indemnifying Party as to such Third Party claim shall not exceed the
amount of such settlement offer. If the Indemnified Party fails to consent to such firm offer and
also fails to assume defense of such Third Party claim, the Indemnifying Party may settle the Third
Party claim upon the terms set forth in such firm offer to settle such Third Party claim. If the
Indemnified Party has assumed the defense pursuant to Section 10.4(c), it shall not agree to any
settlement without the written consent of the Indemnifying Party (which consent shall not be
unreasonably withheld or delayed).

          (e) Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party
claim, the Indemnified Party will cooperate in the defense or prosecution thereof and will furnish
such records, information and testimony, provide such witnesses and attend such conferences,
discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection
with such Third Party claim. Such cooperation will include access during normal business hours
afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of,
records and information that are reasonably relevant to such Third Party claim, and making
employees and agents available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder.

     10.5 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY EXEMPLARY,
SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES, COSTS OR EXPENSES (INCLUDING
LOST

67

 

PROFITS, LOST REVENUES AND/OR LOST SAVINGS) ARISING FROM OR RELATING TO ANY BREACH OF THIS
AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE
FOREGOING, NOTHING IN THIS SECTION 10.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY IN CONNECTION WITH (A) THIRD PARTY CLAIMS UNDER
SECTION 10.1 OR 10.2, (B) DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ARTICLE 11, OR (C) DAMAGES TO
THE EXTENT ARISING FROM OR RELATING TO WILLFUL MISCONDUCT OR FRAUDULENT ACTS OR OMISSIONS OF A
PARTY.

     10.6 Insurance.

          (a) Comprehensive General Liability. Each Party shall maintain at such Party’s sole expense,
comprehensive general liability insurance coverage in amounts reasonably determined by the Parties
from time to time but at least appropriate to the risk involved in Developing, Manufacturing,
transporting, selling or marketing the Products, and listing the other Party as an additional
insured; provided, however, that unless agreed to by the Parties, in no event shall a Party
maintain less than Five Million Dollars (US $5,000,000) of such liability insurance, which can
include a combination of general liability insurance and umbrella policy. Such insurance shall be
in effect as of the Effective Date; provided that each Party reserves the right to satisfy its
obligations under this Section 10.6(a) through self-insurance (as reasonably acceptable to the
other Party).

          (b) Product Liability. As of the Effective Date, Spectrum and TopoTarget shall each establish
and maintain product liability (including clinical trial liability) or other appropriate insurance
in the minimum amount of Five Million Dollars (US $5,000,000) per occurrence, and as of the First
Commercial Sale of any Product in any country, the selling Party shall establish and maintain
product liability (including clinical trial liability) or other appropriate insurance in the
minimum amount of Ten Million Dollars (US $10,000,000) per occurrence, and shall specify the other
Party as an additional insured.

ARTICLE 11

CONFIDENTIALITY

     11.1 Confidentiality. Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing by the Parties, each Party agrees that, for the Term and for five (5)
years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall
not use for any purpose other than as provided for in this Agreement any Confidential Information
of the other Party except for that portion of such information or materials that the receiving
Party can demonstrate by competent proof:

          (a) was already known to the receiving Party or its Affiliate, other than under an obligation
of confidentiality, at the time of disclosure by the other Party;

          (b) was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the receiving Party;

68

 

          (c) became generally available to the public or otherwise part of the public domain after its
disclosure and other than through any act or omission of the receiving Party in breach of this
Agreement;

          (d) is subsequently disclosed to the receiving Party or its Affiliate by a Third Party who is
not bound by an obligation of confidentiality to the disclosing Party with respect to such
information; or

          (e) is subsequently independently discovered or developed by the receiving Party or its
Affiliate without the aid, application, or use of Confidential Information.

     Notwithstanding the foregoing, the receiving Party may disclose without violation of this
Agreement such portion of the Confidential Information as is required or permitted to be disclosed
if, on the advice of counsel, it is required under Applicable Law or pursuant to legal process to
disclose such Confidential Information of the other Party; provided that unless otherwise
prohibited by Applicable Law, the receiving Party first advises the disclosing Party of such
intended disclosure and provides the disclosing Party with the opportunity to seek appropriate
judicial or administrative relief to avoid, or obtain confidential treatment of, such disclosure at
the disclosing Party’s sole cost and expense.

     The confidentiality provisions set forth herein shall supersede and replace the Existing
Confidentiality Agreement and shall be deemed to cover all Confidential Information (as defined in
the Existing Confidentiality Agreement) disclosed or obtained under the Existing Confidentiality
Agreement.

     Under otherwise specified in writing, all documents, record bearing media and materials
containing or embodying Confidential Information provided by the disclosing Party shall remain the
property of the disclosing Party. Upon the written request of the disclosing Party, the receiving
Party agrees to return all such Confidential Information or destroy all documents, record bearing
media and materials created by the receiving Party that contain or embody any Confidential
Information of the disclosing Party, as well as any copies thereof, except for one copy which may
be retained by the receiving Party’s legal counsel for purposes of complying with such Party’s
obligations hereunder.

     11.2 Authorized Disclosure. Each Party may disclose Confidential Information belonging to the
other Party to the extent such Party determines such disclosure is reasonably necessary in the
following situations:

          (a) prosecuting or defending litigation relating to this Agreement;

          (b) disclosure to its and its Affiliates respective directors, officers, employees,
consultants, professional advisors, lenders, insurers and sublicensees only on a need-to-know basis
and solely as necessary in connection with this Agreement, provided that each disclosee must be
bound by obligations of confidentiality and non-use no less stringent than those set forth in
Sections 11.1 and 11.2 prior to any such disclosure; and

          (c) solely with respect to the material terms of this Agreement, disclosure to any bona fide
potential or actual investor, investment banker, acquirer, merger partner, or other

69

 

potential or actual financial partner; provided that each disclosee must be bound by
obligations of confidentiality and non-use no less stringent than those set forth in Sections 11.1
and 11.2 prior to any such disclosure. The receiving Party shall be liable for any breach of such
confidentiality and non-use obligations by any such Third Party.

     11.3 Publicity; Terms of Agreement.

          (a) The Parties shall make separate public announcements of the execution of this Agreement on
or after the Effective Date in the forms attached hereto as Exhibit I. The Parties agree
that the material terms of this Agreement are the Confidential Information of both Parties, subject
to the authorized disclosure provisions set forth in Section 11.2 and this Section 11.3. Each
Party may publicly disclose without violation of this Agreement, such terms of this Agreement as
are, on the advice of counsel, required by the rules and regulations of the United States
Securities and Exchange Commission or any successor (“SEC”), The NASDAQ Stock Market, Inc. or the
Copenhagen Stock Exchange; provided that such Party shall advise the other Party of such intended
disclosures and provide the other Party with reasonable opportunity to request that such Party seek
(at such Party’s expense) confidential treatment of such disclosures to be filed with the relevant
securities exchange. Subject to the immediately preceding sentence, each Party shall consult with
the other Party, and the other Party shall have the right to review and comment with respect to the
redaction of the terms of this Agreement or Confidential Information as part of the confidential
treatment request to the SEC or other securities exchange.

          (b) After release of the press release announcing this Agreement and excluding any public
disclosures of the terms of this Agreement that are authorized by Section 11.3(a), if either Party
desires to make a public announcement concerning the material terms of this Agreement, milestones
achieved under this Agreement or other Confidential Information of the other Party, such Party
shall give reasonable prior advance notice of the proposed text of such announcement to the other
Party for its prior review and approval (except as otherwise provided herein), such approval not to
be unreasonably withheld, conditioned or delayed. A Party commenting on such a proposed press
release shall provide its comments, if any, within one (1) Business Day after receiving the press
release for review. In relation to each Party’s review of such an announcement, such Party may
make specific, reasonable comments on such proposed press release or other public disclosure within
the prescribed time for commentary. Neither Party shall be required to seek the permission of the
other Party to disclose any information already disclosed or otherwise in the public domain,
provided such information remains accurate.

     11.4 Publications. Neither Party shall publicly present or publish results of studies,
clinical or otherwise, carried out under this Agreement (each such presentation or publication, a
“Publication”) without the prior approval of the JDC. The submitting Party shall provide the JDC
with the opportunity to review any proposed Publication at least thirty (30) days prior to the
earlier of its presentation or intended submission for publication. Notwithstanding the foregoing,
Spectrum shall not have the right to publish or present TopoTarget’s Confidential Information
without TopoTarget’s prior written consent, and TopoTarget shall not have the right to publish or
present Spectrum’s Confidential Information without Spectrum’s prior written consent.

70

 

     11.5 Clinical Trial Registries. In connection with any data or other information generated by
a Party hereunder, each Party shall have the right to publish such data and information without
further approval from the other on ClinicalTrials.gov or other public web based data entry system
in accordance with the International Committee of Medical Journal Editors (ICMJE). The Party that
conducts the clinical study in accordance with this Agreement shall be exclusively responsible for
registering the study in accordance with the Food and Drug Administration Amendments Act (FDAAA) of
2007, updating and/or amending such clinical trial registration as appropriate, and publishing the
results of such trial in accordance with Applicable Laws.

ARTICLE 12

TERM AND TERMINATION

     12.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier
terminated pursuant to this Article 12, shall remain in effect until the expiration of the last to
expire royalty obligation with respect to Products under this Agreement (the “Term”). [***].

     12.2 Termination by Spectrum at Will.

          (a) Spectrum shall have the right to terminate this Agreement in its entirety upon [***]
([***]) days written notice to TopoTarget.

          (b) Notwithstanding subsection (a), Spectrum shall have the right to terminate this Agreement
upon written notice effective immediately in the event that:

               (i) the FDA or any other Governmental Authority prohibits the further clinical use of the
Product in the applicable jurisdiction within the Territory and/or terminates the IND under 21 CFR
312.44 on grounds of safety (or equivalent grounds with respect to any Territory outside of the
U.S. Territory). This termination excludes failure of Spectrum to comply with any applicable
requirement of regulations 21 CFR 312.50 or 21 CFR 312.56 (or equivalent grounds with respect to
any Territory outside of the U.S. Territory); or

               (ii) a clinical hold imposed by the FDA or other Governmental Authority is definitively
converted to “inactive status” under 21 CFR 312.45 on grounds of safety (or equivalent grounds with
respect to such other Territory).

     12.3 Termination by Spectrum for Breach by TopoTarget. In the event TopoTarget, after
receiving written notice from Spectrum identifying a material breach by TopoTarget of its
obligations under this Agreement, fails to cure such material breach within [***] ([***]) days from
the date of such notice, then Spectrum may elect to terminate this Agreement, in which case the
licenses granted to Spectrum under Section 2.1 shall terminate, except as necessary for Spectrum to
exercise its continuing rights and fulfill its continuing

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

71

 

obligations under Section 12.7(d), and Spectrum shall be entitled to claim from TopoTarget all
damages which would otherwise be due to Spectrum and to seek all other remedies otherwise available
to Spectrum for such breach as permitted by this Agreement.

     Spectrum shall elect between the remedies provided in this Section 12.3 and Section 12.4 and
shall provide notice in writing to TopoTarget within [***] ([***]) days after the end of the [***]
([***]) cure period set forth above.

     Notwithstanding the foregoing, if TopoTarget is alleged to be in material breach and disputes
such termination through the dispute resolution procedures set forth in this Agreement, then
Spectrum’s right to terminate this Agreement shall be tolled for so long as such dispute resolution
procedures are being pursued by TopoTarget in good faith and if it is finally and conclusively
determined that TopoTarget is in material breach, then prior to any termination becoming effective
or any remedies being enforced, TopoTarget shall have the right to cure such material breach after
such determination within the cure period provided above in this Section 12.3.

     12.4 Alternate Remedies for Breach by TopoTarget. In the event TopoTarget, after receiving
written notice from Spectrum identifying a material breach by TopoTarget of any obligation under
this Agreement, fails to cure such material breach within [***] ([***]) days from the date of such
notice, then Spectrum may elect to allow this Agreement to remain in effect, in which case:

          (a) the JDC, JCC and all subcommittees shall be abolished, and thereafter Spectrum shall have
the right to make the decisions and take the actions previously reserved to the JDC and JCC, and

          (b) the Co-Promotion Option and the Co-Promotion Right shall immediately terminate;

          (c) the Territory shall be expanded to include the China Territory, for no additional
consideration; and

          (d) Damages.

               (i) Spectrum shall be free to seek (without restriction as to the number of times it may seek)
damages and costs that may be available under applicable law and shall be entitled to offset the
amount of any damages and costs obtained in a final, non-appealable judgment (or judgment from
which no appeal was taken within the allowable time period) of monetary damages or costs (as
permitted by this Agreement) against TopoTarget against any amounts otherwise due to TopoTarget
under Article 7; or

               (ii) In the event TopoTarget’s material breach is such that it materially adversely impacts
Spectrum’s ability to develop or commercialize the Product in the Territory on an ongoing basis,
then Spectrum shall have the right on a one-time basis during the Development

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

72

 

Phase and on a one-time basis during the Commercialization Phase, to provide notice to
TopoTarget that Spectrum is seeking to invoke the Payment Reduction Remedy. In the event Spectrum
does so and an arbitration proceeding pursuant to this Agreement determines that TopoTarget’s
material breach materially adversely impacts Spectrum’s ability to develop or commercialize the
Product in the Territory, [***]. The amount of liquidated damages in this subsection (ii) is so
fixed and agreed upon because of the impracticability and extreme difficulty in fixing and
ascertaining the actual damages that Spectrum would sustain in the event of a material breach by
TopoTarget as described in this Section. As used herein, “Development Phase” shall mean the period
commencing with the Effective Date and continuing until Regulatory Approval of the Product in the
U.S. Territory and “Commercialization Phase” shall mean the period commencing at the end of the
Development Phase and continuing until the end of the Term. If Spectrum invokes the Payment
Reduction Remedy during the Development Phase and reduces its royalty and milestone payments as set
forth above, Spectrum shall not have the right to invoke the Payment Reduction Remedy during the
Commercialization Phase. For avoidance of doubt, the royalty rate specified in Section 7.4 for
future Net Sales by Spectrum and the development milestone and sales milestone payments under
Section 7.2 and 7.3, may not be reduced by more than [***] percent ([***]%) pursuant to this
Section 12.4(d)(ii).

     Notwithstanding the foregoing, if TopoTarget is alleged to be in material breach and disputes
such termination through the dispute resolution procedures set forth in this Agreement, then
Spectrum’s remedies under this Section shall be tolled for so long as such dispute resolution
procedures are being pursued by TopoTarget in good faith and if it is finally and conclusively
determined that TopoTarget is in material breach, then prior to any termination becoming effective
or any remedies being enforced, TopoTarget shall have the right to cure such material breach after
such determination within the cure period provided above in this Section 12.4.

     12.5 Termination by TopoTarget.

          (a) Breach by Spectrum. In the event that Spectrum materially breaches this Agreement, and
fails to cure such breach within [***] ([***]) days of receipt of written notice identifying such
breach from TopoTarget (or, in the case of payment obligations, [***] ([***]) days from the date of
such notice), then TopoTarget may terminate this Agreement upon written notice to Spectrum
effective immediately, in which case the licenses granted to Spectrum under Sections 2.1 shall
terminate, and TopoTarget shall be entitled to claim from Spectrum all damages which would
otherwise be due to TopoTarget and to seek all other remedies otherwise available to TopoTarget for
such breach as permitted by this Agreement. The Parties agree that, without limitation, the
following shall constitute a material breach of this Agreement: (a) Spectrum does not engage in
Development activities under the Development Plan for a consecutive period of [***] ([***]) months,
except to the extent such inactivity is the result of any of the events set forth in Section
4.3(d), (b) Spectrum fails to launch the Product in the Territory pursuant to Section 5.3 and fails
to cure such failure for a period of [***] ([***]) days after having received written notification
by TopoTarget regarding such failure, except to the extent such failure is the result of any of the
events set forth in Section 5.2(b)(iv), and (c) Spectrum fails to pay [***].

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

73

 

     Notwithstanding the foregoing, if Spectrum is alleged to be in material breach and
disputes such termination through the dispute resolution procedures set forth in this Agreement,
then TopoTarget’s right to terminate this Agreement shall be tolled for so long as such dispute
resolution procedures are being pursued by Spectrum in good faith and if it is finally and
conclusively determined that Spectrum is in material breach, then prior to any termination becoming
effective or any remedies being enforced, Spectrum shall have the right to cure such material
breach after such determination within the cure period provided above in this Section 12.5.

          (b) Patent Challenge by Spectrum. TopoTarget may terminate this Agreement upon written
notice effective immediately in the event Spectrum brings a challenge (or assists any Third Party
in bringing a challenge) in a court of law or in a proceeding before the USPTO or relevant non-U.S.
patent office that challenges the validity or ownership or enforceability of any of the TopoTarget
Patents or the scope of the claims covered by the TopoTarget Patents.

     In the event Spectrum is aware that its Affiliate or sublicensee is bringing a challenge (or
is assisting any Third Party in bringing a challenge) in a court of law or in a proceeding before
the USPTO or relevant patent office that challenges the validity or ownership or enforceability of
any of the TopoTarget Patents or the scope of the claims covered by the TopoTarget Patents in the
Territory, Spectrum shall use Commercially Reasonable Efforts to cause such Affiliate or
sublicensee to cease such challenge. If such challenge does not stop within thirty (30) days of
Spectrum becoming aware of such challenge, TopoTarget may terminate this Agreement upon written
notice effective immediately.

     For the avoidance of doubt, statements about or any action concerning any TopoTarget Patent
made or taken by or on behalf of Spectrum, its Affiliates or sublicensees in connection with the
prosecution, enforcement or defense of any patent rights shall not be considered a patent challenge
under this Section, provided that, unless otherwise agreed in writing by the Parties, Spectrum, its
Affiliates and/or sublicensees do not make any material adverse admissions or permit any material
adverse inferences to be made as to the validity or ownership or enforceability of any of the
TopoTarget Patents or the scope of the claims covered by the TopoTarget Patents.

     12.6 Termination Upon Bankruptcy. Either Party shall have the right to terminate this
Agreement immediately by providing written notice, if the other Party: (a) applies for or consents
to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a
substantial part of its assets, (b) makes a general assignment for the benefit of its creditors,
(c) is dissolved or liquidated in full or in substantial part, (d) commences a voluntary case under
Chapter 7 (or “Chapter 7 Case”) of the United States Bankruptcy Code or consents to any such relief
or to the appointment of or taking possession of its property by any official in such an
involuntary case or such other proceeding commenced against it, (e) takes any corporate action for
the purpose of effecting any of the foregoing, (f) a case under Chapter 11 of the Bankruptcy Code
in respect of such Party is converted to a Chapter 7 Case, or (g) becomes the subject of an
involuntary Chapter 7 Case or other proceeding seeking liquidation with respect to itself or its
debts under any bankruptcy, insolvency or other similar law now or hereafter in effect that is not
dismissed within sixty (60) days after commencement.

74

 

     12.7 Effect of Termination of the Agreement. Upon termination of this Agreement, the
following shall apply (in addition to any other rights and obligations under Section 12.8 or
otherwise under this Agreement with respect to such termination):

          (a) Licenses; Covenant. In the event of termination of this Agreement by either Party (other
than by operation of Section 12.1), the licenses granted to Spectrum under Section 2.1 and any
other licenses and rights granted to Spectrum under this Agreement shall terminate (and all rights
in the TopoTarget Technology shall return to TopoTarget) and Spectrum agrees to grant and hereby
grants TopoTarget, effective upon such termination, a non-exclusive, royalty-free license under the
Spectrum Patents and Spectrum Know-How solely to the extent necessary (i) to conduct research,
Development and manufacturing activities in the Territory solely in support of Regulatory Approval
worldwide of Products that are in Development or being Commercialized in the Territory as of the
effective date of such termination (“Termination Products”), (ii) to use, distribute, import,
Promote, market, sell, and offer for sale Termination Products in the Territory, and (iii) to make
and have made Termination Products in the Territory for sale in the Territory, under commercially
reasonable terms to be negotiated in good faith. TopoTarget shall have the right to sublicense the
license under the Spectrum Patents without Spectrum’s consent; provided however that in the event
of the termination of this Agreement by Spectrum pursuant to Section 12.3, the license granted by
Spectrum to TopoTarget under this Section 12.7(a) shall be royalty-bearing, at a commercially
reasonable rate to be negotiated in good faith by the Parties, such rate not to exceed, in the
aggregate for the licenses granted under this Section 12.7(a) and Section 12.7(b), [***] percent
([***]%).

     As used herein, (1) “Spectrum Patents” shall mean (A) all patents and patent applications
(excluding Joint Patents) that are Controlled by Spectrum as of the effective date of termination
and that disclose or claim any invention made in the performance of the Development or
Commercialization activities under this Agreement that is necessary for the manufacture, use or
sale of, and relates to, any Termination Product, (B) all divisions, continuations,
continuations-in-part (to the extent directed to the subject matter disclosed in a patent or patent
application described in (A)) and requests for continued examination of any of the foregoing, (C)
all patents claiming priority to any of the foregoing, (D) all reissues, registrations,
re-examinations, extensions and supplementary protection certificates of any of the foregoing, in
each case, in the Territory, and (2) “Spectrum Know-How” shall mean all Information (excluding any
Spectrum Patents or Joint Inventions) that is Controlled as of the effective date of termination by
Spectrum as a result of the performance of the Development or Commercialization activities under
this Agreement and relates to a Termination Product; provided that both terms shall exclude any
intellectual property held or developed by a permitted successor of Spectrum prior to the
transaction in which it became a successor of such Party. The foregoing shall not limit or waive
TopoTarget’s non-disclosure obligations under Article 11.

          (b) Marks. In the event of termination of this Agreement by either Party (other than by
operation of Section 12.1), Spectrum shall assign to TopoTarget all right, title and interest in
and to the TopoTarget Trademarks and Spectrum shall grant TopoTarget a non-

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

75

 

exclusive, royalty-free, sublicensable license under the Spectrum Trademarks solely to
continue the Commercialization of Products in the Territory; provided however that in the event of
the termination of this Agreement by Spectrum pursuant to Section 12.3, the license granted by
Spectrum to TopoTarget under this Section 12.7(b) shall be royalty-bearing, at a commercially
reasonable rate to be negotiated in good faith by the Parties, such rate not to exceed, in the
aggregate for the licenses granted under this Section 12.7(b) and Section 12.7(a), [***] percent
([***]%).

          (c) Regulatory Materials. Spectrum shall transfer and assign, and shall cause its Affiliates
to transfer and assign, to TopoTarget all Regulatory Materials and all Regulatory Approvals for
Products in the Territory that are Controlled by Spectrum or its Affiliates or sublicensees.

          (d) Remaining Inventories. At TopoTarget’s request, TopoTarget may purchase at cost plus a
commercially reasonable margin all of the inventory of bulk or finished Products held by Spectrum
as of the date of termination (including raw materials, intermediates, and finished, unfinished, or
partially finished goods). TopoTarget shall notify Spectrum within ten (10) days after the date of
termination whether TopoTarget wishes to purchase such inventory. In the event TopoTarget does not
purchase such inventory, then Spectrum and its Affiliates shall be permitted to sell such
inventory; provided that such sales occur within six (6) months after termination; and provided
further that Spectrum shall remain obligated to pay, and report to TopoTarget on, Net Sales of such
inventory.

          (e) Sublicense Agreements. The Parties agree that upon termination of this Agreement for any
reason, all sublicenses granted by Spectrum to Affiliates or Third Parties under the TopoTarget
Technology shall immediately terminate.

     12.8 Accrued Liabilities; Other Remedies. Termination or expiration of this Agreement for any
reason shall not release either Party from any liability or obligation that already has accrued
prior to such expiration or termination (including any milestone or other payment that has been
triggered by an event occurring prior to the effective date of termination or expiration), nor
affect the survival of any provision hereof to the extent it is expressly stated to survive such
termination. Termination or expiration of this Agreement for any reason shall not constitute a
waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies
or claims, whether for damages or otherwise, that a Party may have hereunder or that may arise out
of or in connection with such termination or expiration.

     12.9 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by TopoTarget and Spectrum are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property”
as defined under Section 101 of the United States Bankruptcy Code. The Parties agree that each
Party, as licensee of certain rights under this Agreement, shall retain and may fully exercise all
of its rights and elections under the United States Bankruptcy Code. The Parties further agree
that, in the event of the commencement of a bankruptcy proceeding by or

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

76

 

against a Party (such Party, the “Bankrupt Party”) under the United States Bankruptcy Code,
the other Party shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any intellectual property licensed to such other Party and all embodiments of such
intellectual property, which, if not already in such other Party’s possession, shall be promptly
delivered to it (a) upon any such commencement of a bankruptcy proceeding upon such other Party’s
written request therefor, unless the Bankrupt Party elects to continue to perform all of its
obligations under this Agreement or (b) if not delivered under clause (a), following the rejection
of this Agreement by the Bankrupt Party upon written request therefor by the other Party.

     12.10 Survival. The following provisions shall survive any expiration or termination of this
Agreement for the period of time specified: Sections 4.7, 4.9, 4.10, 7.4, 7.6, 7.7, 7.8, 7.9,
7.10, 8.1, 8.2, 8.3(b) and 8.3(c) and Articles 1, 9, 10, 11, 12, 13 and 14.

ARTICLE 13

DISPUTE RESOLUTION

     13.1 Disputes. The Parties recognize that disputes as to certain matters may from time to
time arise during the Term which relate to either Party’s rights and/or obligations hereunder. It
is the objective of the Parties to establish procedures to facilitate the resolution of disputes
arising under this Agreement in an expedient manner by mutual cooperation. To accomplish this
objective, the Parties agree to follow the procedures set forth in this Article 13 if and when a
dispute arises under this Agreement.

          (a) Referred From JDC or JCC. Any dispute, controversy or difference arising from the JDC
pursuant to Article 3 shall be resolved in accordance with Section 3.6 and any dispute, controversy
or difference arising from the JCC pursuant to Article 3 shall be resolved in accordance with
Section 3.11.

          (b) Arising Between the Parties. Other than any dispute, controversy or difference which may
arise from the JDC or JCC, any disputes, controversies or differences which may arise between the
Parties out of or in relation to or in connection with this Agreement, including any alleged
failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or
application of this Agreement, then upon the request of either Party, the Parties agree to meet and
discuss in good faith a possible resolution thereof, which good faith efforts shall include at
least one in-person meeting between the chief executive officers of each Party. If the matter is
not resolved within thirty (30) days following the request for discussions, such matter shall be
submitted to arbitration in accordance with the rules of the London Court of International
Arbitration (“LCIA”). The decision of the arbitrators shall be final and binding upon the Parties
and enforceable in any court of competent jurisdiction, and the Parties expressly exclude any right
to appeal from such decision. The location of arbitration will be London, U.K. The arbitration will
be heard and determined by one (1) arbitrator, who will be jointly selected by Spectrum and
TopoTarget. If, within thirty (30) days following the date upon which a claim is received by the
respondent, the Parties cannot agree on a single arbitrator, the arbitration will be heard and
determined by three (3) arbitrators, with one arbitrator being appointed by each Party and the
third arbitrator being selected by the two Party-appointed arbitrators. If either Party fails to
select an arbitrator, or if the Party-appointed arbitrators cannot agree on a third arbitrator
within sixty (60) days of the respondent receiving the claim, such

77

 

arbitrator will be appointed by LCIA. The arbitration award shall be accompanied by a
reasoned opinion in writing (in English).

     Each Party will bear its own costs and expenses (including its attorney’s fees) associated
with any arbitration initiated under this section; provided that the arbitrator shall assess
against the Party losing the arbitration all of the arbitrator(s)’ and administrative fees
associated with the arbitration and the costs and expenses (including reasonable attorney’s fees)
of both Parties, unless the arbitrator(s) believes that neither Party is the clear loser, in which
case the arbitrator(s) shall, in its/their sole discretion, divide arbitrator(s)’ and
administrative fees and the Parties’ costs and expenses between the Parties.

     The language of the arbitration proceeding will be English. Notwithstanding the provisions of
this Section 13.1(b), each Party shall have the right to seek preliminary or permanent injunctive
or other equitable relief in any court of competent jurisdiction as such Party deems necessary to
preserve its rights and to protect its interests.

     13.2 Injunctive Relief. Nothing in this Article 13 will preclude either Party from seeking
equitable relief or interim or provisional relief from a court of competent jurisdiction, including
a temporary restraining order, preliminary injunction or other interim equitable relief, concerning
a dispute if necessary to protect the interests of such Party or to preserve the status quo.

ARTICLE 14

MISCELLANEOUS

     14.1 Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, sets forth
the complete, final and exclusive agreement and all the covenants, promises, agreements,
warranties, representations, conditions and understandings between the Parties hereto with respect
to the subject matter hereof and supersedes, as of the Effective Date, all prior agreements and
understandings between the Parties with respect to the subject matter hereof, including, the
Existing Confidentiality Agreement. The foregoing shall not be interpreted as a waiver of any
remedies available to either Party as a result of any breach, prior to the Effective Date, by the
other Party of its obligations pursuant the Existing Confidentiality Agreement. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either
oral or written, between the Parties other than as are set forth herein and therein. No subsequent
alteration, amendment, change or addition to this Agreement shall be binding upon the Parties
unless reduced to writing and signed by an authorized officer of each Party. All Exhibits shall be
subject to the terms and conditions of this Agreement. In the event of any conflict or
inconsistency between the terms of this Agreement and the terms of any Exhibit, the terms of this
Agreement shall govern.

     14.2 Force Majeure. Both Parties shall be excused from the performance of their obligations
under this Agreement to the extent that such performance is prevented by force majeure and the
nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse
shall be continued so long as the condition constituting force majeure continues and the
nonperforming Party takes reasonable efforts to remove the condition. For purposes of this
Agreement, “force majeure” shall mean conditions beyond the control of the

78

 

Parties, including an act of God, war, civil commotion, terrorist act, labor strike or
lock-out, epidemic, failure or default of public utilities or common carriers, destruction of
production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of
plant or machinery, provided that such failure could not have been prevented by the exercise of
skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and
experienced person engaged in the same type of undertaking under the same or similar circumstances
and provided further that such condition is not the result of negligence or misconduct by the
nonperforming Party. Notwithstanding the foregoing, a Party shall not be excused from making
payments owed hereunder because of a force majeure affecting such Party.

     14.3 Notices. Any notice required or permitted to be given under this Agreement shall be in
writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate
Party at the address specified below or such other address as may be specified by such Party in
writing in accordance with this Section 14.3, and shall be deemed to have been given for all
purposes when received, if hand-delivered or by means of facsimile or other electronic
transmission, or one Business Day after being sent by a reputable overnight delivery service.

	 	 	 	 
	 
	If to TopoTarget:
	 	TopoTarget A/S

Symbion Science Park

Fruebjergvej 3

2100 København, Denmark

Attention:
	 
	 	 	 
	 

	With a copy to:
	 	Dechert LLP

1775 I Street, NW

Washington, D.C. 20006-2401

Attention: David E. Schulman, Esq.
	 
	 	 	 
	 

	If to Spectrum:
	 	Spectrum Pharmaceuticals, Inc.

701 N. Green Valley Parkway

Henderson, NV 89074

Attention: Legal Department
	 
	 	 	 
	 

	With a copy to:
	 	Edwards Angell Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199

Attention: Marcia H. Anderegg, Esq.

     14.4 No Strict Construction; Headings; Interpretation. This Agreement has been prepared
jointly and shall not be strictly construed against either Party. Ambiguities, if any, in this
Agreement shall not be construed against any Party, irrespective of which Party may be deemed to
have authored the ambiguous provision. The headings of each Article and Section in this Agreement
have been inserted for convenience of reference only and are not intended to limit or expand on the
meaning of the language contained in the particular Article or Section. The definitions of the
terms herein apply equally to the singular and plural forms of the terms defined. Whenever the
context may require, any pronoun will include the corresponding
masculine, feminine and neuter forms. The words “include”, “includes” and “including” will be

79

 

deemed to be followed by the phrase “without limitation.” Unless the context requires otherwise,
(a) any definition of or reference to any agreement, instrument or other document herein will be
construed as referring to such agreement, instrument or other document as from time to time
amended, supplemented or otherwise modified (subject to any restrictions on such amendments,
supplements or modifications set forth herein or therein), (b) any reference to any laws herein
will be construed as referring to such laws and any rules or regulations promulgated thereunder as
from time to time enacted, repealed or amended, (c) any reference herein to any person will be
construed to include the person’s successors and assigns, (d) the words “herein”, “hereof” and
“hereunder”, and words of similar import, will be construed to refer to this Agreement in its
entirety and not to any particular provision hereof, (e) any reference herein to the words
“mutually agree” or “mutual written agreement” will not impose any obligation on either Party to
agree to any terms relating thereto or to engage in discussions relating to such terms except as
such Party may determine in such Party’s sole discretion, except as expressly provided in this
Agreement, (f) as applied to a Party, the word “will” shall be construed to have the same meaning
and effect as the word “shall,” and (g) all references herein without a reference to any other
agreement to Articles, Sections, or Exhibits will be construed to refer to Articles, Sections, and
Exhibits of or to this Agreement.

     14.5 Assignment. Neither Party may assign or transfer this Agreement or any rights or
obligations hereunder without the prior written consent of the other, except that a Party may make
such an assignment without the other Party’s consent to such Party’s Affiliate or to a successor to
(a) all or substantially all of the business of such Party, whether by way of merger, sale of
stock, sale of assets or other transaction or (b) in the case of Spectrum, that portion of
Spectrum’s business to which this Agreement pertains. Any permitted successor or assignee of
rights and/or obligations hereunder shall, in a writing to the other Party, expressly assume
performance of such rights and/or obligations. Notwithstanding any assignment of this Agreement,
the assigning Party shall remain liable for performance of its obligations hereunder, unless the
non-assigning Party agrees otherwise in writing. The TopoTarget Technology shall exclude any
intellectual property held or developed by a permitted successor of TopoTarget prior to the
transaction in which it became a successor of such Party. Any permitted assignment shall be
binding on the successors of the assigning Party. Any assignment or attempted assignment by either
Party in violation of the terms of this Section 14.5 shall be null, void and of no legal effect.

     14.6 Records Retention. Each of TopoTarget and Spectrum will maintain complete and accurate
records pertaining to its activities under this Agreement, including records pertaining to
Development or Commercialization of any Products and reports and information provided to any
Governmental Authority or Regulatory Authority, in accordance with Applicable Law. Each of
TopoTarget and Spectrum will retain such records for a duration prescribed by Applicable Law, but
not in any event for less than five (5) years from creation (or longer if a Party is notified,
ordered or otherwise required to maintain such records for a longer period in connection with a
legal proceeding or government investigation).

     14.7 Governing Law. Resolution of all disputes arising out of or related to this Agreement or
the validity, construction, interpretation, enforcement, breach, performance, application or
termination of this Agreement and any remedies relating thereto, shall be governed by and construed
under the substantive laws of the State of New York, USA excluding any
conflicts or choice of law rule or principle that might otherwise refer construction or

80

 

interpretation of this Agreement to the substantive law of another jurisdiction and without regard
to the United Nations Convention on Contracts for the International Sale of Goods.

     14.8 No Third Party Beneficiaries. This Agreement will be binding upon and inure solely to
the benefit of the Parties and their successors and permitted assigns and no provision of this
Agreement, express or implied, is intended to or will be deemed to confer upon Third Parties any
right, benefit, remedy, claim, liability, reimbursement, claim of action or other right of any
nature whatsoever under or by reason of this Agreement other than the Parties and, to the extent
provided in Sections 10.1 and 10.2, the Indemnified Parties. Without limitation, this Agreement
will not be construed so as to grant employees of either party in any country any rights against
the other Party pursuant to the laws of such country.

     14.9 Performance by Affiliates. Any obligation of TopoTarget under or pursuant to this
Agreement may be satisfied, met or fulfilled, in whole or in part, at TopoTarget’s sole and
exclusive option, either by TopoTarget directly or by any Affiliate of TopoTarget that TopoTarget
causes to satisfy, meet or fulfill such obligation, in whole or in part. Any obligation of
Spectrum under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in
part, at Spectrum’s sole and exclusive option, either by Spectrum directly or by any Affiliate of
Spectrum that Spectrum causes to satisfy, meet or fulfill such obligation, in whole or in part.
With respect to any particular action, the use of the words “TopoTarget will” also means
“TopoTarget will cause” the particular action to be performed, and the use of the words “Spectrum
will” also means “Spectrum will cause” the particular action to be performed. Each of the Parties
guarantees the performance of all actions, agreements and obligations to be performed by any
Affiliates of such Party under the terms and conditions of this Agreement, and shall cause its
Affiliates to comply with the provisions of this Agreement in connection with such performance.
Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be
deemed a breach by such Party, and the other Party may proceed directly against such Party without
any obligation to first proceed against such Party’s Affiliate.

     14.10 Further Assurances and Actions. Each Party, upon the request of the other Party,
without further consideration, will do, execute, acknowledge, and deliver or cause to be done,
executed, acknowledged or delivered all such further acts, deeds, documents, assignments,
transfers, conveyances, powers of attorney, instruments and assurances as may be reasonably
necessary to effect complete consummation of the transactions contemplated by this Agreement, and
to do all such other acts, as may be necessary or appropriate in order to carry out the purposes
and intent of this Agreement. The Parties agree to execute and deliver such other documents,
certificates, agreements and other writings and to take such other actions as may be reasonably
necessary in order to consummate or implement expeditiously the transactions contemplated by this
Agreement.

     14.11 Compliance with Applicable Law. Each Party shall comply with all Applicable Laws in the
course of performing its obligations or exercising its rights pursuant to this Agreement.

     14.12 Severability. If any one or more of the provisions of this Agreement is held to be
invalid or unenforceable by any court of competent jurisdiction from which no appeal
can be or is taken, the provision shall be considered severed from this Agreement and shall
not serve to

81

 

invalidate any remaining provisions hereof. The Parties shall make a good faith
effort to replace any invalid or unenforceable provision with a valid and enforceable one such that
the objectives contemplated by the Parties when entering this Agreement may be realized.

     14.13 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver
as to a particular default or other matter shall not constitute a waiver of such Party’s rights to
the future enforcement of its rights under this Agreement, except with respect to an express
written and signed waiver relating to a particular matter for a particular period of time.

     14.14 Independent Contractors. Each Party shall act solely as an independent contractor, and
nothing in this Agreement shall be construed to give either Party the power or authority to act
for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the
relationship of partners, principal and agent, or joint-venture partners between the Parties.

     14.15 Counterparts. This Agreement may be executed in one (1) or more counterparts, including
by facsimile or other electronic transmission, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

Signature Page to Follow

82

 

CONFIDENTIAL

In Witness Whereof, the Parties have executed this Agreement in duplicate originals by
their duly authorized officers as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	TopoTarget A/S	 	 	 	Spectrum Pharmaceuticals, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	 Hakan Astrom	 	 	 	By:	 	 Rajesh C. Shrotriya	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Hakan Astrom	 	 	 	 	 	Name:	 	Rajesh C. Shrotriya	 	 
	 

	 	Title:
	 	Chairman of the Board	 	 	 	 	 	Title:	 	Chairman, CEO & President	 	 

 

EXHIBITS

	 	 	 
	Exhibit A

	 	Initial Development Plan
	 
	Exhibit B

	 	TPP
	 
	Exhibit C

	 	TopoTarget Patents
	 
	Exhibit D

	 	TopoTarget Trademarks
	 
	Exhibit E

	 	Form of Trademark Assignment
	 
	Exhibit F

	 	JDC Representatives
	 
	Exhibit G

	 	Manufacturing Agreements
	 
	Exhibit H

	 	Permitted Encumbrances
	 
	Exhibit I

	 	Press Releases

SCHEDULES

Schedule 4.4(a) — PTCL Clinical Trial Agreement

Schedule 9.2(h) — Product Description as of Effective Date

Schedule 9.9 — Material Contracts of TopoTarget

 

 

CONFIDENTIAL

Exhibit A

Initial Development Plan

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

CONFIDENTIAL

Exhibit B

TPP

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

CONFIDENTIAL

Exhibit C
Topo Target Patents

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

CONFIDENTIAL

Exhibit D

TopoTarget Trademarks

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

CONFIDENTIAL

Exhibit E

Form of Trademark Assignment

TOPOTARGET A/S, a Danish corporation having its principal offices at Symbion Science Park,
Fruebjergvej 3, 2100 København, Denmark (“TopoTarget”), owning the entire ownership of each of the
trademarks set forth on Schedule A hereto, hereby, for good and valuable consideration received by
TopoTarget, (a) confirms that it has sold and assigned, and does hereby sell and assign, to
SPECTRUM PHARMACEUTICALS, INC, a Delaware corporation having a place of business at 157 Technology
Drive, Irvine, California 92618 U.S.A. (“Spectrum”), its successors and assigns the entire
ownership interest in each of the trademarks set forth on Schedule A hereto and the goodwill
attached thereto, to be held and enjoyed by Spectrum, its successors, assigns or other legal
representatives, to the full end of the term thereof, as may be extended by law as fully and
entirely as the same would have been held and enjoyed by TopoTarget if this assignment and sale
had not been made, including, but not limited to, the right to sue for past infringement, and (b)
authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority
to issue any trademark, and any extensions or Supplementary Protections, resulting from or based in
whole upon said trademarks to Spectrum.

	 	 	 	 	 
	TOPOTARGET A/S 	 	 
	 	 	 
	By:  	 	 	 
	 	Name:  	 	 	 
	 	Title:  	 	 	 
	 

 

 

CONFIDENTIAL

Exhibit F

JDC Representatives

Spectrum:

[***]

TopoTarget:

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

CONFIDENTIAL

Exhibit G

Manufacturing Agreements

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

CONFIDENTIAL

Exhibit H

Permitted Encumbrances

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

CONFIDENTIAL

Exhibit I

Press Releases

(i) COMPANY CONTACTS

Paul Arndt

Senior Manager, Investor Relations

949-788-6700x216

***FINAL COPY — NOT FOR DISTRIBUTION*** — as of 9:17PM PST Monday, February 1, 2010

SPECTRUM PHARMACEUTICALS LICENSES BELINOSTAT, A NOVEL ANTICANCER

DRUG IN A PIVOTAL REGISTRATIONAL TRIAL

	 	•	 	Belinostat, a HDAC Inhibitor, is Currently in a Multicenter, Registrational Trial Under
a Special Protocol Assessment for Peripheral T-Cell Lymphoma (PTCL)

	 	•	 	NDA Filing Expected Next Year (in 2011)
	 
	 	•	 	Granted Fast Track and Orphan Drug Designation by FDA

	 	•	 	Multiple Phase 2 Trials Are Being Pursued In Various Oncology Indications Including
Carcinoma Of Unknown Primary (CUP) For Which No Drug Has Yet Been Approved
	 
	 	•	 	National Cancer Institute (NCI) is Conducting Multiple Trials With Belinostat
	 
	 	•	 	More Than 700 Patients Have Been Treated With Belinostat
	 
	 	•	 	Spectrum and TopoTarget Will Jointly Fund the Future Clinical Development Activities In
a Ratio Of 70:30

Spectrum to host conference call on Thursday Feb 4 at 10AM

IRVINE, California — February XX, 2010 — Spectrum Pharmaceuticals (NasdaqGM: SPPI), a
commercial-stage biotechnology company with a primary focus in oncology, today announced that it
has entered into a co-development and commercialization agreement with TopoTarget A/S for
Belinostat, a novel histone deacetylase (HDAC) inhibitor. Belinostat is currently in a
registrational trial, under a Special Protocol Assessment (SPA), as a monotherapy for relapsed or
refractory Peripheral T-Cell Lymphoma (PTCL), an indication in which it has been granted Orphan
Drug and Fast Track designation by the U.S. Food and Drug Administration (FDA). Belinostat is also
under investigation in a randomized Phase 2 trial, as a combination therapy with carboplatin and
paclitaxel, for cancer of unknown primary (CUP). Additionally, the NCI is currently conducting
several clinical trials of Belinostat in a variety of hematological and solid tumors, both as
monotherapy as well as combination therapy.

“The addition of Belinostat addresses our key strategic goal of in-licensing a late-stage
anti-cancer compound,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and
President of Spectrum Pharmaceuticals. “With this collaboration, we have now completed our
strategic initiatives relating to in-licensing of compounds with near term commercialization
opportunities. Belinostat’s current registrational program is comprehensive and focused in that it
targets key hematological indications such as PTCL and other solid tumor indications. Belinostat
has the potential to be a best-in-class HDAC inhibitor for both hematological and solid tumors. We
look forward to advancing Belinostat in PTCL and other solid tumor indications, with the goal of
providing cancer patients with more effective treatment options as quickly and

 

 

efficiently as possible. With that goal in mind, we currently expect to file the NDA in PTCL in
2011. TopoTarget has laid a solid foundation from which we will further develop Belinostat.”

“So far, Belinostat has demonstrated some unique and differentiating attributes. If approved, it
would give Spectrum access to potentially large markets while allowing for enhanced coordination
with our marketed drugs, Zevalin and Fusilev”, added Amar Singh, Spectrum’s Chief Commercial
Officer. “The recent expansion of our commercial infrastructure positions us to prepare for another
successful launch in the near future”.

“We believe that this partnership will bring together synergies in our combined capabilities that
will result in significant efficiencies in Belinostat’s development,” said Professor Peter Buhl
Jensen, MD, Chief Executive Officer of TopoTarget A/S. “Spectrum as a partner is ideally suited to
exploit the full benefits of the drug for cancer patients.”

Under terms of the agreement, Spectrum acquired the rights to Belinostat for North America and
India, and an option for China, in exchange for an upfront cash payment of $30 million, potential
milestone payments of up to $320 million, and one million shares of Spectrum common stock based
upon the successful achievement of certain development, regulatory and commercial milestones, as
well as double-digit royalties on net sales of Belinostat. Spectrum and TopoTarget will jointly
fund development activities, whereby clinical trial costs will be 70% borne by Spectrum, and 30% by
TopoTarget for new trials to be initiated.

About Peripheral T-Cell Lymphoma

The American cancer Society estimates that approximately 66,000 new cases of non-Hodgkin’s lymphoma
(NHL) were diagnosed in 2009 and of these, approximately 5,600 are classified as Peripheral T-cell
lymphoma (PTCL). PTCL is a group of 13 diverse types of T-cell lymphoma. Most cases of PTCL occur
during adulthood, are aggressive in nature and are difficult to manage with current chemotherapies.
Many patients with PTCL are treated with CHOP (cyclophosphamide, doxorubicin, vincristine and
prednisone) or a CHOP-like regimen, but often patients will stop responding to these therapies.
Studies show that only 25-40% of patients will be alive five years after treatment for PTCL,
creating a real need for more effective therapies.

About Belinostat

Belinostat (PXD 101) is a Class I and II HDAC inhibitor that is being studied in multiple clinical
trials as a single agent or in combination with chemotherapeutic agents for the treatment of
various hematological and solid cancers. Its anticancer effect is thought to be mediated through
multiple mechanisms of action, including the inhibition of cell proliferation, induction of
apoptosis (programmed cell death), inhibition of angiogenesis, induction of differentiation, and
the resensitization of cells that have overcome drug resistance to anticancer agents such as
platinums, taxanes and topoisomerase II inhibitors. Belinostat is the only HDAC inhibitor in
clinical development with multiple potential routes of administration, including intravenous
administration, continuous intravenous infusion and oral administration.

About the Belinostat Registrational Study

Belinostat is currently in registrational trial, under a Special Protocol Assessment (SPA), as a
monotherapy for Peripheral T-Cell Lymphoma (PTCL), an indication which has been granted Orphan Drug
and Fast Track designation by the U.S. Food and Drug Administration (FDA). The registrational
trial is in an open-label, multicenter, single arm efficacy and safety study in patients with
relapsed or refractory peripheral T-cell lymphoma, who have failed at least one prior systemic
therapy. The primary endpoint is objective response rate (ORR).

 

 

About TopoTarget

TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to
finding “Answers for Cancer” and developing improved cancer therapies. The company was founded
and is run by clinical cancer specialists and combines years of hands-on clinical experience with
in-depth understanding of the molecular mechanisms of cancer. For more information, please refer to
www.topotarget.com.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The
Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse
pipeline of late-stage clinical and commercial products. In addition to building an efficient
in-house clinical research organization with regulatory and data management capabilities, the
Company has established a commercial infrastructure for its drug portfolio. Spectrum markets two
oncology drugs, Fusilev(R) and Zevalin(R) and now has two drugs in late stage development,
Apaziquone (EOquin(R)) and belinostat, along with a diverse pipeline. The Company also leverages
the expertise of its worldwide partners to assist in the execution of its strategy. For more
information, please visit the Company’s website at www.sppirx.com.

This press release may contain forward-looking statements regarding future events and the
future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could
cause actual results to differ materially. These statements include but are not limited to
statements that relate to Spectrum’s business and its future, Spectrum’s ability to identify,
acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, NDA filing for PTCL in 2011, that Belinostat has the potential to be a
best-in-class HDAC inhibitor for both hematological and solid tumors, that we look forward to
advancing Belinostat in PTCL and other solid tumor indications, and any statements that relate to
the intent, belief, plans or expectations of Spectrum or its management, or that are not a
statement of historical fact. Risks that could cause actual results to differ include the
possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the
possibility that Spectrum’s existing and new drug candidates may not receive approval from the FDA,
and other regulatory agencies in a timely manner or at all, the possibility that Spectrum’s
existing and new drug candidates, if approved, may not be more effective, safer or more cost
efficient than competing drugs, the possibility that Spectrum’s efforts to acquire or in-license
and develop additional drug candidates may fail, Spectrum’s lack of significant revenues, limited
marketing experience, dependence on third parties for clinical trials, manufacturing, distribution
and quality control and other risks that are described in further detail in Spectrum’s reports
filed with the Securities and Exchange Commission. Spectrum does not plan to update any such
forward-looking statements and expressly disclaim any duty to update the information contained in
this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC. ® is a registered trademark of Spectrum, TURNING INSIGHTS
INTO HOPETM and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals,
Inc.

©
2010 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

 

 

CONFIDENTIAL

	 	 	 
	To NASDAQ OMX Copenhagen A/S

	 	TopoTarget A/S
	Announcement No. 02-XX10 / Copenhagen, XX XX 2010

	 	Symbion
	 

	 	Fruebjergvej 3
	 

	 	DK 2100 Copenhagen
	 

	 	Denmark
	 

	 	Tel: +45 39 17 83 92
	 

	 	Fax: +45 39 17 94 92
	 

	 	CVR-nr: 25695771
	 
	 	 
	 

	 	www.topotarget.com

TopoTarget signs $350 million agreement with Spectrum

Pharmaceuticals for the development and commercialisation of

Belinostat in North America and India

-A telephone conference will be held later today. Call in details will be announced later-

	 	•	 	Potential value of $350 million plus double digit royalties
	 
	 	•	 	TopoTarget to receive $30 million cash upfront
	 
	 	•	 	TopoTarget and Spectrum will jointly develop belinostat with Spectrum contributing 70%
of future development costs
	 
	 	•	 	Spectrum territory North America and India
	 
	 	•	 	TopoTarget can use data to commercialise belinostat in Europe, Japan and rest of the
world

Copenhagen, Denmark & Irvine, California, US — XX XX, 2010 — TopoTarget A/S (NASDAQ-OMX: TOPO.CO)
and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) announced today an agreement to co-develop and
commercialise belinostat, TopoTarget’s lead anticancer drug for cancer in North America and India.
Belinostat, an HDAC inhibitor, is in registrationalclinical trial in Peripheral T-Cell Lymphoma
(PTCL) as monotherapy and in a randomized phase 2 clinical trial for cancer of unknown primary site
(CUP) in combination with carboplatinum and paclitaxel (BelCaP). Belinostat is currently being
investigated in 20 clinical trials in haematological and solid cancers in monotherapy as well as in
combination therapies.

“We are very happy to enter into collaboration with Spectrum — a highly committed successful US
biotech company specialised in development of oncology and haematology products and expert
marketeers” said MD, Professor Peter Buhl Jensen, CEO of TopoTarget. “The partnership with Spectrum
significantly strengthens the global development of belinostat for the treatment of multiple
cancers as well as its successful commercialisation”.

“The addition of Belinostat addresses our key strategic goal of acquiring a late-stage anti-cancer
compound,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of
Spectrum Pharmaceuticals. “Belinostat’s current registrational program is comprehensive and focused
in that it targets key hematological indications such as PTCL and other solid tumor indications.
Belinostat has the potential to be a best-in-class HDAC inhibitor for both hematological and solid
tumors. We look forward to advancing Belinostat in PTCL and other solid tumor indications, with
the goal of providing cancer patients with more effective treatment options as quickly and
efficiently as possible.”

Under the terms of the agreement, TopoTarget will receive an upfront payment of $30 million in
cash. The total potential value of up-front and milestones (for both development and sales) the
agreement, in the event of full commercial success could exceed $350. In addition, TopoTarget will
receive a double digit royalty on sales of belinostat as well as one million Spectrum shares.
Spectrum commits to fund 100% of the costs for the ongoing PTCL study; TopoTarget will fund 100% of
the ongoing CUP study. Spectrum and TopoTarget will split the development costs in a 70 to 30 ratio
for future development of belinostat.

Under the agreement it is now expected that the BELIEF trial will be finalised and NDA filed with
the FDA in 2011 the previous timeline announced by TopoTarget was December 2010. The CUP trial
will be fully

 

 

recruited in 2010 — the previous timeline announced by TopoTarget was H1 2010. In addition other
randomised clinical trials in indications such as NSCLC are expected to be initiated.

Taking into account the 70:30 cost sharing arrangement under the collaboration, the sign on
fee and existing cash resources TopoTarget will, as a result of entering into the Agreement with
Spectrum, have sufficient cash resources to take it into 2012. The agreement also includes
diligence provisions on development and commercialisation as well as an option to co-promote under
certain conditions.

Belinostat an HDACi is a novel way of treating cancer. Belinostat has been developed to address the
serious issue of drug resistance — in addition to having its own cancer cell killing effect as
monotherapy belinostat resentizises the sensitivity to several anticancer agents including platins,
taxanes and topoisomerase II drugs where resistance has been developed.

Today’s news does not change TopoTarget’s 2009 full-year financial guidance. The impact on 2010
will be included in TopoTarget’s financial outlook for 2010 to be announced 25 March 2010.

TopoTarget A/S

For further information, please contact:

	 	 	 	 	 
	Peter Buhl Jensen

	 	Telephone
	 	+45 39 17 94 99
	CEO

	 	Mobile
	 	+45 21 60 89 22

2. Background information

About belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the
treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or
in combination with other active anti-cancer agents, including carboplatin, paclitaxel,
doxorubicin, idarubicin, cis-retinoic acid, azacytidine and Velcade® (bortezomib) for
injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that
target HDAC enzymes, and have been shown to: arrest growth of cancer cells (including drug
resistant subtypes); induce apoptosis, (programmed cell death); promote differentiation; inhibit
angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with
other anti-cancer agents. Company-sponsored trials of IV-administered belinostat include a pivotal
trial in peripheral T-cell lymphoma (PTCL), a randomized controlled Phase 2 trial in cancer of
unknown primary (CUP), and studies in ovarian, colorectal and soft tissue sarcoma patients.
NCI-sponsored trials (single agent and in combination with anti-cancer therapeutics) with
IV-administered belinostat include studies in hepatocellular, thymoma, Myelodysplastic Syndrome
(MDS), and other solid and hematologic cancers. Continuous intravenous administration (CIV) is
being evaluated in clinical trials in solid tumours as well as in AML. An oral formulation of
belinostat is also being evaluated in a Phase 1 clinical trial for patients with advanced solid
tumors and lymphomas. These NCI-sponsored clinical studies are being conducted under a Clinical
Trials Agreement with TopoTarget. Furthermore TopoTarget has a Cooperative Research and Development
Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in
order to better understand its anti-tumor activity and to provide supporting information for
clinical trials.

About TopoTarget

TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to
finding “Answers for Cancer” and developing improved cancer therapies. The company was founded
and is run by clinical cancer specialists and combines years of hands-on clinical experience with
in-depth understanding of the molecular mechanisms of cancer.

TopoTarget has a broad clinical pipeline but is currently focusing on the development of
belinostat, which has shown proof of concept as monotherapy in treating haematological malignancies
and positive results in solid tumours where it can be used in combination with full doses of
chemotherapy, and is in a pivotal trial in PTCL. TopoTarget’s expertise in translational research
is utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget is directing its
efforts on key cancer targets including HDACi, NAD+, mTOR, FasLigand and topoisomerase II
inhibitors. The company’s first marketed product Savene®/Totect® was approved
by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget’s own sales force in Europe and
the US. For more information, please refer to www.topotarget.com.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The
Company’s strategy is comprised of acquiring and developing a broad and diverse pipeline of
late-stage clinical and commercial

 

 

products; establishing a commercial organization for its approved drugs; continuing to build a team
with people who have demonstrated skills, passion, commitment and have a track record of success in
its areas of focus; and, leveraging the expertise of partners around the world to assist it in the
execution of its strategy. For more information, please visit the Company’s website at
www.sppirx.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our
expectations of the progression of our preclinical and clinical pipeline including the timing for
commencement and completion of clinical trials and with respect to cash burn guidance. Such
statements are based on management’s current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those described in the
forward-looking statements. TopoTarget cautions investors that there can be no assurance that
actual results or business conditions will not differ materially from those projected or suggested
in such forward-looking statements as a result of various factors, including, but not limited to,
the following: The risk that any one or more of the drug development programs of TopoTarget will
not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment
issues or based on new information from non-clinical or clinical studies or from other sources; the
success of competing products and technologies; technological uncertainty and product development
risks; uncertainty of additional funding; TopoTarget’s history of incurring losses and the
uncertainty of achieving profitability; TopoTarget’s stage of development as a biopharmaceutical
company; government regulation; patent infringement claims against TopoTarget’s products, processes
and technologies; the ability to protect TopoTarget’s patents and proprietary rights; uncertainties
relating to commercialization rights; and product liability expo-sure; We disclaim any intention or
obligation to update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, unless required by law.

 

 

CONFIDENTIAL

Schedule 4.4(a) — PTCL Clinical Trial Agreement

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

Schedule 9.2(h) — Product Description as of Effective Date

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

 

Schedule 9.9 — Material Contracts of TopoTarget

[***]

 

			
	[***]:	 	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]